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Summary 
Nucleotide excision repair (NER) plays a key role in repairing a wide variety of DNA 
damage including bulky DNA adducts caused by ultraviolet radiation and exposure 
to harmful substances like tobacco smoke and alcohol. Genetic variations and 
somatic mutations in NER genes might affect cancer risk and therapy. However, 
both these aspects are not well understood. 
The first part of the thesis deals with the role of NER in modulation of laryngeal 
cancer risk. The major risk factors for laryngeal cancer are smoking and high alcohol 
consumption. Polymorphisms in NER genes might therefore affect laryngeal cancer 
susceptibility. In a population-based case-control study including 248 cases and 647 
controls, the association of laryngeal cancer with 11 single nucleotide 
polymorphisms (SNPs) in 7 NER genes (XPC, ERCC1, ERCC2, ERCC4, ERCC5, ERCC6 
and RAD23B) was analyzed with respect to smoking and alcohol exposure. For 
genotyping, sequence specific hybridization probes were used. Data were 
evaluated by conditional logistic regression analysis, stratified for age and gender, 
and adjusted for smoking, alcohol consumption and education. Pro-carriers of 
ERCC6 Arg1230Pro showed a decreased risk for laryngeal cancer (OR=0.53, 95% CI 
0.34-0.85), being most protective in heavy smokers and high alcohol consumers. 
ERCC5 Asp1104His was associated with risk in heavy smokers (OR=1.70, 95% CI 1.1-
2.5). Val-carriers of RAD23B Ala249Val had an increased cancer risk in heavy 
smokers (OR=1.6, 95% CI 1.1-2.5) and high alcohol consumers (OR=2.0, 95% CI 1.1-
3.4). The combined effect of smoking and alcohol intake affected risk, at high 
exposure level, for ERCC6 1230Pro carriers (OR=0.47, 95% CI 0.22-0.98) and 
RAD23B 249Val carriers (OR=2.6, 95% CI 1.3-4.9). When tested for gene-gene 
interaction, presence of 3 risk alleles in the XPC RAD23B complex increased the risk 
2.1 fold. SNPs in the other genes did not show a significant association with 
laryngeal cancer risk. We conclude that common genetic variations in NER genes 
can significantly modify laryngeal cancer risk. 
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The second part of the thesis deals with the question how NER affects cancer 
therapy. NER genes become deficient in many cancer types. By employing methods 
to target these deficiencies, tumor cells can be killed more effectively. Two NER 
deficient cell lines i.e., XP3BE (XPC deficient cells) and GM10902 (ERCC6 deficient 
cells) and a normal cell line GM01310 were exposed to 72 traditional Chinese 
medicine (TCM) drugs. Cytotoxicity screening revealed that 13 of the drugs killed 
NER deficient cells more efficiently compared to normal cells. Depending on the 
effect and available amount, 6 drugs were selected for further analysis and their 
IC50 values, effects on cell cycle distribution and DNA damage induction were 
measured. Ascaridol was found to be the most effective compound with a 
difference of more than 1000 fold in resistance between normal and NER deficient 
cells (IC50 for GM10902 0.025 µg/ml, XP3BE 0.03 µg/ml and GM01310 > 30 µg/ml). 
The drug had a strong and differential effect on cell cycle distribution of the three 
cell lines. Ascaridol produced around three times more DNA damage in NER 
deficient cells compared to normal cells. Results obtained for ascaridol were 
validated in a second set of cell lines having isogenic background. XPC deficient 
(XP4PA; IC50 0.013 µg/ml) and ERCC6 silenced (IC50 0.095 µg/ml) cells were more 
sensitive to the drug than XPC proficient (XP4PA-SE2; IC50 2.19 µg/ml) and 
Luciferase siRNA treated (IC50 3.0 µg/ml) cells. Following ascaridol exposure, XPC 
deficient and ERCC6 silenced cells gathered around 1.5 to 3 times more DNA 
damage than repair competent cells. Ascaridol was also characterized for its ability 
to generate oxidative DNA damage. A dose-dependent increase in intracellular 
peroxide levels was observed in ascaridol treated cells. Ascaridol (1 µg/ml) treated 
XPC deficient (Fpg sensitive lesions 13.78 ± 1.72) and ERCC6 silenced (Fpg sensitive 
lesions 19.33 ± 1.2) cells also had a strong increase in the amount of oxidized bases 
(8-oxodG sites). Both XPC proficient and Luciferase siRNA cells did not show such 
an increase. Thus we showed, for the first time that ascaridol is mediating DNA 
damage by reactive oxidative intermediates. We identified that ascaridol is 
specifically affecting NER deficient cells and this might provide a new therapeutic 
option for differentially killing tumor and normal cells. 
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Zusammenfassung 
Nukleotid Exzisions Reparatur (NER) spielt eine wichtige Rolle bei der Reparatur 
vieler verschiedener Arten von DNA-Schäden, dazu gehören auch DNA-Addukte, 
die durch ultraviolette Strahlung und durch Exposition gegenüber schädlichen 
Substanzen wie Tabakrauch und Alkohol entstehen. Genetische Variationen und 
somatische Mutationen in NER-Genen können möglicherweise Auswirkungen auf 
Krebsrisiko und Therapie haben. Der Kenntnisstand hierüber ist jedoch gering. 
Der erste Teil der Arbeit untersucht die Rolle von genetischer Variation in NER-
Genen bei der Modulation des Kehlkopfkrebs-Risikos. Die wichtigsten 
Risikofaktoren für Kehlkopfkrebs sind Rauchen und hoher Alkoholkonsum. 
Polymorphismen in NER-Genen könnten sich daher auf die Anfälligkeit für 
Kehlkopfkrebs auswirken. In einer populationsbezogenen Fall-Kontroll-Studie mit 
248 Fällen und 647 Kontrollen wurden die Assoziationen von Kehlkopfkrebs mit 11 
Einzel-Nukleotid-Polymorphismen (SNPs) in 7 NER-Genen (XPC, ERCC1, ERCC2, 
ERCC4, ERCC5, ERCC6 und RAD23B) unter Berücksichtigung von Rauchen und 
Alkoholkonsum analysiert. Für die Genotypisierung wurden Sequenz-spezifische 
Hybridisierungssonden verwendet. Die für Alter und Geschlecht, sowie Rauchen, 
Alkoholkonsum und Bildung adjustierten Daten wurden mittels logistischer 
Regressionsanalyse ausgewertet. Träger der Pro-Allele in ERCC6 Arg1230Pro 
zeigten ein vermindertes Risiko für Kehlkopfkrebs (OR=0,53, 95% KI 0,34 - 0,85), 
welches bei starken Rauchern und Pro-Allel-Trägern mit hohem Alkoholkonsum am 
stärksten reduziert war. ERCC5 Asp1104His war mit dem Risiko bei starken 
Rauchern assoziiert (OR=1,70, 95% KI 1,1 - 2,5). Val-Allel-Träger von RAD23B 
Ala249Val hatten ein erhöhtes Krebsrisiko, wenn sie starke Raucher waren (OR=1,6, 
95% KI 1,1 - 2,5) oder viel Alkohol konsumierten (OR=2,0, 95% KI 1,1 - 3,4). Die 
kombinierte Wirkung von Rauchen und Alkoholkonsum beeinflusste das Risiko bei 
starker Exposition und zwar für ERCC6 1230Pro (OR = 0,47, 95% KI 0,22 - 0,98) und 
RAD23B 249Val (OR=2,6, 95% KI 1,3 - 4,9). Bei der Untersuchung von Gen-Gen-
Interaktionen erhöhte die Anwesenheit von 3 Risikoallelen im XPC-RAD23B-
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komplex das Risiko um das 2,1-fache. SNPs in den anderen Genen zeigten keine 
signifikante Assoziation mit dem Risiko für Kehlkopfkrebs. Wir schließen daraus, 
dass häufige genetische Variationen in NER-Genen das Kehlkopfkrebs-Risiko 
erheblich beeinflussen können. 
Der zweite Teil der Arbeit hat die Frage zum Thema, wie sich NER-Defizite auf den 
Erfolg einer Krebstherapie auswirken. NER Gene sind in vielen Krebszellen mutiert. 
Der Einsatz von Substanzen, die diese Zellen gezielt angreifen, könnte die 
Therapiewirkung bei gleichzeitiger Schonung des Reparatur-kompetenten 
Normalgewebes verstärken. Zwei NER-defiziente Zelllinien, XP3BE (XPC-defiziente 
Zellen) und GM10902 (ERCC6-defiziente Zellen) sowie eine normale Zelllinie 
GM01310 wurden mit 72 Substanzen aus der traditionellen chinesischen Medizin 
(TCM) behandelt. Ein Screening ergab, dass 13 dieser Substanzen in NER-
defizienten Zellen deutlich zytotoxischer wirken als in normalen Zellen. Abhängig 
von ihrer Wirkung sowie der verfügbaren Menge wurden 6 dieser Substanzen zur 
weiteren Analyse ausgewählt, um ihre IC50 Werte, Auswirkungen auf den Zellzyklus 
und ihre Fähigkeit zur Induktion von DNA-Schäden zu bestimmen. Die wirksamste 
Substanz war Ascaridol, mit einer über 1000-fach höheren Resistenz von normalen 
gegenüber NER-defizienten Zellen (IC50 für GM10902 0,025 µg / ml, XP3BE 0,03 µg / 
ml und GM01310 > 30 µg / ml). Diese Substanz hatte starke und unterschiedliche 
Auswirkungen auf die Zellzyklus Verteilung der drei Zelllinien. Ascaridol verursachte 
etwa drei mal mehr DNA-Schäden in NER-defizienten Zellen im Vergleich zu 
normalen Zellen. Die Ergebnisse für Ascaridol wurden in einem zweiten Set von 
isogenen Zelllinien validiert. XPC-defiziente (XP4PA; IC50 0,013 µg / ml) und mit 
ERCC6-siRNA-behandelte Zellen (IC50 0,095 µg / ml) waren empfindlicher 
gegenüber diesem Wirkstoff als XPC-kompetente (XP4PA-SE2; IC50 2,19 µg / ml) 
und Luciferase-siRNA-behandelte Kontroll-Zellen (IC50 3,0 µg / ml). Nach 
Ascaridolexposition zeigten XPC-defiziente und ERCC6-siRNA-behandelte Zellen 1,5 
bis drei mal mehr DNA-Schäden als Reparatur-kompetente Zellen. Außerdem 
wurde eine dosisabhängige Erhöhung der intrazellulären Peroxidmenge durch 
Ascaridol in den Zellen beobachtet. Mit Ascaridol (1 µg / ml) behandelte XPC-
Zusammenfassung 
XVII 
defiziente und ERCC6-siRNA-behandelte Zellen zeigten auch einen starken Anstieg 
in der Menge der oxidierten Basen, der weder in XPC-kompetenten noch in 
Luciferase-siRNA-behandelten Kontroll-Zellen sichtbar war. Diese Ergebnisse zeigen 
zum ersten Mal, dass Ascaridol DNA-Schäden über reaktive oxidative 
Zwischenprodukte verursacht, und dass Ascaridol besonders NER-defiziente Zellen 
angreift. Dies könnte eine neue therapeutische Option für das selektive Abtöten 
von Tumorzellen darstellen. 
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1. Introduction 
DNA repair is of fundamental importance in maintaining (Cheng et al., 2000) 
genomic stability after exogenous exposures such as smoking and protects against 
cancer (Hoeijmakers, 2001a; Wu et al., 2007a). Impaired DNA repair contributes to 
tumorigenesis and its overexpression is a mechanism for tumor resistance to 
chemotherapy (Brabec & Kasparkova, 2002). More than 160 human DNA repair 
genes are known (Wood et al., 2001). These can be sub-grouped into genes 
associated with DNA damage signaling and regulation of the repair system and 
genes working with distinct repair pathways such as mismatch repair, base excision 
repair, nucleotide excision repair (NER), direct damage reversal and DNA double-
strand break repair. This thesis is concentrating on NER. 
1. 1. Nucleotide excision repair (NER) 
NER eliminates a wide variety of different forms of DNA damage. It eliminates 
mainly the bulky or helix-distorting DNA adducts (Buschta-Hedayat et al., 1999) 
such as those caused by ultraviolet (UV) radiation (Lindahl et al., 1997) and 
polycyclic aromatic hydrocarbons (PAH) (Platt et al., 2008). PAHs are commonly 
present in tobacco smoke (Ding et al., 2008), coal tar, pesticides and herbicides 
(Becher et al., 2005). NER also removes lesions caused by DNA crosslinking agents 
e.g., cisplatin (Furuta et al., 2002). There are around 30 proteins involved in NER 
(Andressoo et al., 2006). 
1. 1. 1. Molecular mechanisms of NER 
NER consists of two sub-pathways, Global genome repair (GGR) and Transcription 
coupled repair (TCR). GGR mainly repairs DNA lesions arising in non-transcribing 
regions of the genome (Fousteri & Mullenders, 2008; Shuck et al., 2008). TCR is 
involved in damage repair at actively transcribing sites (Fousteri & Mullenders, 
2008). 
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Figure.1.1 is a schematic representation of NER. The complex interaction of NER 
proteins in the pathway is not completely known yet, but damage recognition is 
specific for each of the sub-pathways. In GGR, two heterodimers XPC-RAD23B and 
UV-DDB (heterodimer of DDB1-DDB2) recognize DNA distortion and bind to the 
damaged site (Fousteri & Mullenders, 2008; Shuck et al., 2008). In TCR, RNA 
polymerase II gets blocked at the damaged site. This blockade is recognized and 
removed by the proteins ERCC6 (CSB) and ERCC8 (CSA) (Fousteri & Mullenders, 
2008). In the next step, the basal transcription factor IIH (TFIIH) complex unwinds 
the DNA duplex. TFIIH comprises up to 10 subunits (Volker et al., 2001) including 
the ATP dependent helicases ERCC2 (XPD) and ERCC3 (XPB) which unwind the 
duplex DNA in 3´ - 5´ and 5´ - 3´ direction, respectively. This generates an open DNA 
structure around the lesion making place for the RPA-XPA complex which stabilizes 
the open DNA structure and assembles the pre-incision complex (Sugasawa, 2008). 
ERCC5 (XPG) and the ERCC1-ERCC4 (XPF) heterodimer are structure specific 
endonucleases that incise the DNA at the 3' and 5' junctions between single-
stranded and double-stranded DNA thus releasing a 24 to 32 bases long DNA piece 
creating a single-strand gap in the DNA. This gap is filled by DNA polymerases δ and 
ε, and ligase I (Shuck et al., 2008; Fousteri & Mullenders, 2008) which use the 
undamaged strand as a template for DNA resynthesis. 
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1. 1. 2. Syndromes caused by defects in NER 
Mutations in NER genes cause distinct disorders including Xeroderma pigmentosum 
(XP), Cockayne syndrome (CS) and Trichothiodystrophy (TTD). Table.1.1 outlines 
important NER genes, their implication in the pathway and diseases associated with 
the genes. 
Xeroderma pigmentosum is the first disorder where, in 1968, a direct link between 
DNA repair and carcinogenesis was found (Cleaver, 1968). It is a rare autosomal 
recessive disorder, characterized by severe photosensitivity and predisposition to 
skin cancer at very young age (reviewed in Sugasawa, 2008; Leibeling et al., 2006). 
Cells from XP patients are extremely sensitive to UV light and have a defect in NER.  
Eight NER genes are involved in XP (XPA to XPG, XPV). 
Cockayne syndrome is a rare disorder associated with many clinical symptoms 
including dwarfism, mental retardation and photosensitivity. CS is not associated 
with enhanced incidence of skin cancer. Cells from CS patients are hypersensitive 
to UV exposure. Defects in two NER genes, ERCC6 (CSB) and ERCC8 (CSA) lead to CS 
(Leibling et al., 2006; Fousteri and Mullenders, 2008). A third group comprises 
patients exhibiting both XP and CS symptoms. They have been associated with 
mutations in three NER genes, ERCC2 (XPD), ERCC3 (XPB) and ERCC5 (XPG). 
Individuals suffering from Trichothiodystrophy exhibit photosensitivity, Ichthyosis, 
brittle hair, impaired intelligence, decreased fertility and short stature (Itin et al., 
2001). TTD is also not associated with predisposition to cancer. Certain mutations 
in ERCC2 (XPD), ERCC3 (XPB) and ERCC5 (XPG) genes have been linked to TTD. 
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Table.1.1. Genes implicated in NER 
Gene location Gene functiona Involved inb Associated 
syndromec GGR TCR 
XPC 3p25.1 Damage detection In GGR. 
 RAD23B and XPC work as a 
complex 
Y N XP 
RAD23B 9q31.2 Y N - 
UV-DDB2 11p12-p11 Damage detection In GGR.  Y N XP 
ERCC6 / CSB 10q11.23 Damage detection and 
removal of RNA polymerase II 
blockade in TCR  
N Y CS 
ERCC8 / CSA 5q12.1 Damage detection and 
removal of RNA polymerase II 
blockade in TCR 
N Y CS 
XPA 9q22.3 stabilizes the open DNA 
structure 
Y Y XP 
ERCC1 19q13.32 5´Endonuclease, works as a 
complex with ERCC4 / XPF 
Y Y - 
ERCC2 / XPD 19q13.32 3´ - 5´ Helicase Y Y XP, CS, TTD 
ERCC3 / XPB 2q21 5´ - 3´ Helicase Y Y XP, CS, TTD 
ERCC4 / XPF 16p13.12 works as a complex with 
ERCC1 
Y Y XP 
ERCC5 / XPG 13q33.1 3´Endonuclease Y Y XP, CS, TTD 
a GGR, global genome repair; TCR, transcription coupled repair. 
b Y, Yes; N, No. 
c XP, xeroderma pigmentosum; CS, Cockayne syndrome; TTD, Trichothiodystrophy. 
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1. 2. NER and cancer risk 
Cancer is a complex disease manifested by genetic and epigenetic changes in cells, 
accumulating over a period of time (Frank, 2004; Heng et al., 2009). Individuals vary 
in their ability to develop cancer. Age, genes and environmental factors like eating 
habits and life style play a major role in defining this ability (Bartsch & Hietanen, 
1996; Brose et al., 2003). The cross-talk between genetics and environment does 
not directly cause cancer but greatly affects the risk of developing it in future. 
Genetic factors like highly penetrant mutations cause strong predisposition to 
nearly every cancer type (Mohandas, 2001). Major mutations in several NER genes 
(Table.1.1) cause XP syndrome with predisposition to skin cancer. As these 
mutations are an evolutionary disadvantage they are rare. On the other hand, low-
penetrance genetic variations, also known as polymorphisms, might also influence 
cancer susceptibility (Frank, 2004). Genetic polymorphisms generally have a higher 
frequency, appearing in at least 1% of a population. Single nucleotide 
polymorphisms (SNPs) are genetic variations that occur when a single nucleotide in 
a DNA sequence is altered (Au, 2006; Orr & Chanock, 2008). SNPs are usually 
considered point mutations having evolutionarily success to recur in a significant 
proportion of the population. 
Many SNPs have been associated with higher cancer risk. Table.1.2 lists some of 
the SNPs present in NER genes associated with increased cancer risk. The 
mechanism by which these SNPs could impact cancer risk is still unclear. Variations 
in DNA repair genes suggest variation in the ability to repair. Decrease in DNA 
repair capacity results in increased mutation rates and genetic instability that leads 
to cancer development (Matakidou et al., 2007). This hypothesis is firmly 
supported by the presence of breast-ovarian cancer syndrome, XP syndrome and 
many other heredity cancer types (Brose et al., 2003). With the advances in 
technology and increasing knowledge, the hypothesis has also been applied to the 
general population to ascertain cancer risk (Shuck et al., 2008). 
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Table.I.2 summarizes common SNPs present in NER genes which were reported to 
be associated with increased risk of head and neck, lung, breast, bladder or other 
cancer types. A good example is ERCC2. Three most common SNPs in the gene, 
Arg156Arg, Asp312Asn and Lys751Gln, have been the center of many studies. A 
meta-analysis by Manuguerra et al., (2006) revealed that Arg156Arg, which is a 
synonymous polymorphism, is important in skin cancer whereas Asp312Asn and 
Lys751Gln are linked with breast and lung cancer. Peripheral blood lymphocytes 
from individuals with 312Asn and 751Gln had higher UV sensitivity compared with 
312Asp and 751Lys (Au, 2006). The finding was consistent with decreased NER 
capacity. XPC Lys939Gln has been associated with lung cancer, bladder cancer and 
advanced colorectal adenoma (Huang et al., 2006; Sanyal et al., 2004; Shen et al., 
2005). The SNP maps to C-terminal domain of XPC, which is essential for interaction 
with TFIIH through ERCC3 and p62 subunits, and crucial for NER (Uchida et al., 
2002). This might explain the significance of the SNP in decreased repair capacity 
and increased cancer risk.  
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Table.1.2. Cancer associated SNPs in NER genes. 
Gene 
Polymorphisma 
Nucleic acid, amino 
acid 
Associations reported for Cancer 
XPC A/C, Lys939Gln Advanced Colorectal Adenoma (Huang et al., 2006), lung cancer (Shen et al., 2005), bladder cancer (Sanyal et al., 2004) 
 C/T, Ala499Val Squamous cell carcinoma of the head and neck (An et al., 2007) 
RAD23B C/T, Ala249Val Lung cancer (Shen et al., 2005) 
XPA G/A, G23A Lung cancer (Popanda et al., 2004) 
ERCC1 T/C, Asn118Asn Lung cancer (Kiyohara & Yoshimasu, 2007; Zienolddiny et al., 2006), bladder Cancer (Matullo et al., 2005) 
 C/A, C8092A Squamous Cell Carcinoma of the Head and Neck (Sturgis et al., 2002), adult-Onset Glioma (Chen et al., 2000) 
 C/A, IVS5+33 Bladder Cancer (Garcia-Closas et al., 2006) 
ERCC2 A/C, Arg156Arg Lung Cancer (Yin et al., 2007; Shen et al., 2005; Yin et al., 2005), Bladder Cancer (Garcia-Closas et al., 2006), basal cell carcinoma 
(Vogel et al., 2001) 
 A/C, Lys751Gln Lung cancer (Kiyohara & Yoshimasu, 2007; Zienolddiny et al., 2006; Zhou et al., 2002), esophageal adenocarcinoma (Liu et al., 2007), 
multiple primary melanoma (Millikan et al., 2006), basal cell carcinoma (Vogel et al., 2001) 
 G/A, Asp312Asn Lung cancer (Kiyohara & Yoshimasu, 2007; Zhou et al., 2002), multiple primary melanoma (Millikan et al., 2006), basal cell 
carcinoma (Vogel et al., 2001) 
ERCC4 G/A, Arg415Gln Smoking and breast cancer (Mechanic et al., 2006), prostate cancer (Lockett et al., 2005) 
ERCC5 G/C, Asp1104His Lung cancer (Kiyohara & Yoshimasu, 2007), lung cancer and SCC of the oropharynx, larynx and esophagus (Cui et al., 2006), Smoking 
and breast cancer (Mechanic et al., 2006), bladder cancer (Sanyal et al., 2004),  breast cancer (Kumar  et al., 2003) 
 T/C, His46His Lung cancer (Kiyohara & Yoshimasu, 2007; Zienolddiny et al., 2006) 
ERCC6 A/G, Arg1213Gly Colorectal cancer (Berndt et al., 2006), Smoking and breast cancer (Mechanic et al., 2006) 
a SNP500Cancer Database and NCBI; For each polymorphism nucleotide, codon number and amino acid change, if adequate, is provided. 
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1. 2. 1. Laryngeal cancer 
1. 2. 1. 1. Larynx 
The larynx (Figure.1.2), also known as the ‘voice box’, is located in the neck and is 
visible as 'Adam's apple', just below the chin (Schnke et al., 2005). It is the top part 
of trachea (windpipe). During inhalation, air passes into the larynx and down the 
trachea towards the lungs. Larynx comprises vocal cords and epiglottis. Vocal cords 
are 'V' shaped ridges of muscle tissue on the inside lining of the larynx. They vibrate 
when air passes between them to produce speech. Epiglottis is a flap of cartilage 
tissue at the back of the tongue. During the swallowing process, epiglottis closes 
over the entrance to the larynx, making sure that food goes down the esophagus 
and not down the trachea. 
Figure.1.2. Human Larynx. Larynx comprises epiglottis and vocal cords. Inset: 
cross section of larynx. Taken and modified from http://www.taxotere.com 
Introduction 
10 
1. 2. 1. 2. Facts about larynx cancer 
Laryngeal cancer is the most frequent form of head and neck cancers in Germany 
(Batzler et al., 2008) and the second most common form of respiratory tract 
cancers in the US (American Cancer Society, 2006). The average age of onset of the 
disease is 64 years and it is more common in males than in females (6:1 ratio). 
Nevertheless, laryngeal cancer is listed as a "rare disease" by the Office of Rare 
Diseases (ORD) of the National Institutes of Health (NIH) (Beenken et al., 2009). In 
Germany, an estimated 3000 men and 400 women are diagnosed with this disease 
each year (Batzler et al., 2008). The 5 years survival rate is around 61%. It is 
however to be noted that quality of life is strongly affected by this disease as it 
effects the speaking and swallowing abilities of the patients (Starmer et al., 2008). 
1. 2. 1. 3. Larynx cancer risk factors 
 Age and gender 
As with most cancers, larynx cancer is more common in older people than in 
younger.  Half of the patients are above 65 years of age. The disease is 6 to 7 times 
more common in men. The higher incidence in males can be attributed to their 
smoking and drinking habits (Batzler et al., 2008; American Cancer Society, 2006). 
 Smoking and alcohol consumption 
Cigarette smoking and alcohol consumption are well acknowledged risk factors for 
laryngeal cancer (Hashibe et al., 2007; IARC, 2002; La et al., 2008; Ramroth et al., 
2004; Talamini et al., 2002). Cancer risk is directly related with duration and 
number of cigarettes smoked, and considerably increased in individuals consuming 
more than 50 g of alcohol per day. Tobacco smoke contains many carcinogens 
including a group of N-nitrosamines that produce carcinogenic methyl and 
pyridyloxobutyl DNA adducts (Hecht, 2001). A further constituent of tobacco 
smoke is the highly toxic acetaldehyde (Stein et al., 2006; Smith et al., 2000) which 
produces genotoxic 1,N2-propano-2′-deoxyguanosine DNA adducts (Stein et al., 
2006; Brooks & Theruvathu, 2005). Acetaldehyde is also an intermediate product of 
ethanol metabolism and its concentration increases in a multiplicative manner in 
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individuals who are simultaneously smoking and drinking alcohol (Salaspuro & 
Salaspuro, 2004). This observation might explain the synergistic and multiplicative 
effect found for alcohol and smoking in laryngeal cancer risk (Talamini et al., 2002; 
Hashibe et al., 2007). 
 Occupational exposure 
Workers in construction industry are exposed to polyaromatic hydrocarbons 
(Becher et al., 2005). Exposure to chemicals e.g., paint fumes, soot or coal dust 
over a period of time increases the risk of larynx cancer. Exposure to coal and wood 
as a fuel source in household over many years has also been linked to a higher risk 
of laryngeal cancer (Sapkota et al., 2008). 
 Eating habits and physical health  
A weak Immune system and poor eating patterns increase larynx cancer risk 
(American Cancer Society, 2006).  Intake of fresh or salt-preserved meat and fish 
increases the risk whereas whole grains, fruits and vegetables protect against 
larynx cancer (Garavello et al., 2009; Kasum et al., 2002; Zheng et al., 1992). 
 Other risk factors 
Racial variations and some gastro esophageal reflux problems like heartburn are 
also linked to increased risk of larynx cancer (Qadeer et al., 2005). 
1. 2. 2. NER and larynx cancer risks 
Although development of laryngeal cancer can widely be attributed to exogenous 
exposures by smoking and alcohol consumption, only a small portion of exposed 
individuals develop cancer, suggesting the involvement of genetic predisposition 
(Brose et al., 2003; Bartsch & Hietanen, 1996).  
Few studies report association between SNPs in NER genes and laryngeal cancer 
risk.  Wen et al., (2006) reported that individuals heterozygous for ERCC5 
Asp1104His have an increased risk for larynx cancer. Cui et al., (2006) reported that 
individuals carrying at least one copy of ERCC5 1104His allele have an increased risk 
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for oropharyngeal, laryngeal and esophageal cancer, this risk increased in heavy 
smokers and high alcohol consumers. 
SNPs in important NER genes are hypothesized to modulate an individual’s ability 
to repair tobacco smoke-induced DNA damage thus contributing to cancer 
susceptibility (Shuck et al., 2008). Genetic profiling helps to identify high-risk 
individuals who then can be enrolled in preventive measures or treated by 
personalized therapies (Bartsch et al., 2007). The current study is aimed to 
contribute to such risk profiles for larynx cancer by analyzing SNPs in NER pathway. 
1. 2. 3. The Rhein-Necker study 
Our project is in collaboration with Prof. Heiko Becher and Dr. Heribert Ramroth, 
Department of Tropical Hygiene and Public Health, University of Heidelberg, 
Germany, and Prof. Andreas Dietz, Department of Otolaryngology, Plastic Surgery, 
University of Leipzig, Germany. A population-based laryngeal cancer case-control 
study is being carried out in the Rhein-Necker-Odenwald region southwest of 
Germany (Becher et al., 2005). A total of 257 patients and 769 randomly selected 
population-based controls were recruited (n = 1026; case-control ratio of 1:3, 
matched for age and gender). Personal and job specific data were collected by well-
trained interviewers using specific questionnaires. A strong affect of cigarette 
smoking, alcohol consumption (Ramroth et al., 2004) and exposure to polycyclic 
aromatic hydrocarbons (Becher et al., 2005) on the laryngeal cancer risk was 
observed. Rajaee-Behbahani et al., (2002) found a reduced Poly (ADP-ribose) 
polymerase activity in peripheral blood lymphocytes from the laryngeal cancer 
patients. Genetic polymorphisms in ADH1B, ADH1C, GSTM1 and GSTT1, the ethanol 
and tobacco carcinogen metabolizing enzymes, did not show any significant 
association with larynx cancer risk (Risch et al., 2003).  
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1. 3. NER and cancer therapy 
Cancer therapy means exposing the body to agents that selectively kill cancer cells 
but produce less harm to normal cells (Helleday et al., 2008). Chemotherapy has 
become a valuable tool for the control of cancer. In chemotherapy, chemical 
compounds are used to damage cancer cells and stop them from growing and 
dividing. The treatment has proven remarkably effective at treating many cancers, 
especially in combination with radiotherapy, but is plagued with toxic side effects. 
Most established chemotherapy drugs show insufficient specificity towards tumor 
cells, they kill healthy cells as well as cancerous ones (Liang et al., 2009). Therefore 
we need improved antitumor drugs with higher recognition for cancer cells. 
1. 3. 1. Targeted Cancer therapy 
Tumors develop multiple genetic deficiencies e.g., in DNA damage response, that 
differentiate them from normal cells. Knowing the molecular defect in tumors has 
opened up the possibility to design the treatment of cancer, with a potential 
increase of the therapeutic index. In particular, by defining a sub-set of tumors 
carrying specific defects in DNA repair pathways allows to differentially treat the 
patients whose tumors harbor such defects (Damia & D'Incalci, 2007; Martin et al., 
2008). Several cancer chemotherapy drugs work by producing excessive DNA 
damage that causes cell death directly or following DNA replication (Helleday et al., 
2008).  
As highlighted in Figure.1.3 tumors with DNA repair defects can be treated 
systemically by DNA damaging anticancer drugs. Examples of targeted therapy 
include the treatment of testicular cancer. NER is compromised in testicular cancer 
and 80% of the patients suffering with this disease respond to cisplatin therapy 
(Welsh et al., 2004). Patients with completely resected non-small cell lung ERCC1-
negative tumors appear to benefit from adjuvant cisplatin-based chemotherapy 
expressed as longer survival, whereas patients with ERCC1-positive tumor do not 
(Olaussen et al., 2006). NER deficient cell lines are sensitive to several alkylating 
agents used in cancer chemotherapy, including cisplatin and melphalan 
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(Selvakumaran et al., 2003). Ongoing clinical studies test PARP inhibitors as single 
agents in BRCA1/2 deficient tumors (Farmer et al., 2005). 
In addition to the examples discussed, many new drugs can be developed to target 
cancer based on the concept of targeted therapy, particularly in the context of NER 
deficiency.  
Because of great genetic variations between tumors, targeted cancer therapy 
cannot be pursued in all cancer patients and using the same regimes, but it should 
DNA damaging agents 
Normal cells  
(Proficient in DNA repair) 
 
Cancer cells 
(deficient in DNA repair) 
 
Tumor cells shrink and die 
 
Normal cells repair the DNA 
damage 
Tumor Regression 
Figure.1.3. Targeted therapy of tumor cells deficient in DNA repair. 
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be tailored according to the specific tumor DNA repair pattern. The efficacy and 
tolerability of a specific treatment can be predicted by genetic analysis of the 
tumors (Damia & D'Incalci, 2007; Di et al., 2004). By tailoring chemotherapy 
regimens for specific predictive markers, one will improve response and survival in 
subgroups of patients, hence in the management of cancer (Rosell et al., 2007). 
There is a need to find new truly disease related and target oriented drugs. It will 
help in achieving stronger effects at lower doses of the drugs, reducing side effects 
and economic burden.  
1. 3. 2. NER deficiencies in tumors 
NER pathway is defective in many cancer types. Table.1.3 shows that NER genes 
exhibit loss of heterozygosity (LOH) in ovarian, colon, lung, oral and breast cancer. 
Genes involved in the pathway also show a reduced expression and loss of normal 
co-ordination in several tumor types. 
An important NER regulator is p53. It effects both dependent and independent 
transactivation of NER (Rubbi & Milner, 2003; SenGupta & Harris, 2005) especially 
by mediating expression of the GGR-specific damage recognition genes, XPC and 
DDB2 (Adimoolam & Ford, 2003). Thus, cells mutant in p53 are also deficient in 
GGR. p53 defects are the most common event in human cancer and occur in at 
least 50% of all malignancies (Hoogervorst et al., 2005). This suggests that a high 
percentage of tumors are devoid of GGR. 
In short, NER deficiencies are common in tumors and these can be exploited for 
therapeutic purpose. By employing methods to target these deficiencies, tumor 
cells can be killed more effectively. 
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Table.1.3. Somatic NER deficiencies reported in different tumor types 
NER genes  Type of impairment Cancer type  Reference  
Genetic defects in NER genes 
XPA, XPC, ERCC2, 
XPE, ERCC4, ERCC5 
and ERCC6  
Loss of heterozygosity (LOH)  ovarian tumors (62.1 %),  of 
colon (16.7%) and  lung 
(22.2%) carcinomas  
(Takebayashi 
et al., 2001) 
ERCC2, ERCC3, 
ERCC4 
LOH  30% of oral carcinoma 
patients  
(Miyashita et 
al., 2001) 
XPA LOH  
promoter hypermethylation  
20% of breast carcinoma 
Late-onset breast 
carcinoma 
(Sinha et al., 
2008) 
NER gene network 
Reduced expression of NER genes. 
Most impaired and highly 
reduced gene expression  
Brain, breast, cerebellum, 
stomach and many other 
sporadic solid tumors.  
(Castro et al., 
2007) 
ERCC1 and ERCC2  Lose of normal co-ordination 
at mRNA level  
glioma  (Dabholkar et 
al., 1995) 
ERCC3 with ERCC1, 
XPA and both. 
ERCC6 with ERCC1 
and ERCC2 
Degree of disorder in co-
ordination  at mRNA level 
increases with advancing 
cancer stage  
glioma  (Dabholkar et 
al., 1996) 
XPC  Reduced gene expression  bladder cancer  (Chen et al., 
2007) 
XPA, ERCC1 and 
ERCC4  
Highly reduced expression  testicular cancer  (Welsh et al., 
2004) 
ERCC1  Highly reduced expression  ovarian cancer  (Dabholkar et 
al., 1994) 
XPC XPC promoter 
hypermethylation reduced its 
expression and caused p53 
mutations 
non-smokers with lung 
cancer 
(Wu et al., 
2007c) 
XPA Reduced expression Colorectal cancer (Yu et al., 
2006b) 
XPC Reduced expression Non-small cell lung cancer 
in 
1. Nonsmokers 
2. advanced cancer stage 
(stage III) 
(Wu et al., 
2007b) 
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1. 3. 3. Traditional Chinese medicine (中医, 中醫) 
Traditional Chinese medicine (TCM) is a 2000 to 3000 years old unique medical care 
system developed in China to diagnose and cure illness (Han, 1988; Yu et al., 
2006a). It is a complete system of healing and includes herbal and dried animal 
medicine (Figure.1.4), acupuncture, moxibustion and massage, etc. In the western 
world, TCM is considered an alternative medical system (Yu et al., 2006a).  
1. 3. 3. 1. Importance of TCM 
With increased understanding of therapeutic benefits, the demand for natural 
products has also increased. Knowledge gained over centuries is becoming the 
center of active search for new medicines. The evolution from traditional to 
empirical and to molecular screening has increased the chances of discovering new 
drug candidates from natural sources (Wang et al., 2007) esp. the traditional folk 
medicines (Lobo et al., 2009). 
TCM has a very ancient history and a lot of experience has been gathered. The 
medicinal value of some of the herbs used in TCM has already been confirmed by 
modern scientific research. TCM is also a vast source of fascinating novel chemical 
structures which could be used as a rational for designing more ideal synthetic or 
semisynthetic new drugs (Han, 1988). In recent decades, many pharmacological 
functions have been suggested by experimental research. 
Figure.1.4. Some ingredients of traditional Chinese medicine 
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More than 3000 single chemical compounds with novel structures have been 
identified from TCM since the 1950s and several of them are now used as 
medicines, including artemether, salvicine, huperzine A and depside salts (Wang et 
al., 2007).  
1. 3. 3. 2. TCM drugs as cancer therapeutics 
TCM are a rich source of potential anticancer agents (Han, 1988). Several powerful 
anticancer drugs have been found including arsenic trioxide, indirubin, 
camptothecin, vinblastine, vincristine and etoposide (VP-16). 
Tan et al., (2008) claimed TCM has been used to treat colorectal cancer for around 
6000 years. Currently several TCM remedies are being used in clinics in China 
during perioperative period to relive the patients of surgical stress, intestinal 
obstruction and urinary retention after rectal surgery in combination with western 
medicine. 
Arsenic trioxide has been a component of TCM for more than 2000 years. Currently 
it is sold under the trade name Trisenox (manufacturer: Cephalon). Arsenic trioxide 
is a chemotheraputic agent of idiopathic function used to treat leukemia that is 
unresponsive to "first line" agents. It kills cancer cells by inducing apoptosis, shows 
antiproliferative activity, and inhibits angiogenesis (Miller, Jr. et al., 2002). 
Indirubin is the active ingredient of Danggui Longhui Wan, a mixture of plants that 
is used in traditional Chinese medicine to treat chronic diseases including 
myelogenous leukemia. Indirubin inhibits cyclin-dependent kinases (CDKs) and 
induces cell cycle arrest and apoptosis in human colorectal cancer cells (Kim et al., 
2009). 
Camptothecin is a cytotoxic quinoline alkaloid which inhibits the DNA enzyme 
topoisomerase I (topo I). It was discovered in 1958 by M. E. Wall and M. C. Wani in 
systematic screening of natural products for anticancer drugs (Wall & Wani, 1996). 
Currently two Camptothecin analogues Camptosar (irinotecan) and Hycamtin 
(topotecan) are used in chemotherapy of lung, ovarian, cervix and advanced 
colorectal cancer (Lorence & Nessler, 2004). 
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Salvianolic acid B, Oxymatrine and Tetrandrine are undergoing clinical trials in 
China for the treatment of liver fibrosis and cancer. Glycyrrhizin, triptolide, 
celastrol and berberine show anti-inflammatory and antineoplastic activity both in 
in vitro and in vivo studies (Luk et al., 2007). 
1. 3. 4. Our investigations on TCM drugs 
Our project is in collaboration with Prof. Xiaojiang Hao, Kunming Institute of 
Botany, the Chinese Academy of Sciences, Kunming, China. Two hundred and fifty 
three extracts from 76 TCM plants were tested for antitumor activity against 
leukemia cells and 23 (9%) of these reduced the cell growth significantly (Efferth et 
al., 2008). Further analysis lead to the identification of 25-O-acetyl-23,24-dihydro-
cucurbitacin F (Quisqualis indica) and miltirone  as the most promising compounds. 
In another study 22 TCM compounds were tested for their activity against leukemia 
cell lines. Homoharringtonine, artesunate and bufalin showed potent anticancer 
activity. Artesunate and bufalin also increased uptake of daunorubicin 
(chemotherapeutic agent) in multidrug-resistant leukemia cells (Efferth et al., 
2002a). Cantharidin, an active principle ingredient of Mylabris, was found to cause 
oxidative stress that provoked DNA damage and p53-dependent apoptosis in 
leukemia and lymphoma cell lines (Efferth et al., 2005). Recently, 734 TCM 
compounds were screened for their specific activity against 60 cell lines of different 
tumor origin. 531 of these were cytotoxic to tumor cells. A database for these 
compounds was also established (Konkimalla & Efferth, 2008). 
1. 4. Aim of the present thesis  
The role of NER in modulation of cancer risk and therapy is not well understood. 
Therefore, the first part of this thesis focuses on the role of NER in modulation of 
laryngeal cancer risk. A major reason for our study is that reports on NER and 
laryngeal cancer risk are rare (Hall et al., 2007; An et al., 2007). Recent studies 
mainly focused on lung, bladder or breast cancer (Table.1.2). The table summarizes 
SNPs present in NER genes which were reported to be associated with increased 
cancer risk, their position in the gene and their reported risk allele. We suggested 
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that individuals carrying these repair gene SNPs are generally at higher cancer risk 
for cancers with an etiology strongly related to external carcinogen exposure such 
as smoking, as it is the case for laryngeal cancer. To increase our knowledge on this 
type of cancer, we established a population-based case-control study with 257 
laryngeal cancer patients and 769 population-based controls recruited in the Rhein-
Necker-Odenwald region southwest of Germany. We measured 11 SNPs (Table.1.4) 
present in seven NER genes (XPC, RAD23B, ERCC1, ERCC2, ERCC4, ERCC5 and 
ERCC6), and evaluated that three of these SNPs located in ERCC5, ERCC6 and 
RAD23B modified laryngeal cancer risk. 
The second part of the thesis deals with the question how NER affects cancer 
therapy. As NER deficiencies are frequent in different tumor types (Table.1.3), and 
we aim to target NER deficient tumor cells to improve the therapeutic response. To 
deal with the question, two key NER genes i.e., XPC and ERCC6 were selected. In 
the light of increased demand for new therapies, the precious source of TCM drugs 
is being explored for compounds specifically targeting XPC and ERCC6 deficient 
cells. Both these genes become active at a very early stage of damage recognition. 
Table.1.1 shows XPC is involved only in GGR whereas ERCC6 is involved only in TCR. 
Selection of these genes enables to screen for TCM drugs specifically effecting one 
or both sub-pathways. Appropriate cell lines deficient in XPC and ERCC6 genes 
were used. A total of 72 TCM drugs (pure compounds; saturated solutions) were 
analyzed for their cytotoxic activity against two NER deficient cell lines i.e., XP3BE 
and GM10902 and a normal cell line GM01310. Depending on the effect and 
available amount, 6 drugs were selected for further analysis and their IC50 values 
(by dose-response curves), effects on cell cycle distribution (FACs) and DNA 
damage induction were measured. Results obtained for the most promising 
compound ‘Ascaridol’ were validated in a second cellular model. Ascaridol was also 
characterized for its ability to generate oxidative DNA damage. 
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Table.1.4. Cancer associated SNPs in NER genes which were analyzed in the Rhein-Neckar Odenwald larynx cancer study. 
Genea 
db SNP cluster 
IDb 
Polymorphismb 
Nucleic acid, amino acid 
Exonb 
Rare allele 
frequency c 
(published) 
Risk Allele 
Cancer Associations reported for head and neck, lung and other 
cancer types 
XPC rs2228001 A/C, Lys939Gln Ex16 0.41 C Huang et al., 2006; Shen et al., 2005; Sanyal et al., 2004 
RAD23B rs1805329 C/T, Ala249Val Ex.8 0.15 T Shen et al., 2005 
ERCC6 rs4253211 G/C, Arg1230Pro Ex.19 0.11 - no associations reported 
 rs2228527 A/G, Arg1213Gly Ex.19 0.20 G Berndt et al., 2006; Mechanic et al., 2006 
ERCC2 rs238406 A/C, Arg156Arg Ex.6 0.49 AA 
Shen et al., 2005; Yin et al., 2005; Yin et al., 2007; Garcia-Closas et al., 
2006; Vogel et al., 2001 
ERCC1 rs11615 T/C, Asn118Asn Ex4 0.35 TT 
Kiyohara & Yoshimasu, 2007; Zienolddiny et al., 2006; Matullo et al., 
2005 
 
 
rs3212986 C/A, C8092A 196bp 3' of STP 0.23 CC Sturgis et al., 2002; Chen et al., 2000 
 rs3212961 C/A, IVS5+33 Intron 5 0.13 AA Garcia-Closas et al., 2006 
ERCC4 rs1800067 G/A, Arg415Gln Ex8 0.074 A Mechanic et al., 2006; Lockett et al., 2005 
ERCC5 rs17655 G/C, Asp1104His Ex.15 0.27 GG 
Kiyohara & Yoshimasu, 2007; Cui et al., 2006; Mechanic et al., 2006; 
Sanyal et al., 2004 
 rs1047768 T/C, His46His Ex2 0.45 CC Kiyohara & Yoshimasu, 2007; Zienolddiny et al., 2006 
a Genes are arranged according to their position in NER pathway. 
b SNP500Cancer Database and NCBI; For each polymorphism nucleotide, codon number and amino acid change, if adequate, is provided. 
c NCBI. European Caucasian population NCBI Reference Assembly, CEU_GENO_PANEL. 2007; Available from: URL: www.ncbi.nlm.nih.gov 
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2. Materials and Methods 
2. 1. Materials 
2. 1. 1. Equipment 
Name  Manufacturer 
384 well plates (PCR) Steinbrenner Laborsystems GmBH 
96 well plates (PCR) Becton Dickinson 
Agilent 2100 bioanalyzer Agilent Technologies, Inc., Palo Alto, 
USA 
Biophotometer  Eppendorf AG, Hamburg 
Blunt 20-gauge needle (BD MicrolanceTM 
3) 
Becton Dickinson 
Cell culture plates (6, 24, 96 well) Greiner Bio-One GmbH, Frickenhausen 
Cellcoat - Collagen Type 1 coated plates 
(6, 24, 96 well) 
Greiner Bio-One GmbH, Frickenhausen 
Cellstar cell culture flaskes, 50 ml (T25), 
250 ml (T75) 
Greiner Bio.One GmbH, Frickenhausen 
Centrifuge 5402  Eppendorf AG, Hamburg 
Centrifuge 5415C  Eppendorf AG, Hamburg 
Classic E.O.S. (Type 5270/100) AGFA 
CO2 Incubator Jouan IG 150 Astel SA, Chateau Gontier, Frankreich 
Color printer with cartridge  Migge, Heidelberg 
Combitips plus (0.2, 0.5, 1.0, 10 ml) Eppendorf AG, Hamburg 
Comet Slides Trevigen/AMS, Wiesbaden 
Cover slips (24 x 70 mm) Menzel, Braunschweig 
Cryo 1°C Freezing Container Nalge Europe Ltd., Neerijse, Belgium 
Cryovials (2 ml, 5 ml) Greiner Bio-One GmbH, Frickenhausen 
CytoFlour multi well plate reader, series 
4000 
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Name  Manufacturer 
Digital camera (NV8, Samsung) Staurn, Mannheim 
Disposable cuvettes Brand GmbH, Wertheim 
Electrophoresis power supply EPS 300  
Amersham Pharmacia Biotech GmbH, 
Freiburg 
Electrophoresis power supply EPS 3500  
Amersham Pharmacia Biotech GmbH, 
Freiburg 
FACSCalibur flow cytometer Becton Dickinson Biosciences 
Filter tips, sterile 
(10, 20, 100, 200, 1000 μl) 
Nerbe Plus GmbH, Winsen/Luhe 
Fluorescent microscope (Laborlux 11) Leica 
Horizontal electrophoreses gel chamber  
Renner GmbH, Dannstadt-
Schauernheim 
HP Scanjet 8290  Hewlett-Packard GmbH, Böblingen 
Hypercassette Amersham GE  Healthcare, Munich 
Hyperfilm Amersham Biosciences, Little Chalfont, UK 
Invitrolon PVDF membrane Invitrogen GmbH, Karlsruhe 
Light microscope (Diavert) Leica 
LightCycler 480 Roche Diagnostics GmbH, Mannheim 
Mastercycler ep Eppendorf AG, Hamburg 
Micro wave MT 832C  Robert Bosch GmbH, Stuttgart 
Minifuge T  Heraeus, Hanau 
Minifuge Universal  Hettich, Tuttlingen 
Multi dispencer - Multipette® Stream Eppendorf AG, Hamburg 
Multi-channel pipettes 
(0.5 – 10, 10 – 100 μl) 
Eppendorf AG, Hamburg 
Nanodrop spectrophotometer (ND1000) PeQlab biotechnologie GmBH 
Neubauer-counting chamber Migge, Heidelberg 
NuPAGE Novex Bis-Tris Gels Invitrogen GmbH, Karlsruhe 
pH-Meter pH 211 Hanna Instruments Deutschland 
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Name  Manufacturer 
GmbH. Kehl am Rhein 
Pipette aid TecNoMara, Ruhberg 
Pipette tips (unsterile, without filter; 10, 
20, 200, 1000 μl) 
Starlab GmBH, Attrensburg 
Pipettes 
(0.1 - 2.5, 0.5 – 10, 2 – 20, 10 – 100, 20 – 
200 and 100 - 1000 μl) 
Eppendorf AG, Hamburg 
Powerpack 25  Whatman Biometra GmbH, Göttingen 
Reaction tubes (0.2, 0.5, 1.5 and 2.0 ml) Eppendorf AG, Hamburg 
RNase-free syringe (BD DiscarditTM II) Becton Dickinson Labware, Heidelberg 
Round bottom tubes (5, 14 ml) Becton Dickinson Labware, Heidelberg 
Serological pipettes 
(2, 5 and 10 ml) 
Corning B.V. Life Sciences, Schiphol-
Rijk, Niederlande 
Shaker Duomax 1030 Heidolph Instruments GmbH, 
Schwabach 
Single use weighing boats (7 ml, 100 ml) Neolab, Heidelberg 
SpectraMax: GEMINIXS microplate 
Fluorometer 
Molecular devices 
Sterile filter (0.2 μM, 0.45 μM)  Millipore, Molsheim 
Sterile Werkbank Biogard Hood KL II Baker, Stanford, USA 
Thermomixer Comfort Eppendorf AG, Hamburg 
UV-Densitometer Herolab, Wiesloch 
UV-Kuvettes mikro Brand GmbH, Wertheim 
Vertical electrophoresis gel chamber ‘X 
Cell Sure Lock’ 
Invitrogen, Karlsruhe 
Vortex Genie 2  Bender & Hobein, Zürich, Schweiz 
Water bath WG  Neolab, Heidelberg 
Weighing machine A200S  Sartorius AG Göttingen 
Weighing machine Typ 1518  Sartorius AG, Göttingen 
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Name  Manufacturer 
Wide bore Tips (200 μl) Stratagene, La Jolla, USA 
2. 1. 2. Chemicals 
Name  Manufacturer 
0.5 X LightCycler480 genotyping master 
mix  
Roche Applied Sciences 
10 X PCR buffer Qiagen, Hilden, Germany 
10% NuPAGE precast Bis-Tris 
polyacrylamide mini-gels (1.5 mm X 10 
well) 
Invitrogen GmbH, Karlsruhe 
6 X DNA gel loading dye MBI Fermentas GmbH, St. Leon 
Absolute Ethanol  Sigma Aldrich Chemie GmbH, Munich 
Agarose, low melting (SeaPlaque®GTG® 
agarose) 
Biozym Diagnostics, Hameln 
Agarose, PeqGold Universal Agarose  PeqLab, Erlangen 
BD FACS Flow Becton Dickinson Labware, Heidelberg 
BD FACS Rinse Becton Dickinson Labware, Heidelberg 
Benzonase nuclease Merck, Darmstadt 
BioRad protein assay Bio-Rad Laboratories, Munich 
BSA New England biolabs 
Complete Mini, Protease Inhibitor Cocktail 
Tablets 
Roche Diagnostics GmbH, Mannheim 
DharmaFECT-4 (DF4) Dharmacon 
Diethylpyrocarbonat (DEPC) Sigma-Aldrich Chemie GmbH, Munich 
Dimethylsulfoxid (DMSO)  Merck, Darmstadt 
DL-Dithiothreitol (DTT) Sigma-Aldrich Chemie GmbH, Munich 
DNA damage quantification assay-AP site 
counting kit 
DOJINDO molecular technologies, Inc. 
dNTP mixture  MBI Fermentas GmbH, St. Leon-Rot 
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Name  Manufacturer 
(dTTPs, dATPs, dCTPs, dGTPs) 10 mM  
Dulbecco's modified Eagle's medium (DME) Sigma-Aldrich Chemie GmbH, Munich 
Ethidium bromide (1 mg/ml),  Bio-Rad Laboratories GmbH, Munich 
Ethylene diamine tetraacetic acid 
Disodium-solution (EDTA-Na2), 0,5 M 
Sigma-Aldrich Chemie GmbH, Munich 
Fetal calf serum (FCS) PAA, Pasching, Österreich 
Flare buffer Trevigen 
Fluorescein-siRNA New England Biolabs 
Fpg solution New England Biolabs 
GAPDH siRNA (nM) Dharmacon 
Hyromycin B (1g) GERBU biotechnik GmBH, Gaiberg 
Isopropanol Sigma-Aldrich Chemie GmbH, Munich 
L-Glutamin 200 mM Invitrogen GmbH, Karlsruhe 
LightCycler FastStart DNA Master SYBR 
Green I Kit  
Roche Diagnostics GmbH, Mannheim 
LIVE/DEAD® Viability/Cytotoxicity assay Invitrogen 
Magic Mark XP, Western protein standard Invitrogen GmbH, Karlsruhe 
Methanol Sigma-Aldrich Chemie GmbH, Munich 
MgCl2 Qiagen, Hilden, Germany 
Milk powder Carl Roth GmbH, Karlsruhe 
NEBuffer-1 New England Biolabs 
NuPAGE antioxidant Invitrogen GmbH, Karlsruhe 
NuPAGE LDS sample buffer (4 x) Invitrogen GmbH, Karlsruhe 
NuPAGE MOPS SDS buffer (20 x) Invitrogen GmbH, Karlsruhe 
NuPAGE sample reducing agent (10 x) Invitrogen GmbH, Karlsruhe 
NuPAGE transfer buffer (20 x) Invitrogen GmbH, Karlsruhe 
ON-TARGETplus ERCC6 SMARTpool Dharmacon 
Penicillin-Streptomycin-solution (10.000 
units/μl) 
Invitrogen GmbH, Karlsruhe 
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Name  Manufacturer 
Phenyl methyl sulfonyl fluorid (PMSF)  Sigma-Aldrich Chemie GmbH, Munich 
Phosphate buffered saline (PBS) Invitrogen GmbH, Karlsruhe 
Propidium iodide (PI) Sigma-Aldrich Chemie GmbH, Munich 
pUC19 DNA/MspI (HpaII) Marker, 23 MBI Fermentas, St. Leon 
Q solution  Qiagen, Hilden, Germany 
QIAamp DNA blood Midi kit  Qiagen GmbH, Hilden 
QIAquick Gel extraction kit Qiagen GmbH, Hilden 
QIAquick PCR purification kit  Qiagen GmbH, Hilden 
QuantiTect SYBR Green PCR kit Qiagen GmbH, Hilden 
Random hexamer primers Thermo Fisher Scientific GmbH, Ulm, 
Germany 
Ribonuclease (RNase) Sigma-Aldrich Chem. GmbH, Munich 
RNasin Ribonuclease inhibitor 40 units/μl  Promega GmbH, Mannheim 
RNeasy Mini Kit Qiagen GmbH, Hilden 
Roswell Park Memorial Institute medium 
(RPMI) 1640 
PAA Laboratories GmBH, Pasching, 
Austria 
Sodium chloride (NaCl) Sigma-Aldrich Chemie GmbH, Munich 
Sodium dodecyl Sulfate (SDS) Sigma-Aldrich Chemie GmbH, Munich 
Sodium hydroxide (NaOH) Sigma-Aldrich Chemie GmbH, Munich 
ß-Mercaptoethanol Sigma-Aldrich Chemie GmbH, Munich 
Superscript III - Reverse Transcriptase (200 
units/μl) 
Invitrogen GmbH, Karlsruhe 
SYBR-Green I Moleculare Probes, Leiden 
Taq DNA polymerase (5 units/μl)  Qiagen GmbH, Hilden 
Trishydroxymethylaminomethan (Trizma 
base)  
Sigma-Aldrich Chemie GmbH, Munich 
Triton X-100 Sigma-Aldrich Chemie GmbH, Munich 
Trypsin-EDTA Invitrogen GmbH, Karlsruhe 
Tween 20 Sigma-Aldrich Chemie GmbH, Munich 
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Name  Manufacturer 
ultraPURETM Water, DNase, RNase frei  Invitrogen GmbH, Karlsruhe 
Western Lightning Chemiluminescence 
Reagent Plus 
Perkin Elmer, Life Sciences, Inc., 
Boston, USA 
2. 1. 3. Primers 
Primers for genotype analysis were obtained from TIB MOLBIOL GmbH, Berlin. 
Other primers were obtained from Thermo Fisher Scientific Inc. 
Table.2.1. Primers for genotype analysis 
Gene Polymorphism Sequence (5´- 3´) Annealing 
temp. (°C) 
Primer ratio 
for real 
time PCR 
XPC Lys939Gln GCC TCA AAA CCG AGA AGA TGA 
CTC GTC TCC CCT GAC CC 
61 5:1 
RAD23B Ala249Val TTA CAG GGA ATC CCT GGA GAT AGA 
TCC CCA TCC AGA AGA TTC C 
60 1:1 
ERCC6 Arg1230Pro 
GCA CAA GTC AAA AAC AAA ACA TCA 
ATC CCT GTG GCA AAC GTA TC 
60 1:1 
ERCC6 Arg1213Gly 
ERCC2 Arg156Arg CAC AGC CTC ACA GCC TCC TAT GT 
TCA TCC AGG TTG TAG ATG CCA 
59 1:1 
ERCC1 Asn118Asn GGC CCT GTG GTT ATC AAG G 
TTC CTG AAG TCT GGG GTG G 
57 1:1 
ERCC1 C8092A CCT GAA GCC AGG GCA ACT 
AGC TGC CAA GGA AAC CC 
60 1:5 
ERCC1a IVS5+33 GCT GCT CCC TAG CCA G XT C 
LC- RED640-3´ 
CCA TGT CAT CTC AGA TGT GAA AAA C 
59 3:1  
ERCC4 Arg415Gln CTT CGG GTG AAG GAA TAA G 
TTC TCA AAG GTT TTC CTG TAG 
58 1:1 
ERCC5 Asp1104His TTT CAG ATT CTA AAC GAA AGA ATA 
GAG TTC TGC GAA TCT GAA GCA C 
56 1:1 
ERCC5 His46His AAC AAT TCT CCC AGA TAT TAG C 
GAA AAA ATA AGA GTT TGC AGA G 
59 1:1 
a For ERCC1 IVS5+33 forward primer was labeled with LC-Red640 at 3´position. 
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Table.2.2. Primers used for confirmation of XPC and ERCC6 mutation reported 
in XP3BE and GM10902 
Gene Sequence (5´- 3´) Amplicon size 
[bp] 
Annealing 
temperature (°C) 
XPC 
GGC GAA GAC AAG AGA AAG AAG 
GGT TTG AGA GGT AGT AGG TGT CC 254 57 
ERCC6 
ATC TGG CAA AGA AAG GCT CA 
TTG CAA TCA TTT CCC ACT GA  
245 61 
Table.2.3. Gene specific primers used for relative quantification 
Name Sequence (5´- 3´) 
Amplicon 
size [bp] 
Annealing 
temperature (°C) 
ERCC6  
AAG GAA CAG AGC AAT GAC GAT T  
CTT CTG CCT CCA CCA GTA CAT  
130 60 
GAPDH 
GAG TCC ACT GGC GTC TTC AC 
GTT CAC ACC CAT GAC GAA CA 
120 60 
HPRT1 
TGA CCT TGA TTT ATT TTG CAT ACC 
CGA GCA AGA CGT TCA GTC CT 
102 60 
Table.2.4. Clathrin Primer Sequence 
Name Sequence (5´- 3´) 
Amplicon 
size [bp] 
Annealing 
temperature (°C) 
5’ –Clathrin GAC AGT GCC ATC ATG AAT CC  
TTT GTG CTT CTG GAG GAA AAG AA  
570  56 
3’ –Clathrin GCT CAC ARG GGA ATG TTC AC  
ATG TTG TCA AAG TTG TCA TAA  
550  56 
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2. 1. 4. LCTM Hybridization probes 
LCTM Hybridization probes (Hybprobes) were obtained from TIB MOLBIOL GmbH, 
Berlin. 
Table.2.5. Hybprobes for genotype analysis 
Gene Polymorphism Probe Sequence (5´- 3´)a 
XPC Lys939Gln CTC AGC TCA CAG CTT CTC AAA TGG GAA CA FL-3´ 
5´LC- RED640-GTG GGA AGC TGC TGC TTT CTT TTC CCT TTT GG p 
RAD23B Ala249Val TGA AGA CTG AGG AAC CCC A FL-3´ 
5´LC- RED640-CTA GCT GCT TGA GGG GGG TCA p 
ERCC6 Arg1230Pro CCT TGG CCT CAC TCT TGT TTT CAC TGT C FL-3´ 
5´LC- RED610-GCT TCT GGT AAG GCC TTT TCT TC p 
ERCC6 Arg1213Gly TGG CGT CTC CGC AAT GCT T FL-3´ 
5´LC- RED640-GAG TTC TTA GGC TTT TGC TTT GGT CTC AGA T p 
ERCC2 Arg156Arg CGC AGT ACC AGC ATG ACA CCA GCC T FL-3´ 
5´LC- RED640-CCC CAC TGC CGC TTC TAT p 
ERCC1 Asn118Asn CGC AAC GTG CCC TGG GAA T FL-3´ 
5´LC- RED640-TGG CGA CGT AAT TCC CGA CTA TGT GCT G p 
ERCC1 C8092A GAC AAG AAG CGG AAG CAG CAG C FL-3´ 
5´LC- RED640-GCA GCA GCC TGT GTA GTC TGC CCC C p 
ERCC1b IVS5+33 CCA CTG CAC AAC CTC AAA GCC CTG TGA GA FL-3´ 
ERCC4 Arg415Gln CAT GTT CGG TCA TCA CTT GC FL-3´ 
5´LC- RED610-CAA ATC AGT ACT TGA CCT GAA AAT AGA AAA CA p 
ERCC5 Asp1104His TCA AGT GAA GAT GCT GAA AGT TC FL-3´ 
5´LC- RED640-CTT TAA TGA ATG TAC AAA GGA GAA CAG CTG p 
ERCC5 His46His TCG CCA CGG GAA CTC AAT FL-3´ 
5´LC- RED670-GAA AAT CCT CAT CTT CTC ACT TTG TTT CAT CG p 
a FL-3: probe is labeled with fluorescence at 3´position; 5´LC- RED**: probe is labeled with 
LightCycler-RedTM at 5´position; the position of polymorphism is underlined. 
b For ERCC1 IVS5+33 forward primer was labeled with LC-Red640 at 3´position. 
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2. 1. 5. Restriction enzymes 
Restriction enzymes were obtained from New England biolabs. 
 
Table.2.6. Restriction enzymes for genotype analysis 
Gene Polymorphism Restrictio
n enzyme 
Restriction site Sequence around SNP 
Wild type allele Variant allele 
RAD23B Ala249Val Ban11 5´…G  R G C YC …3´ 
3´…C Y C G R  G…5´ 
5´….. TGGGGCT CCT….3´ 5´….. TGGGGTT×CCT…..3´ 
ERCC6 Arg1230Pro Hae111 5´…G GC C…3´ 
3´…C C G G…5´ 
5´…..AGG×CGTTA…..3´ 5´…..AGGCCTTA…..3´ 
ERCC6 Arg1213Gly HpyCH4V 5´…T GC A…3´ 
3´…A CG T…5´ 
5´…..CATTGCAGAGA…..3´ 5´…..CATTG×CGGAGA…..3´ 
ERCC2 Arg156Arg Fnu4H1 5´…G CN G C…3´ 
3´…C G   NC G…5´ 
5´…..ACTGC×CGATTC…..3´ 5´…..ACTGCCGCTTC…..3´ 
ERCC1 IVS5+33 MspI 5´… CC G G …3´ 
3´… G  G CC …5´ 
5´…..GCCTCACCGGGCTT….
.3´ 
5´…..GCCTCAC×AGGGCTT….
.3´ 
ERCC4 Arg415Gln XmnI 5´…GAANNNNTTC…3´ 
3´… CTTNNNNAAG…5´ 
5´..ACCGAACATGTTCCCA..
3´ 
5´...ACCAAACA×TGTTCCCA..
3´ 
ERCC5 Asp1104His Nla111 5´…  C A T G…3´ 
3´…G T A C  …5´ 
5´…..GAAGATG×CTG …..3´ 5´…..GAACATGCTG…..3´ 
ERCC5 His46His Nla111 5´…  C A T G…3´ 
3´…G T A C  …5´ 
5´…..CGCCATGGGA…..3´ 5´…..CGCCACG×GGA…..3´ 
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2. 1. 6. Cell lines  
 The cell lines were obtained from Coriell Cell Repositories. 
 
2. 1. 7. Traditional Chinese medicine compounds 
Seventy-two drugs (saturated solutions) derived from traditional Chinese medicine 
(TCM) and their solvents are given in Table.8.2. 
  
Table.2.7. Cell lines analyzed for TCM sensitivity 
Cell line / Coriell code Cell type Gene defect 
GM01310 B lymphocytes Normal 
GM10902 B lymphocytes ERCC6 deficient cell line, carries a point 
mutation (C2282T) generating a pre-
mature stop codon and a truncated 
protein (734 amino acids) (Colella et al., 
2000). 
XP3BE / GM02248 B lymphocytes XPC deficient cell line, carrying an 83bp 
insertion following codon Lys90, causing 
a frame shift mutation and generating a 
pre-mature stop codon (Li et al., 1993). 
XP4PA / GM15983 Fibroblast XPC deficient cell line, harbours a 
dinucleotide (TG) deletion at position 
1483-1484 causing a frameshift at codon 
Val431 and a premature stop codon (Li et 
al., 1993). 
XP4PA-SE2 / GM16248 Fibroblast Fully corrected form of XP4PA by stable 
transfection using pXPC-3 plasmid 
(Emmert et al., 2000; Legerski & 
Peterson, 1992). 
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2. 1. 8. Computer Softwares and Databases 
Name Link / Provider 
Adobe Photoshop 7.0  Adobe Systems Inc., San Jose, USA 
CellQuestPro Software Becton Dickinson Biosciences 
Ensembl Genome Browser http://www.ensembl.org 
Estimating Haplotypes EH (Version 
1.2) 
Rockefeller University, New York 
Heidelberg Unix Sequence Analysis 
Resources 
http://husar.dkfz-heidelberg.de  
Image J (version 1.41o) Rasband, NIH, USA 
Komet 4 Software Kinetic Imaging Ltd., Liverpool, UK 
LightCycler Software (version 1.5.0) Roche Diagnostics GmbH, Mannheim 
Microsoft Office 2007 Microsoft Corporation 
National Center for Biotechnology 
Information (NCBI) 
http://www.ncbi.nlm.nih.gov 
PHASE v 2.2.1.1 Software  Code by M Stephens, 
http://www.stat.washington.edu/ 
stephens/phase/download.html 
SAS (version 9.2) SAS Institute, Inc., Cary, North Carolina, 
USA 
Sequencing - bi-directional ‘single run 
- Run24’  
GATC Biotech AG 
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2. 2. Methods 
2. 2. 1. NER and cancer risk 
2. 2. 1. 1. Study population 
Study population (Table.2.8) was collected by our collaborators in this project and 
has been published as Becher et al., (2005). This population-based case control 
study was carried out in the Rhein-Neckar-Odenwald region, south west of 
Germany comprising the cities of Heidelberg, Mannheim, Ludwigshafen, Darmstadt 
and Heilbronn, with a population of about 2.7 million. Treatment of laryngeal 
cancer is only done in the clinics of these cities. Larynx cancer patients coming to 
these clinics between 1998 and 2000 were obtained. Local practitioners were 
additionally contacted to check for possible cases sent to other more distant clinics 
and to verify complete case ascertainment. Incidence rates in districts within the 
study were calculated and compared internally and with incidence rates from a 
cancer registry in a neighbouring state (Saarland). Cases and controls were 
restricted to German Caucasians aged up to 80 who were registered as citizen in 
the study region. 
Histologically-confirmed cases (n = 257; 236 males, 21 females; ages: 36 – 80 years) 
effected with squamous cell cancer of larynx were contacted through their 
physician. Eleven cases refused participation, and 20 patients could not be 
interviewed because of speaking impairment or poor health status (response rate 
89.2 %). Ethical clearance was received by the ethical committee of the University 
of Heidelberg and informed consent was obtained from the participants through 
collaborating physicians.  
Randomly selected population controls (n = 1233; case-control ratio of 1:3, 
matched for age and gender) with no previous or present record of head and neck, 
esophageal or lung cancer were contacted. 769 controls completed interviews 
(response rate 62.4 %). All interviews were conducted by five well-trained 
interviewers under standardized conditions, who interviewed both cases and 
controls at similar proportions. Information on smoking, alcohol consumption, 
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occupational exposure, family history of cancer and nutrition was collected with a 
comprehensive, standardized questionnaire. Overall 253 of 257 cases and 664 of 
769 controls provided blood samples. A complete data set and DNA was finally 
available for 248 (96.4%) cases and 647 (84.1%) controls. A profile of non-
responders has not been created. However, the fact of non-participation can be 
assumed to be independent from the genotypes, thus, a non-responder bias is not 
expected. Blood buffy coats were stored at – 80 °C until DNA extraction. 
Table.2.8. Characteristics of larynx cancer cases and controls 
Characteristics Cases  Controls 
 Male Female  Male Female 
 n (%) n (%)  n (%) n (%) 
 Age (years)  
36-45 8 3.4 2 9.5  22 3.1 8 11.9 
46–55 40 16.9 4 19.0  122 17.4 17 25.4 
56–65 93 39.4 8 38.1  277 39.5 19 28.4 
66–75 81 34.3 5 23.8  225 32.1 16 23.9 
76-80 14 5.9 2 9.5  56 8.0 7 10.4 
 Smoking (pack-years)  
≤20 34 14.4 9 42.9  446 63.5 58 86.6 
>20 202 85.6 12 57.1  256 36.5 9 13.4 
 Alcohol consumption (g ethanol/day)  
≤25 57 24.2 12 57.1  303 43.2 51 76.1 
>25–50 51 21.6 4 19.0  169 24.1 9 13.4 
>50 128 54.2 5 23.8  230 32.8 7 10.4 
 Educational level (years of school education)  
9 or less 206 87.3 18 85.7  436 62.1 43 64.2 
10 16 6.8 2 9.5  105 15 15 22.4 
More than 10 14 5.9 1 4.8  161 22.9 9 13.4 
Total 236 100 21 100  702 100 67 100 
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2. 2. 1. 2. DNA extraction 
Genomic DNA was extracted using QIAamp DNA blood midi kit (Qiagen, Hilden, 
Germany) by our technician. Optical densities of DNA samples were measured on a 
Biophotometer (version 1.35, eppendorf) and concentration of the stock solutions 
was set to 40 ng/ml. For genotyping, DNA dilutions (10 ng/ml) were prepared in 96 
well plates, making it easy to work with 96 well plate format of light cycle 480 (LC-
480). Three negative control (dH2O) samples were placed in every fourth column of 
each plate. Samples were stored at 4°C until genotyping. 
2. 2. 1. 3. Genotyping analysis 
2. 2. 1. 3. 1. Single nucleotide polymorphisms (SNPs) 
For genotyping, 11 SNPs in 7 NER genes XPC, Rad23B, ERCC1, ERCC2, ERCC4, ERCC5 
and ERCC6 (Table.1.4.) were selected. The SNPs had a reported rare allele 
frequency of > 10% in Caucasians, with exception of ERCC4 Arg415Gln with a rare 
allele frequency of 7.4 %. Among the selected SNPs, seven are non-synonymous, 
three are synonymous and one intronic. Selection favored SNPs with evidence for 
association with cancer risk reported for head and neck and lung cancer, or any 
type of cancer.  
2. 2. 1. 3. 2. Optimization of PCR conditions 
The PCR protocol for three SNPs XPC Lys939Gln, ERCC1 Asn118Asn and C8092A was 
already set in the Lab. Methodology for all other SNPs was established during the 
present study. A generalized starting recipe of the PCR reaction mixture and cycling 
conditions used for optimization is given in Table.2.9 and 2.10. PCR was performed 
at a suitable annealing temperature gradient on Mastercycler (Eppendorf). The 
suitable temperature gradient was defined by the calculated melting temperature 
(Tm) of the primers ± 5 °C. Tm was calculated by the formula given below. 
Tm = [(G + C) X 4] + [(A + T) X 2]. 
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Amplified samples were checked for the expected sizes on 1.5 % Agarose gel in 1 X 
TAE buffer. pUC19 DNA/MspI M,23 (Fermentas) was used as a size reference. The 
best suited annealing temperature was selected. If there was need of further 
optimization varying concentrations of MgCl2 (1.5mM, 2.0mM, 2.5mM) were used. 
The list of primers optimized for genotyping the SNPs is provided in Table.2.1. 
 
Table.2.9. PCR reaction mixture 
Reagent Final concentration 
DNA template 20 ng 
10 X PCR buffer (Qiagen) 1 X PCR buffer 
MgCl2 1.5 mM 
10 µM dNTPs 0.2 µM dNTPs 
5 µM Forward Primer 0.5 µM 
5 µM Reverse Primer 0.5 µM 
5U Taq polymerase (Qiagen) 0.5U 
ultraPURETM H2O To fill up the volume 
Final reaction volume 20 µl 
 
 
 
Table.2.10. PCR cycling conditions 
 Step Temperature time 
1 cycle initial denaturation 95°C 3 min 
35 cycles i- denaturation 95°C 25 sec 
 ii- Annealing suitable temperature gradient 25 sec 
 iii- extension 72°C 25 sec 
1 cycle elongation 72°C 5 min 
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2. 2. 1. 3. 3. Optimization of real time PCR 
For optimization of real time PCR, different primer ratios (1:1, 1:5), suitable 
concentration of LCTM Hybridization probes (Hybprobes) to be detected on LC-480 
and varying concentration of MgCl2 were considered. A generalized starting recipe 
of the PCR reaction mixture and cycling conditions used for optimization is given in 
Table.2.11 and 2.12. 
 
Table.2.11. PCR reaction mixture for real time PCR  
Reagent Final concentration 
DNA template 10 ng 
10 X PCR buffer (Qiagen) 1 X PCR buffer 
MgCl21 1.5 mM  
10 µM dNTPs 0.2 µM dNTPs 
5 µM Forward Primer 0.5 µM 
5 µM Reverse Primer 0.5 µM 
2 μM sensor probe 0.2 µM 
2 μM anchor probe 0.2 µM 
5U Taq polymerase (Qiagen) 0.5U 
ultraPURETM H2O To fill up the volume 
Final reaction volume 10 µl 
1 for XPC Lys939Gln, ERCC1 C8092A and IVS 5+33 2.5 mM MgCl2 was used 
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Table.2.12. PCR cycling conditions for real time PCR 
Program name cycles Analysis mode 
Target temperature 
(°C) 
Acquisition 
mode 
Ramp rate (°C 
/ sec) 
acquisition 
rate (per °C) 
Hold 
Pre-incubation 1 None 95 None 4.4 - 3 min 
amplification 44 Quantification 95 None 4.4 - 10 sec 
   
suitable temperature  
(Table.2.1) 
Single 2.2 - 15 sec 
   72 None 4.4 - 12 sec 
Melting curve 1 Melting curves 95 None 4.4 - 1 min 
   40 None 2 - 1 min 
   80 Continuous - 2.5 - 
cooling 1 None 40 none 2.2 - 30 sec 
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2. 2. 1. 3. 4. Validation of optimized conditions 
Optimized PCR conditions were validated by restriction fragment length 
polymorphism (RFLP). RFLP is a technique used to differentiate between 
homologous DNA samples having different restriction sites for a certain restriction 
enzyme. SNP specific restriction enzymes (Table.2.6) were searched at DKFZ HUSAR 
site using the Program MAPSORT. For each SNP, restriction enzymes were selected 
to cut specifically at the SNP site, so that differentiation between wild type, variant 
and heterozygous samples was possible. 20 to 25 samples were amplified by PCR 
(final reaction volume = 20 µl). Digestion mixture for the respective restriction 
enzymes was prepared according to the manufacturer protocol and samples were 
incubated with the mixture for 16 hours at 37 °C. The reaction was inactivated at 
65 °C for 20 min. Digestion products were separated on 3% agarose gel at 100 volt 
for one hour. The selected samples were also genotyped on LC-480. Results 
obtained via both techniques were compared. A 100% concordance of the results 
validated the optimized conditions. 
2. 2. 1. 3. 5. Genotyping by Fluorescence-based Real time PCR 
SNP detection in all 895 samples was performed by real-time PCR on LightCycler 
480 (Roche, Mannheim, Germany) using Hybprobes (Table.2.5). Either mono- or 
multiplex Hybprobe assays were used. Hybprobe detection format is based on 
melting curve analysis and uses fluorescence resonance energy transfer (FRET) for 
analysis of polymorphic sites. It comprises of two sequence-specific oligonucleotide 
probes known as donor and acceptor. Donor probe is labeled with fluorescein 
(excitation at 483 nm) at the 3´-end and acceptor with a LightCycler Red 
fluorophore at the 5´-end. The acceptor probe is also 3´-phosphorylated to prevent 
extension. The probes are specifically designed to bind the target sequences in a 
head-to-tail manner. The probe designed to bind across the SNP site is called 
“sensor” where as the probe designed to hybridize to an adjacent site is known as 
“anchor”. During annealing phase of PCR, the HybProbe pair binds to the 
complementary template. This brings the probes in close proximity. The donor dye 
excites the acceptor fluorophore, hence, producing FRET. As temperature is raised, 
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the probes will melt at their corresponding Tms and no longer produce FRET. This 
melting coincides with a drop in fluorescence signal. The temperature at which the 
sensor probe melts depends on the underlying sequence. Thus, if sensor probe 
binding site carries a SNP, the complex is destabilized and melts at a lower 
temperature compared to the perfect match. Genotyping assays were done 
without knowledge of the clinical diagnosis. 
2. 2. 1. 3. 5. 1. Monoplex Hybprobe assay 
The SNPs XPC Lys939Gln, RAD23B Ala249Val, ERCC1 Asn118Asn, ERCC1 C8092A, 
ERCC1 IVS5+33, ERCC4 Arg415Gln and ERCC5 Asp1104His were genotyped by 
monoplex Hybprobe assay. Table.2.11 and 2.12 gives the recipe for PCR reaction 
mixture and PCR conditions for the genotyping. For XPC Lys939Gln detection, 0.5 x 
Q solution and 0.1% BSA was additionally added to the reaction mixture. Table.2.1 
and 2.5 provide the primer ratio and Hybprobe concentration used in the assays. 
2. 2. 1. 3. 5. 2. ERCC1-IVS 5+33 
The SNP lies in a region full of high binding stem loops. To overcome this problem 
an internally labeled primer (iLC mis; Table.2.1) containing a mismatch was 
designed. Furthermore the sensor probe used has a high Tm value. PCR products 
amplification for the SNP was carried out using 20 ng of DNA, 1 X buffer, 2.5 mM 
MgCl2, 0.2 µM dNTPs, 1 X Q solution, 0.5U Taq polymerase (Qiagen, Hilden, 
Germany), 0.5 µM of iLC mis primer and 0.1 µM of reverse primer and the sensor 
probe, with a final reaction volume of 10 µl. 
2. 2. 1. 3. 5. 3. Multiplex Hybprobe assay 
In two cases, two SNPs were analyzed in one reaction using multiplex Hybprobes.  
ERCC6 Arg1230Pro and ERCC6 Arg1213Gly  
ERCC6 Arg1230Pro and ERCC6 Arg1213Gly are located in the same exon therefore it 
was possible to detect both SNPs using a single pair of primers and two separate 
pairs of probes, labeled with different dyes (RED640 for Arg1230Pro and RED610 
for Arg1213Gly). Recipe for PCR reaction mixture is provided in Table.2.13. 
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ERCC2 Arg156Arg and ERCC5 His46His 
ERCC2 Arg156Arg and ERCC5 His46His are located on different chromosomes, so 
two separate pairs of primers and two differently labeled probe-pairs were used 
(RED640 for ERCC2 Arg156Arg and RED670 for ERCC5 His46His). Recipe for PCR 
reaction mixture is provided in Table.2.14. Cycling conditions were same as 
described earlier and the multiple peaks were resolved by color compensation for 
the respective probes.  
 
  
Table.2.13. PCR reaction mixture For ERCC6 Arg1230Pro and ERCC6 Arg1213Gly 
Reagent Final concentration 
DNA template 10 ng 
10 X PCR buffer (Qiagen) 1 X 
MgCl2 1.5 mM 
dNTPs (10 µM) 0.2 µM 
Primer Mix (5 µM) 0.5 µM 
each probe (2 µM) 0.1 µM 
Taq polymerase (5U / µl; Qiagen) 0.5U 
ultraPURETM H2O To fill up the volume 
Final reaction volume 10 µl 
Table.2.14. PCR reaction mixture for the detection of ERCC2 Arg156Arg and ERCC5 His46His 
Reagent Final concentration 
DNA template 10 ng 
5 X LightCycler480 genotyping master mix (Roche Applied 
Sciences) 
0.5 X 
MgCl2 2 mM 
Primer Mix  for ERCC5 His46His (5 µM) 0.5 µM 
Primer Mix  for ERCC2 Arg156Arg (5 µM) 0.5 µM 
each probe (2 µM) 0.2 µM 
Final reaction volume 10 µl 
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2. 2. 1. 3. 6. Color compensation 
Color Compensation is a tool to calibrate the LightCycler® Instruments. It corrects 
for the spectral overlap of fluorescence channels in multiplex Hybprobe assays. 
Conditions for color compensation are provided in Table.2.15. Figure.2.1 provides 
the plate setup of the different reaction mixtures. The reaction was performed at 
an annealing temperature of 59°C. After the run, Color Compensation data were 
analyzed to generate a color compensation object ‘CC Object’. The ‘CC Object’was 
later used to resolve the complex peaks obtained during multiplex assays. 
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Figure.2.1. PCR plate setup for color compensation 
Table.2.15. PCR reaction mixture for color compensation 
Reagent Final concentration 
 Blank 
Fluorescein-
labeled probe 
Acceptors dye-
labeled probe 
DNA template 10 ng 10 ng 10 ng 
10 X PCR buffer (Qiagen) 1 X 1 X 1 X 
MgCl2 1.5 mM 1.5 mM 1.5 mM 
dNTPs (10 µM) 0.2 µM 0.2 µM 0.2 µM 
Primer mix (5 µM) 0.5 µM 0.5 µM 0.5 µM 
probe (2 µM) - 0.3 µM 1.0 µM 
Taq polymerase (5U / µl; Qiagen) 0.5U 0.5U 0.5U 
ultraPURETM H2O    
Final reaction volume 10 µl 10 µl 10 µl 
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2. 2. 1. 3. 7. Validation of genotyping data 
2. 2. 1. 3. 7. 1. Restriction fragment length polymorphism (RFLP) 
10% of randomly selected samples were repeated and genotyping data was 
confirmed by RFLP. Results obtained were compared with the genotyping data by 
LC-480 by two investigators, independently. A 100% concordance was found.  
2. 2. 1. 3. 7. 2. Sequencing 
As ERCC2 Arg156Arg and ERCC5 His46His were genotyped in multiplex Hybprobe 
assay, they were further validated by sequencing. Six samples were selected, two 
of these were homozygous for wild type allele, two were heterozygous and two 
homozygous for variant allele of each SNP. The samples were amplified following 
standardized PCR protocol and cycling conditions (Table.2.9 & 2.10) with a final 
reaction volume of 50 μl. Samples were separated on 1.5 % TAE Agarose gels at 90 
volts for 1.5 hrs. DNA bands were cut from the gel using a sharp razor and were 
extracted with a QIAquick® Gel extraction kit (Qiagen, Hilden, Germany). Figure.2.2 
shows two samples amplified for ERCC2 Arg156Arg (PCR product size = 221 bp) and 
ERCC5 His46His (PCR product size = 131 bp) in multiplex PCR before (Lane 1, 2) and 
after (Lane 3, 4, 5, 6) agarose gel extraction. Optical densities of the extracted 
samples were measured on a Biophotometer (version 1.35, eppendorf) and their 
concentration was set between 20 to 30 ng / μl. Quality of the extracted samples 
was checked on 1.5 % TAE - Agarose gel (90 volts for 45 min). Samples were sent to 
GATC Biotech AG for sequencing ‘single run - Run24’. Samples were sequenced bi-
directional i.e., by both forward and reverse primers. Results obtained were 100% 
concordant. 
  
Figure.2.2. Lane 1 and 2 represent two samples 
amplified for ERCC2 Arg156Arg (PCR product 
size = 221 bp) and ERCC5 His46His (PCR product 
size = 131 bp). Lane 3, 4, 5 and 6 represent the 
same samples after being cut out of the Agarose 
gel and extracted with a QIAquick® Gel 
extraction kit. M = pUC19 DNA/MspI M,23 
(Fermentas) was used as size reference. 
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2. 2. 1. 3. 7. 3. RAD23B Ala249Val  
As genotyping data for RAD23B Ala249Val deviated from Hardy-Weinberg principle 
(χ2 = 6.28), all the genotyping data for this SNP was rechecked, additional 5% 
samples were genotyped by RFLP, and some of the samples were also sequenced. 
2. 2. 2. NER and cancer therapy 
2. 2. 2. 1. Cell culture 
2. 2. 2. 1. 1. Culture conditions 
GM01310, XP3BE and GM10902 were maintained as suspension cultures in RPMI-
1430 supplemented with 15% FCS and 1% Penicillin (100 units/mI) and 
Streptomycin (100 g/ml) at 37°C in a humidified 5% CO2 atmosphere. Cultures were 
passaged twice a week at 2.5 x 105 cells/ml and grown in T75 culture flasks (250 ml, 
Greiner Bio-One) in vertical posture. 
XP4PA and XP4PA-SE2 were maintained as monolayer cultures in DME (high 
glucose) supplemented with 10% not inactivated FCS, 2mM L-glutamine and 1% 
Penicillin (100 units/mI) and Streptomycin (100 g/ml) at 37 °C in a humidified 8% 
CO2-atmosphere. For XP4PA-SE2 Hyromycin B (0.2 mg/ml) was also added. Cultures 
with 70 to 90% confluency were passaged at 3 x 104 to 3.5 x 104 cells/ml every five 
days by trypsinization with 1 ml 0.5 mM trypsin/EDTA for 1 min at room 
temperature. 
9 to 10 weeks old cultures were discarded and new cells were grown. 
2. 2. 2. 1. 2. Contamination check 
All cultures were controlled for contaminations by multiplex cell contamination test 
through Genomics and Proteomics Core Facility at DKFZ. Samples were tested 
before starting any experiments and after six weeks. Multiplex cell contamination 
test is a high-throughput test and can detect 37 contamination markers for viral 
contamination, mycoplasma, and Cross-contamination by other cell lines in a single 
PCR reaction. 
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2. 2. 2. 1. 3. Freezing 
Cells were collected and counted. The culture media was removed by 
centrifugation (1200 rpm, 5 min, 4 °C) and cell pellets were resuspended in an 
appropriate volume of pre-cooled freezing medium (respective culture medium + 
10% DMSO) to yield approximately ten million viable cells/ml for suspension cell 
culture and 5 X 105 viable cells/ml for adherent cell culture. The cell suspension was 
dispensed in 1-ml aliquots into cryovials (Greiner Bio-One). Samples were frozen 
passively in a pre-cooled (4 °C) isopropanol bath at the rate of -1 °C / min to -80 °C 
placed in a -80°C freezer overnight and subsequently stored in liquid nitrogen.  
2. 2. 2. 1. 4. Thawing 
Cells were recovered by thawing at room temperature and quickly re-suspending 
the vial contents in culture medium. Samples were centrifuged at 1200 rpm for 5 
min at room temperature. Suspension cells were re-suspended in 10 ml medium 
and placed in T25 culture flask (50 ml, Greiner Bio-One) in standing position.  
Adherent cells were resuspended in 5 ml of culture media and placed in horizontal 
position. Samples were allowed to grow at respective culturing conditions. After 
two days 5 to 7 ml of the old media were removed and fresh medium was added. 
Samples were allowed to grow for another two days before being handled as 
normal cell culture.  
2. 2. 2. 1. 5. Doubling time 
Cultures (> 90% viability), 5 X 105 cells/ml for suspension cells and 6 X 104 cells/ml 
for adherent cells, were grown in Petri dishes (35 x 10 mm, Becton Dickinson). 
Number of viable cells was counted on Neubauer-counting chamber via Trypanblue 
staining (Lindl 2002) every 24hrs for seven days. Each time half of the old culture 
medium was also replaced with fresh media. Experiment was repeated three times. 
Growth curves were generated. Number of generations and the doubling time for 
each cell line were calculated using the following formulas 
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N0 is the number of viable cells at time point ‘0’  
N is the number of viable cells at the end of experiment 
 
 
 
N0 is the no. of viable cell at the start of Log phase of cell growth 
Nx is the no. of viable cells at the end of Log phase of cell growth 
 
2. 2. 2. 2. Mutation confirmation 
Mutations reported for the cell lines used in this project were confirmed. GM01310 
was included as normal control. In addition, the cell lines were checked for their 
p53 protein expression. 
2. 2. 2. 2. 1. XP3BE 
The cell line and has an insertion of 83bp at position 462 in the cDNA of XPC leading 
to a frame-shift mutation and generating a pre-mature stop codon (Li et al., 1993). 
Insertion was checked in cDNA by PCR using gene specific primers (Table.2.2) and 
standard PCR protocol (Table.2.16). PCR products were separated on 2% agarose 
gel (90 volts, 45 min). The protein was analyzed by western blotting. 
Table.2.16. Reaction mixture used for confirmation of XPC and ERCC6 mutations 
Reagent Final concentration 
Qiagen 10 x PCR buffer  1 X 
MgCl2 [25mM] 2.0 mM (for ERCC6 only) 
dNTPs (10 mM)  0.2 mM  
Forward Primer (10 μM)  0.5 μM  
Reverse Primer (10 μM)  0.5 μM  
Qiagen Taq DNA Polymerase (5 U/μl)  0.05 U/μl  
ultraPURETM H2O To fill up the volume 
DNA / H2O 0.1 μl/μl of reaction mix  
Total volume 50 μl 
No. of generations = (log N – log N0) / Log 2 
Doubling time = (tx – t0) X log2) / (log Nx – logN0) 
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2. 2. 2. 2. 2. GM10902 
It is an ERCC6 deficient cell line and harbors a point mutation at position C2282T in 
cDNA (Colella et al., 2000). To confirm the mutation, genomic DNA of the cell line 
was sequenced and compared with the sequence of the normal cell line. DNA 
samples were amplified using gene specific primers (Table.2.2) following 
standardized PCR protocol (Table.2.16) with a final reaction volume of 50 μl. 
Amplification was checked on 1.5% Agarose gels (90 volts, 45min). Optical densities 
of the amplified samples were measured on a Biophotometer (version 1.35, 
eppendorf) and final concentration was set to 30 ng/μl. Samples were sent to GATC 
Biotech AG for bi-directional ‘single run - Run24’ sequencing. The protein was 
analyzed by western blotting. 
2. 2. 2. 2. 3. XP4PA and XP4PA-SE2 
The cell lines were checked for presence of XPC and ERCC6 protein by western 
blotting (see 2. 2. 2. 14. 3). 
2. 2. 2. 3. Knockdown experiments 
ERCC6 gene was silenced in XP4PA-SE2 cells using ON-TARGETplus SMARTpool 
(Dharmacon). It is a pool of four individual duplexes and under optimized 
conditions it is guaranteed to silence ERCC6 gene by 75% or more.  
2. 2. 2. 3. 1. Optimization of conditions for transfection 
For effective silencing of the gene following experimental parameters were 
determined: a suitable plating density (cells/ml), a suitable transfection reagent, its 
concentration needed to deliver enough siRNA into the cells to silence the gene 
and the plating effect. The best combination of these parameters was picked for 
the silencing experiments. 
2. 2. 2. 3. 1. 1. Plating density 
As in our experimental setup we need to transfect cells for upto 96hrs after 
transfection, an optimum plating density is required that yields enough cells after 
24hrs for mRNA extraction and after 96hrs cells are still growing in monolayer. 
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Three plating densities were tested for the cell line (2 x 104, 4 x 104, 6 x 104 
cells/ml) and samples were checked for confluency after every 24hr for 96hrs. 6 x 
104 cells/ml was considered as a suitable cell density. 
2. 2. 2. 3. 1. 2. Suitable transfection reagent, its transfection efficiency and plating 
effect 
DharmaFECT-4 (DF4) was suggested by Dharmacon as suitable to deliver siRNA into 
the fibroblast cells. In addition polyFECT (Qiagen) was tested for its efficiency in our 
cells. Exponentially growing XP4PA-SE2 cells (> 90% viability, 6 x 104 cells/ml) were 
incubated with different volumes of DF4 and polyFECT in normal and collagen 
coated plates (Cellcoat, Greiner Bio-One) for 4 and 24 hrs. 15 nM Fluorescein-siRNA 
was used as transfection control (New England Biolabs). Untreated cells were 
included as control. Table.2.17 provides the conditions for the transfection media 
used. The experiment was performed once with five replicates of each treatment. 
 After 4 hrs of incubation (37°C, 8% CO2) samples were observed by fluorescent 
microscope (Laborlux 11, Leica) in blue (wavelength 390 to 490 nm) and white 
light. The number of cells visible in both lights was counted and transfection 
efficiency was calculated as follows.  
 
  
 
For plating effects, cells were grown for 24hrs, cultures were observed under a light 
microscope (Diavert, Leica) and cellular viability was measured by trypan blue 
staining. 
2. 2. 2. 3. 2. General protocol for ERCC6 gene silencing 
ERCC6 gene silencing was performed using the general protocol provided by the 
company. Table.2.18 provides the transfection media used in the experiment. Each 
experiment included the following samples in quadruplicates: 1) ERCC6 siRNA 
Transfection efficiency =                             x 100 
Number of cells visible in blue light  
Number of cells visible in white light 
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(100nM) at two different ratios of DF4 / siRNA (DF4/ERCC6 siRNA – 0.88, 
DF4/ERCC6 siRNA – 1.76), 2) GAPDH siRNA (100nM) as positive control siRNA, 3) 
Luciferase siRNA (100nM) as negative control siRNA, 4) DF4 control and 5) 
Untreated cells. In separate tubes the appropriate volume of siRNA and DF4 were 
mixed gently with serum-free culture medium and incubated for 5min at room 
temperature. The two solutions were mixed and incubated for another 20min at 
room temperature and the required volume of antibiotic-free complete medium 
was added to the mixture. In exponentially growing cells (> 90% viability, 6 x 104 
cells / ml) culture medium was replaced with appropriate volume of transfection 
medium and samples were incubated at 37°C in 8% CO2 for 24 to 96 hrs for both 
mRNA and protein analysis. To avoid cytotoxicity caused by DF4, transfection 
medium was replaced with complete medium after 24 hours. 
 
 
 
 
 
 
Table.2.17. Transfection media used for optimizing transfection efficiency. 
Transfection 
reagent 
Ratio of 
Transfection 
reagent / 
siRNA 
Tube 1 Tube 2 
Medium 
(μl) to be 
added 
Transfection 
Medium (μl) 10 μM 
Fluorescein 
siRNA (μl) 
serum-free 
Medium (μl) 
Transfection 
reagent (μl) 
serum-free 
Medium (μl) 
DharmaFECT
-4 5:1 0.75 49.25 0.54 49.5 400 500 
 
10:1 0.75 49.25 1.08 48.9 400 500 
PolyFECT  8:1 0.75 49.25 0.87 49.1 400 500 
 
16:1 0.75 49.25 1.74 48.3 400 500 
Note: Antibiotics were not added to medium used in transfection experiments. 
c) 
a) 
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2. 2. 2. 4. UV sensitivity 
In exponentially growing cells (> 90% viability) culture media was replaced with PBS 
and cells were exposed to varying intensities of UVC (J/m2) by Stratagene UV- 
StratalinkerTM 2400 and cells were allowed to grow for 48 hrs at normal culture 
conditions. Each experiment included an unexposed sample as a control. Relative 
growth was measured by Calcein assay and growth curves were generated against 
UVc intensity. The experiment was performed twice with three replicates for each 
treatment. 
2. 2. 2. 5. Live / Dead assay 
Fluorescence based ‘LIVE/DEAD® Viability/Cytotoxicity assay’ (Invitrogen) was used 
to measure live and dead cells in the cultures simultaneously. The assay comprises 
two fluorescent dyes, Calcein AM (Cal AM) and Ethidium homodimer (Eth HD). Cal 
AM enters live cells freely and is cleaved by nonspecific cellular esterases into a 
fluorescent product i.e., Calcein (excitation: 485nm, emission: 520nm), which is 
 Table.2.18. Transfection medium used for ERCC6 knockdown.  
  
Ratio of  
DF 4 / 
siRNA1 
Tube 1 Tube 2 
Culture 
Medium (μL) 
to be added 
Transfection 
Medium 
(μL) 
 
2 μM 
siRNA (µl) 
serum-free 
Medium 
(μL) 
DF 41 (μL) 
serum-free 
Medium 
(μL) 
ERCC6 siRNA 0.88 25 25 0.59 49.4 400 500 
ERCC6 siRNA 1.76 25 25 1.18 48.8 400 500 
GAPDH siRNA 1.77 25 25 1.18 48.8 400 500 
Luciferase siRNA 1.77 2.5 47.5 1.18 48.8 400 500 
DharmaFECT 4 
control 
- 0 50 1.18 48.8 400 500 
Untreated cells - 0 50 0 50 400 500 
1DF 4,  DharmaFECT-4 
Note: Antibiotics were not added to the medium used in transfection experiments. 
e) 
c) 
a) 
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retained by intact cells. When excited the dye gives a green fluorescence. Eth HD 
(Ex: 520nm, Em: 620nm) intercalates into nucleic acids and produces a red 
fluorescence. It is a large molecule and can only enter cells with ruptured 
membranes therefore it is ideal for measuring dead cells. The assay allows high-
through put (microtiter plates) screening and is a basic research tool for studying 
apoptosis and cell proliferation. It is also useful for screening compounds that 
induce cytotoxicity. 
A typical experiment included 100% live culture, 100% dead culture and 
experimental samples. Cells not exposed to any treatment were considered as 
‘100% live culture’. ‘100% dead culture’ was prepared by treating cells with 70% 
methanol for 45min. Samples were taken in triplicates on a 96 well plate (Becton 
Dickinson). Cells were washed once with PBS and incubated with the dyes at 37 °C 
for 30 min. As controls, ‘mix dye’, ‘Cal AM only’, and ‘Eth HD only’ solutions were 
included. Fluorescence was measured on SpectraMax: GEMINIXS microplate 
Fluorometer (Molecular devices). Before calculations, fluorescence from the dyes 
was subtracted from respective sample readings. Percentage viability was 
calculated relative to unexposed sample and percentage of dead cells was 
calculated relative to 100% dead culture. Calculations were done by using following 
formulas. 
 
F(520)max: Reading for 100% live culture + mix dye  
F(520)min: Reading from 100% dead sample + mix dye  
F(520)sam: Reading from experimental sample  + mix dye  
F(620)max: Reading for 100% dead culture + mix dye  
F(620)min: Reading from 100% live culture + mix dye  
F(620)sam: Reading from experimental sample + mix dye  
F(520)sam - F(520)min 
F(520)max - F(520)min 
% Live cells =      X 100% 
F(620)sam - F(620)min 
F(620)max - F(620)min 
 
% Dead cells =     X 100% 
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2. 2. 2. 5. 1. Optimization of dye concentration 
Optimal dye concentrations for each cell line were determined according to the 
user’s manual provided with the kit. Briefly, exponentially growing cultures (> 90% 
viability) were exposed to different concentrations of dye (0.1, 1.0, 2.0, 3.0, 4.0, 5.0 
µM). No cells + 5.0 µM dye and no cells + no dye (PBS only) were included as 
controls. Fluorescence was measured after every five min for 45 min. The minimum 
dye concentration and a suitable time producing the highest signal were 
considered as optimum for a given cell line. The experiment included samples in 
triplicates. 
2. 2. 2. 5. 2. Calibration of the assay 
Calibration curves for the cell lines were generated by mixing live and dead cells in 
different proportions (live/dead ratio: 10:0, 9:1, 8:2, 7:3, 6:4, 5:5, 4:6, 3:7, 2:8, 1:9, 
0:10). Samples, in triplicates, were incubated with optimized dye concentrations for 
30 min at 37 °C, readings were taken and relative percentage viability and relative 
percent of dead cells was calculated. Calibration curves were generated by plotting 
relative percentage of the cells against proportions of live/dead cells. 
2. 2. 2. 6. Screening of the traditional Chinese medicine (TCM) compounds 
2. 2. 2. 6. 1. Determination of a suitable time for drug exposure – an experiment 
with arsenic trioxide 
In order to select the time points when we can see maximum effect of the drugs, a 
time-line experiment was performed with Arsenic trioxide. Exponentially growing 
cells (> 90% viability, 7.5 x 105 cells/ml) of the three cell lines (GM01310, XP3BE, 
GM10902) were exposed to 10 µg/ml of arsenic trioxide for 10 min, 3 hrs, 6 hrs and 
24 hrs. Relative percentage viability and relative percent of dead cells was 
calculated by ‘LIVE/DEAD® Viability/Cytotoxicity assay’ (Invitrogen) and viability 
curves over a time period were designed.  
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2. 2. 2. 6. 2. Cytotoxicity screening of the TCM drugs 
All TCM drugs and their solvents were screened for cytotoxicity against three cell 
lines GM01310, XP3BE and GM10902. Healthy cultures (> 90% viability; 7.5 X 105 
cells/ml) were seeded in 96 well plates (Becton Dickinson) a day before the actual 
experiment. Just before treatment with the drugs, culture media was carefully 
replaced with fresh media. Cultures were incubated with saturated solutions of the 
drugs (1 µl/ 100 µl of the cell suspension) for 10 min; to observe an early effect and 
24 hrs; to observe a later effect at 37 °C. Unexposed samples were included as 
experimental controls. The relative percentage of viable and dead cells was 
measured by ‘LIVE/DEAD® Viability/Cytotoxicity assay’ (Invitrogen). The experiment 
was performed twice with three replicates of each sample. 
2. 2. 2. 7. IC50 values 
IC50 (Inhibition Concentration 50, IC50) is the concentration of a drug required to 
inhibit 50% of cell growth. IC50 values of the selected TCM drugs were determined 
through dose-response curves. Exponentially growing cultures (> 90% viability; 7.5 
X 105 cells/ml) were exposed to serial dilutions of the selected TCM drugs for 24 hrs 
at 37 °C. Unexposed and solvent exposed samples were included as experimental 
controls. The relative percentage of viable and dead cells was calculated by 
‘LIVE/DEAD® Viability/Cytotoxicity assay’ (Invitrogen) and dose-response curves for 
viable cells were generated. Experiment included four replicates of each sample. 
IC50 values of the drugs were calculated by the formula given below. 
 
 
 
 
 
‘a’ and ‘b’ are the drug concentrations producing ‘just more than 50%’ and ‘just less than 
50%’ viable cells, respectively and ‘c’ is the percent viability produced by drug 
concentration ‘a’, and ‘d’ is the percent viability produced by drug concentration ‘b’. 
                    [(b - a)(50% - d)] 
               (c – d) 
 
IC50 = b -  
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2. 2. 2. 8. Cell cycle analysis by flow cytometry 
Cell cycle analysis is an important tool for testing new drugs e.g., for cancer therapy 
(Jayat & Ratinaud, 1993). It helps in understanding drug cytotoxicity and its 
influence on a specific cell cycle phase, where it arrests and kills the cells. As an 
increased SubG1 fraction depicts cell killing by apoptosis (Kong et al., 2005), the 
technique allows emphasizing the portion of cells undergoing apoptosis after drug 
treatment. In vitro characterization of a potential drug helps forecast its activity in 
vivo (Jayat & Ratinaud, 1993). 
Flow cytometry follows the principle of hydrodynamic focusing. During the process, 
samples are injected into the center of a liquid sheath flow, forcing them in a way 
that single cells are presented to a light excitation source e.g., a laser. As cells pass 
through the laser they scatter light. The Forward Scatter (FSC) and Side Scatter 
(SSC) represent the size and structure of the particles. Information is collected on 
light scattering, light excitation, and emission of fluorochrome molecules using 
specific detectors to generate specific multi-parameter data. 
If cells are stained with a DNA staining dye e.g., Propidium iodide (PI), the emitted 
fluorescence will be proportional to DNA content present in cells (Jayat & Ratinaud, 
1993). For a particular sample it will give a picture of different cell cycle phases. 
Figure.2.3. Different phases of cell cycle as observed with flow cytometry 
using PI (Propidium iodite) staining. 
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Cells (Figure.2.3) with a single DNA content (diploid cells) are in G1 phase, cells with 
doubled DNA content (tetraploid cells) are in G2/M phase and cells with an 
intermediate DNA content lie in S phase of cell cycle. The apoptotic cells have less 
DNA than diploid cells and come in subG1 phase. 
2. 2. 2. 8. 1. Determination of a suitable time for drug exposure – an experiment 
with arsenic trioxide 
In order to determine a suitable time for TCM drug exposure to see a clear effect 
on cell cycle distribution, exponentially growing cells (> 90% viability; 7.5 X 105 
cells/ml) of GM01310 were exposed to 0.73 and 2.2 µg/ml (IC50 value for the cell 
line) of arsenic trioxide for 4 hrs, 8 hrs and 24 hrs. Cells were harvested by 
centrifugation (1000 rpm, 5 min, 4°C) and washed (2 X) with PBS. Cells were fixed 
by ice-cold fixative (70% Ethanol, 20% deionized H2O, 10% PBS) added drop wise 
while vortexing. Fixed samples remained at -20°C for overnight followed by 
centrifugation (1000 rpm, 5 min, 4°C). Cell pellets were washed with PBS and 
samples were incubated with staining solution (100 µg/ml RNaseA, 50 µg/ml PI) for 
30 min in dark. DNA content of the samples was measured by flow cytometry on a 
FACSCalibur flow cytometer (Becton Dickinson Biosciences) with the help of 
‘CellQuestPro’ (Becton Dickinson Biosciences) software. 10,000 cells per sample 
were gated as single cells and three readings per sample were recorded. The 
parameters recorded were Forward Scatter (FSC), Side Scatter (SSC), FL2-Height, 
FL2-Area und FL2-Width (FL2 stands for Fluorescence 2 and represents PI 
fluorescence). Gating out of doublet cells or clumps and boundaries of different cell 
cycle phases (sub G1, G1, S, G2/M) in the samples was based on the unexposed 
samples. 
2. 2. 2. 8. 2. Effect of TCM drugs on cell cycle distribution 
To analyze the effect of selected drugs and their solvents on cell cycle distribution 
in NER deficient and proficient cells, exponentially growing cultures (> 90% viability; 
7.5 X 105 cells/ml) of GM01310, XP3BE and GM10902 were treated with different 
doses of the drugs for 24 hrs. The drug concentrations were picked from dose-
response curves generated during IC50 calculations. As control, unexposed samples 
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were included in each experiment. Samples were handled as explained above and 
experiments were performed twice with three replicates for each treatment. 
2. 2. 2. 9. Single cell gel electrophoresis (Alkaline Comet assay) 
The single cell gel electrophoresis or ‘Alkaline Comet assay’ was performed to 
quantify the genotoxic effects of the selected TCM drugs and their solvents on 
repair deficient and repair proficient cell lines. The assay was carried out as 
described by Singh et al., (1988) with some modifications (Popanda et al., 2003). 
Briefly exponentially growing cells (> 90% viability) were exposed to different 
concentrations of the selected drugs and their solvents for one hour. As control, 
unexposed samples were included. Cells were collected and kept on ice to minimize 
repair processes. Samples were centrifuged (1000 rpm, 5 min, 4°C) to wash out the 
drugs and resuspended (2.7 X 105 cells/ml) in basic culture medium (RPMI1430 + 
Penicillin / Streptomycin). To prevent additional DNA damage, further steps were 
performed under red light. 25 µl of sample were embedded in 175 µl of 0.7% low-
melting agarose (SeaPlaque®GTG® agarose; Biozym, Oldendorf, Germany) and 
spotted on 20 spot comet assay slides (Trevigen) in triplicates. Cells were incubated 
in lysis buffer (2.5 M NaCl, 10 mM Trizma-Base at pH 10.0, 100 mM Na2 EDTA, 1 % 
sodium sarcosinate, 1 % Triton X-100, 10 % DMSO) for overnight at 4°C. Slides were 
Figure.2.4. Comet from a damaged cell. 
Materials and Methods 
59 
kept in a pre-chilled alkaline solution (NaOH 0.3 M, EDTA-Na2 1.0 M; pH 13.1) for 20 
min to allow unwinding of DNA followed by electrophoresis (25 V, 300 Amp, 20 
min). Larger DNA molecules will stay in the nuclei whereas smaller fragments will 
move out towards anode forming a tail and give a comet like shape (Figure.2.4) to 
the cells. If the amount of damaged DNA is high, more fragments will move out. 
The slides were then immersed two to three times in absolute ethanol and air 
dried. Slides were stained with SYBR-green (Biozol; 0.2 µl/ml TE buffer) for 30 min 
and analyzed with the software ‘Komet 4’ (semi automated system; Kinetic Imaging 
Ltd., Liverpool, UK). The program is designed to differentiate comet head from tail 
and to measure a variety of parameters including tail length, percentage of total 
fluorescence in head and tail, and ‘tail moment’. Fifty one cells per replicate (153 
cells per treatment) were scored and olive tail moment was determined. Olive Tail 
Moment (Olive et al., 1990) is defined as the product of the tail length and the 
fraction of total DNA in the tail.  
Note: Tail length is the distance of DNA migration from the body of the nuclear 
core and it is used to evaluate the extent of DNA damage. 
 
As Olive tail moment has a skew distribution, median values of the three replicates 
were taken and means ± standard deviation was calculated for each treatment. Tail 
moment relative to unexposed sample was determined. For the data, back ground 
damage, drug induced damage, and effect of the solvent were estimated. The 
analysis did not include the edges and damaged parts of the gel as well as debris, 
superimposed comets and ghost cells.  
2. 2. 2. 10. Formamidopyrimidine DNA glycosylase (Fpg)-modified comet assay 
Fpg is a repair glycosylase that detects primarily 8-oxo-7,8-dihydro-2'-
deoxyguanosine (Dianov et al., 1999) sites in DNA samples (Azqueta et al., 2009). 
The Fpg-modified comet assay was performed to quantify the oxidative DNA 
Olive tail moment = tail length X % DNA in tail 
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damage potentially caused by Ascaridol in repair-deficient and repair-proficient cell 
lines. The assay was performed as described previously (Collins et al., 1993, Collins 
et al., 2001, Domijan et al., 2006, Eiberger et al., 2008) and its procedure was 
essentially similar to the alkaline comet assay.  Exponentially growing cells (> 90% 
viability) were treated with the drug for one hour. Cells were harvested and 
centrifuged (1000 rpm, 5 min, 4°C) to wash out the drugs. Cells were resuspended 
(2.7 X 105 cells/ml) in basic culture medium (RPMI1430 + Penicillin / Streptomycin) 
and embedded in 0.7% agarose gel (SeaPlaque®GTG® agarose; Biozym, Oldendorf, 
Germany) and spotted on 20 spot comet assay slides (Trevigen) in quadruplicates. 
Two identical slides were prepared for each cell line. Cells were lysed for overnight 
and slides were immersed thrice in 1X Flare buffer (Trevigen) for 15 min. One of the 
slides was incubated with freshly prepared Fpg solution (New England Biolabs; 
8U/ml 1X NEBuffer-1) for 50 min at 37°C. The second slide was incubated with 1X 
NEBuffer-1 (New England Biolabs) at the same conditions. Afterwards, they were 
placed on ice for 40 min to solidify the agarose gel again. Slides were than 
immersed in a pre-chilled alkaline solution (NaOH 0.3 M, EDTA-Na2 1.0 M; pH 13.1) 
three times for 15 min each. To allow unwinding of DNA they were kept in this pre-
chilled alkaline solution for 20 min followed by electrophoresis (25V, 300Amp, 20 
min). The slides were immersed two to three times in absolute ethanol and air 
dried. Staining was performed by SYBR-green (Biozol; 0.2 µl/ml TE buffer) for 30 
min and slides were analyzed the software ‘Komet 4’ (Kinetic Imaging Ltd., 
Liverpool, UK). One hundred and fifty-three cells per treatment were scored and 
olive tail moment was determined. 
The NEBuffer-1 treated slides provide an estimate of the background of DNA strand 
breaks (SB). The Fpg-treated slides reveal strand breaks and oxidized bases (SB + 
OX). Assuming a linear dose-response of either % DNA in tail or in arbitrary units, 
subtraction of (SB) from (SB + OX) gives a measure of oxidised pyrimidines/purines 
in the samples. Therefore  
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OTMFpg: Olive tail moment of Fpg treated samples 
OTMBuffer: Olive tail moment of buffer treated samples 
 
For each treatment the Fpg sensitive lesions (mean ± standard error) were 
considered as a measure of oxidative DNA damage.  For the data, back ground 
damage, drug induced damage, and effect of the solvent were estimated. 
2. 2. 2. 11. Reactive oxygen species (ROS) production 
Intracellular ROS was detected by the fluorescent dye 2´,7´-
dichlorodihydrofluorescein diacetate (H2DCFDA). The dye enters the cells where it 
gets cleaved by intracellular esterases forming a nonfluorescent molecule, 2´, 7´-
dichlorofluorescein (DCFH). In the presence of H2O2, DCFH gets oxidized to the 
fluorescent compound dichlorofluorescein (DCF). XP4PA and XP4PA-SE2 cells were 
seeded (6 X 104 / ml) in 96 well plates for overnight. Cultures were washed once 
with PBS and wells were loaded with 25µM H2DCFDA. Immediately before starting 
the measurement, cells were exposed to different ascaridol concentrations, DMSO 
(solvent) and different H2O2 concentrations as a positive control. Unexposed 
samples and samples without cells were also included as control. Fluorescence in 
the samples was measured by CytoFlour multi well plate reader, series 4000 at Ex / 
Em : 485 / 520 nm for 40 min. The rate of ROS production was generated in terms 
of arbitrary fluorescence units per min (Rate ROS = AFU/min) and rate of ROS 
production relative to the unexposed sample (RRRos) was calculated for each cell 
line. 
2. 2. 2. 12. Aldehyde reactive probe (ARP) assay 
Apurinic / apyrimidinic site (AP) sites are one of the major type of lesions in DNA.  
AP sites can be formed by spontaneous depurination. They also occur as an 
intermediate in base excision repair (Boiteux & Guillet, 2004). In this process, a 
damaged base is recognized and cleaved by a DNA glycosylase, leaving an AP site. 
Fpg sensitive lesions = OTM Fpg  – OTM Buffer 
Materials and Methods 
62 
The AP site can then be cleaved either by an AP endonuclease or by bifunctional 
glycosylase-lyases. Both mechanisms form a single-strand break, which is then 
repaired by base excision repair. Detection of AP sites can be a measure of 
oxidative damage. 
AP sites were counted using the DNA damage quantification assay-AP site counting 
(DOJINDO molecular technologies, Inc.). The assay constitutes of aldehyde reactive 
probe (ARP), a biotinylated alkoxyamine that reacts specifically with the aldehyde 
group in the ring opened AP site. AP sites are thus tagged with a biotin residue. 
These sites can then be quantified with an ELISA-like assay, using avidin-biotin 
complex conjugated with horseradish peroxidase (HRP) as an indicator enzyme. 
Cells were incubated with drugs for 24 hours, harvested and DNA was extracted 
using QIAamp DNA blood mini kit (Qiagen). DNA samples (100 μg/ml) were coupled 
with 10 mM biotinylated ARP solution for 1hr at 37 °C, than diluted in TE buffer, 
and filtered twice to purify the ARP-tagged DNA. The tagged DNA was bound to the 
wells of a 96-well microtiter plate in the dark at room temperature overnight. The 
samples were washed thoroughly and incubated with HRP-streptavidin solution (1 
in 4000 dilution) for 1hr at 37 °C, washed again and incubated with HRP substrate 
for 1hr at 37 °C. The absorbance was measured at 650 nm using SpectraMax: 
GEMINIXS microplate Fluorometer (Molecular devices). The number of AP sites in 
the treatment group was measured relative to the solvent control and was 
quantified by using standard ARP labeled DNA solution (Dojindo Molecular 
Technologies, Inc.). Standard ARP labeled DNA solution has a known amount of AP 
sites, ranging from 0 to 40 per 1 × 105 base pairs of calf thymus DNA. 
2. 2. 2. 13. Determination of gene expression 
2. 2. 2. 13. 1. RNA extraction and quantification 
Total RNA was extracted using RNeasy mini kit (Qiagen, Hilden, Germany) and spin 
technology according to the protocol provided by the company. The following 
options were used during the extraction. After lyses samples were homogenized by 
passing at least 5 times through a blunt 20-gauge needle (BD MicrolanceTM 3) fitted 
to an RNase-free syringe (BD DiscarditTM II). Final elution of RNA was performed 
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twice to increase the yield, first with 30µl, then with 10µl RNase-free water. Optical 
densities of RNA samples were measured on nanodrop spectrophotometer (ND 
1000, PeQlab biotechnologie GmBH). The samples were handled on ice and stored 
at -80°C. 
2. 2. 2. 13. 2. Reverse Transcription and cDNA amplification (RT-PCR) 
Using the total RNA samples, first-strand cDNA was synthesized using Random 
Hexamer primers (Thermo Fisher Scientific GmbH, Ulm, Germany) and superscript 
III reverse transcription (Invitrogen). Random hexamers are random oligo 
deoxyribonucleotides. They have higher sensitivity and can amplify short and 
fragmented mRNA with or without a poly-A tail. Random hexamers are ideal for 
mRNA samples having low concentration as they provide higher yields. 
As cDNA was later to be used for gene expression studies, same amount of RNA (1 
µg) was taken for all samples. Reverse transcription comprised two steps. 
Table.2.19 gives the reaction mixtures for both steps. First the Mini mix (12 μl) was 
incubated at 65°C for 5 min following incubation on ice for 1 min. Next Master mix 
(8 μl) was added and samples were incubated at 25°C for 5 min, at 42°C for 50 min. 
Table.2.19. Reaction mixture for the two step RT-PCR 
            Reagents Final concentration  
Mini mix (volume = 12 μl)  
            Total RNA 1μg  
            Random primer (200 ng/ml)  0.025 μg/μl  
            dNTPs (10 mM)  0.5 mM  
            ultraPURETM H2O  To fill the volume 
Master mix (volume = 8 μl)  
            5 x first strand buffer 1 x  
            DTT (0.1 M)  0.01M  
            SuperScriptTM III RT (200 U/μl)  10 U/μl  
           Rnasin (40 u/μl)  2 u/μl  
Final reaction volume 20 μl 
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The reaction was inactivated at 70°C for 15 min. 2 µl of the cDNA was aliquoted to 
check reverse transcription and the remaining samples were diluted to 1:10 and 
stored at -80°C till further experiments. 
 2. 2. 2. 13. 3. RNA/cDNA Quality check assay  
To check quality of RNA and resultant cDNA, Clathrin gene was amplified at 5’- and 
3’-ends. Clathrin is a large gene with mRNA around 6000 bp. The gene was 
amplified by specific primers (Table.2.4) to yield a 570 bp fragment at 5’- end and a 
550 bp fragment at 3’- end. In case of complete conversion of mRNA into cDNA, the 
amount of both PCR products will be same. Table.2.20 and 2.21 provided PCR 
conditions for the reactions. PCR products (Fig.2.5) were separated on a 1.5% 
agarose gel (300 mA, 100 V, 30 min). 
 
 
 
 
 
 
Table.2.20. Clathrin-PCR program 
 Step Temperature (°C) time 
1 cycle initial denaturation 95 15 min 
30 cycles i- denaturation 94 30 sec 
 ii- Annealing 56 30 sec 
 iii- extension 72 60 sec 
1 cycle elongation 72 7 min 
Figure.2.5. Amplification of Clathrin gene 
                sample 1        sample 2         sample 3 
     M         5´        3´         5´        3´         5´       3´ 
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2. 2. 2. 13. 4. Relative quantification of ERCC6 and GAPDH by real time PCR 
Relative quantification was done by real time PCR using gene specific primers and 
QuantiTect SYBR Green PCR master mix (Qiagen) on a lightcycler480 (Roche, 
Mannheim, Germany). Samples were analyzed by LightCycler®480 software 
(version 1.5.0). QuantiTect SYBR Green PCR master mix contains HotStarTaq DNA 
polymerase, PCR buffer, dNTPs and fluorescent dyes (SYBR Green I and ROX). In 
solution, the unbound SYBR Green I exhibits very little fluorescence; however, 
fluorescence (wavelength, 530 nm) is greatly enhanced upon intercalation to 
double stranded DNA. During PCR, a laser excites the dye and signal is measured 
after every cycle (real time) by specific detectors. The increase in SYBR Green I 
fluorescence is directly proportional to the amount of double-stranded DNA 
generated. The software plots the measured fluorescence against the no. of cycles 
and generates a sigmoid curve (Figure.2.6). From these plots it automatically 
calculates the Crossing Point (Cp) values. The Cp values represent the PCR cycle 
when the signal raises from the threshold. The quantity of target gene is compared 
with the reference sequence in the same samples and final result is expressed as a 
ratio of these targets. This step corrects for the differences in starting RNA/cDNA 
quantity, and RNA quality. 
Table.2.21. Clathrin-PCR reaction mixture  
Reagents Final concentration  
ultraPURETM H2O  To fill up the volume 
Qiagen 10 x PCR buffer  1 x  
Forward Primer (50 μM)  0.5 μM  
Reverse Primer (50 μM)  0.5 μM  
dNTPs (10 mM)  0.2 mM  
Qiagen Taq DNA Polymerase (5 U/μl)  0.05 U/μl  
cDNA  0.05 μl/μl of reaction mix  
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2. 2. 2. 13. 4. 1. Establishing and optimization of real time PCR 
For each gene three primer pairs were designed and PCR conditions were 
optimized as described previously (2.2.1.2.3 Optimization of PCR conditions). The 
best performing primer pair was selected for real time quantification. Real time 
PCR was established in 384 well plate (Steinbrenner Laborsystems GmBH). This 
format allowed keeping target and reference genes in the same run therefore 
calibrators were not needed. The target gene was quantified in samples with two 
different cDNA concentrations (undiluted, 1:10). The Cp values for both 
concentrations were calculated by the software. As PCR product doubles after 
every cycle, the PCR efficiency was automatically picked by the software as 2. The 
dilution of cDNA, and number of cycles required to produce enough signal were 
plotted. PCR program and conditions followed are given in Table.2.22 and 2.23.  
Samples were measured in triplicates and for calculations mean Cp values were 
taken. As a check for cross contamination negative control (no cDNA) samples were 
placed at different positions on the plate. The cDNA dilution allowing easier 
detection of the target genes was considered as suitable and annealing 
Fig.2.6. A typical sigmoid plot obtained by florescence measurement during 
mRNA quantification. Arrow represents the Cp value of the gene. 
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temperature producing least difference among replicates was considered as 
optimum. 
2. 2. 2. 13. 4. 2. Relative quantification of ERCC6 and GAPDH 
ERCC6 and GAPDH were quantified using gene specific primers (Table.2.3) and 
standardized PCR conditions (Table.2.22 and 2.23). HPRT (mean Cp value = 22.8) 
was included as housekeeping gene and quantification of ERCC6 and GAPDH was 
done relative to HPRT (Relative quantity of target gene = Target Cp /Reference Cp). 
 
 
   
Table.2.22. Reaction mix for quantitative PCR 
  Reagents Final concentration 
cDNA   
Quantitect (2 X) 1 X 
Gene specific primer mix (10 µM) 0.5 µM 
ultraPURETM H2O to fill the volume 
Final reaction volume  7 µl 
Table.2.23. Cycling conditions for real time quantification PCR. 
Program 
name 
Cycles 
Analysis 
mode 
Target 
temperature 
(°C) 
Acquisition 
mode 
Ramp rate 
(°C / sec) 
Acquisition 
rate (per °C) 
Hold 
Pre-
incubation 
1 None 95 None 4.4 - 15 min 
Amplification 44 Quantification 95 None 2.2 - 30 sec 
   60 None 2.2 - 30 sec 
   72 Single 4.4 - 30 sec 
Melting curve 1 
Melting 
curves 
95 None 4.4 - 1 min 
   40 None 2.2 - 1 min 
   80 Continuous - 2 - 
Cooling 1 None 40 none 2.2 - 10 min 
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2. 2. 2. 14. Protein extraction 
Depending on the cell type, cells were harvested either by centrifugation or by 
trypsinization. Samples were washed with PBS, centrifuged (1000 rpm, 5 min, 4°C) 
and cell pellets were resuspended in 100 µl per 1 X 106 cells of lysis buffer (20mM 
Tris, 7 M urea, 100mM DDT, 1% Triton-X 100, Roche Complete Mini Tabs as 
Protease inhibitor, 1 mM MgCl2 and 1 mM Phenylmethylsulfonyl fluoride). Samples 
were incubated on ice for 30 min followed by Benzonase (1 µl / 100µl lysis buffer) 
addition and incubation at 37°C for 30 min. Samples were centrifuged (13000 rpm, 
5 min, 4°C) to settle the cell debris down, supernatant was carefully collected in 
clean tubes and samples were stored at –80°C. 
2. 2. 2. 14. 1. Quantification of protein samples 
Protein samples were quantified by Bio-Rad protein assay, based on the method of 
Bradford, which is a spectroscopic analytical procedure (Bradford, 1976; Compton 
& Jones, 1985). The assay comprises of an acidic solution of Coomassie® Brilliant 
Blue G-250 dye which binds to proteins causing a spectral shift from 465nm - 
595nm. A subsequent measurement at 595 nm with a spectrophotometer and 
comparison to a standard curve provides a relative measurement of protein 
concentration.  
Briefly, protein samples (2 µl) were incubated with H2O (798 µl) and Bradford 
reagent (200 µl, protein assay, Bio-Rad) for 5 min at room temperature. Lysis buffer 
was used as a blank sample. Absorbance was measured on Biophotometer (version 
1.35, eppendorf). Protein concentration was calculated as follow. 
 
 
 
400 is the dilution factor for the protein sample. 
 
2. 2. 2. 14. 2. Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
Under denaturing conditions, protein samples can be separated according to their 
size on polyacrylamide gels (Goldenberg & Creighton, 1984; Laemmli, 1970). Mixing 
Total conc. (µg / ml) = measured protein reading X 400 
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protein solutions with anionic detergents like sodium dodecyl sulfate (SDS) 
denatures secondary and non–disulfide–linked tertiary structures, giving nearly a 
uniform negative charge along the length of the polypeptide. As voltage is applied, 
the anions migrate toward the anode (positive electrode) allowing protein 
fractionation by size. 
Protein samples were denatured in the presence of LDS-sample buffer (1:4 ratio, 
Invitrogen) and ‘NuPAGE sample reducing agent’ (1:10 ratio, Invitrogen) at 70°C for 
10 min and were placed quickly on ice. Samples were loaded on 10% NuPAGE 
precast Bis-Tris polyacrylamide mini-gels (1.5 mm X 10 well, Invitrogen) in SDS 
running buffer (1 X NuPAGE MOPS, Invitrogen), set in a vertical electrophoresis 
chamber (X Cell Sure Lock System, Invitrogen). Proteins were separated at 200 volts 
for one hour. MagicMark XP molecular weight marker (Invitrogen) was used as a 
size reference. 
2. 2. 2. 14. 3. Western blotting 
The proteins separated by SDS-PAGE were blotted on Polyvinylidene flouride 
(PVDF) membrane (0.45 µm, Invitrolon, Invitrogen). The PVDF membranes were 
soaked in 100% methanol for 30 sec, washed with dH2O and equilibrated in 
transfer buffer (Table.2.24) for at least 5 min. Separately 2 filter papers and 4 to 6 
foam pads were soaked in the transfer buffer. For blotting, foam pads, gel, PVDF 
membrane and filter papers were arranged, as shown in Figure.2.7, carefully so 
Figure.2.7. Arrangement of blotting apparatus 
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that no air bubbles are present. Blotting apparatus was filled with chilled transfer 
buffer and running chamber filled with chilled ddH2O. Blotting was performed at 30 
Volts for 70 min at room temperature. 
Further steps were performed carefully with gentle shaking on a shaker (DuoMax 
1030, Heidolph). The PVDF membrane was briefly washed twice with dH2O and 
blocked with 5% milk solution in Tris Buffered Saline-Tween (TBST; 10 mM Tris pH 
8.0, 150 mM NaCl, 0.05% Tween 20) at 4°C for overnight. Membrane was washed 
(3 x 5 min) with TBST and incubated with protein specific primary antibody 
(Table.2.25) for one hour at room temperature. Membrane was washed (4 x 10 
min) again and incubated with secondary antibody solution for one hour at room 
temperature. Membrane was washed (3 x 15 min) again and incubated with 
‘Western Lightning Chemiluminescense reagent plus’ system (Perkin Elmer) for 3 
min. Extra solution was removed and membrane was placed in a transparent 
plastic bag. Under red light the membranes were exposed to Hyperfilm 
(Amersham) films and developed on Classic E.O.S. (Type 5270/100, AGFA). 
Developed films were photographed with digital camera (NV8, Samsung) and target 
protein bands were quantified with the help of Image J (version 1.41o; Rasband, 
NIH, USA). Quantification was relative to ß-actin band. 
2. 2. 2. 14. 4. Stripping antibodies off the PVDF membranes 
In order to quantify more than one protein on one blot, the membranes were 
stripped off of the antibodies. The membranes were incubated with 50 ml strip 
buffer (1 mM Tris pH 6.8, 10% SDS, 0.08% ß-Mercaptoethanol) at 50°C for 15 min in 
a rotating oven (Biometra OV2) followed by washing  with TBST. The membranes 
were again blocked and immunostained. 
Table.2.24. Transfer buffer for western blotting.  
Reagents   Volume (for one gel)  Volume  (for two gels) 
20 x Transfer buffer  50 ml  50 ml  
Methanol  100 ml  200 ml  
dd H2O 850 ml  750 ml 
Note: Before use add 1ml Antioxidant 
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2. 2. 2. 15. Statistical analysis 
2. 2. 2. 15. 1. Genotype frequencies 
Allele frequencies were calculated by following formulas. 
 
 
 
 
 
 
2. 2. 2. 15. 2. Hardy-Weinberg equilibrium 
Allele and genotype frequencies were tested for Hardy-Weinberg equilibrium using 
the Chi-square test of goodness of fit with one degree of freedom. The formula 
used is given below. The Tcritical = 3.84 for 1 degree of freedom. A chi-square value 
larger than this means that the genotype distribution deviates significantly from 
Hardy-Weinberg equilibrium. 
Table.2.25. Primary and secondary antibodies used during the course of study. 
Primary antibody 
(santa cruz) 
Company 
code 
product 
size (kDa) 
dilution 
used 
type 
secondary 
antibody 
(santa cruz) 
dilution 
used 
anti-XPC sc-30156 (H-300) 125 1:500 rabbit 
polyclonal 
goat anti-
rabbit 
1:2000 
anti-p53  sc-55476 (C-11) 53 1:500 mouse 
monoclonal 
goat anti-
mouse 
1:5000 
anti-CSB sc-10459 (E-18) 168 1:500 goat 
polyclonal 
donkey anti-
goat 
1:2000 
anti-ß actin sc-47778 (C4) 43 1:3000 mouse 
monoclonal 
goat anti-
mouse 
1:5000 
                          (aa*2) + Aa 
                        N*2 
  Wild type allele frequency (p) = 1 – q 
 
‘aa’ is the no. of individuals homozygous for variant allele  
‘Aa’ is the no. of heterozygous individuals  
‘N’ is the total no. of individuals 
 
  
  
  
         
       
  Rare allele frequency (q) =    
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2. 2. 2. 15. 3. Logistic regression analysis 
Statistical analysis of the data was performed by using the statistical software 
package SAS (version 9.2). Odds ratios (OR) with 95% confidence intervals (CI) were 
computed by multivariate conditional logistic regression analysis, conditioned on 
age and gender and adjusted for smoking behavior, alcohol consumption and 
education. These potential confounders were differently distributed among cases 
and controls. The high frequency allele was taken as the reference genotype.  
2. 2. 2. 15. 4. Gene-environment interaction 
For estimating gene-environment interaction, the population was divided into 
subgroups. Smoking was quantified by the degree of tobacco consumption as pack-
year (py) groups with ≤  20 py and > 20 py (1 py = 20 cigarettes/day for 1 year). 
Regarding alcohol consumption population was subgrouped as: less than 25 g of 
alcohol intake/day, between 25–50 g of alcohol intake/day and above 50 g of 
alcohol consumed/day. For estimating a possible combined effect of smoking and 
alcohol intake on genotype and cancer risk, the study population was divided in the 
following three groups, (i) a group with a low exposure level included individuals 
with ≤ 20  py of smoking and ≤ 50 g of alcohol intake/day, (ii) a group with a 
medium exposure level included persons with ≤ 20 py of smoking and > 50 g 
alcohol consumption/day or > 20 py but ≤ 50 g of alcohol intake/day,  whereas 
individuals with high exposure level had > 20 py and > 50 g of alcohol intake/day. 
                (ObsAA - ExpAA)
2        (ObsAa - ExpAa)
2              (Obsaa – Expaa)
2 
          ExpAA        ExpAa                  Expaa 
 
‘Obs’ is the observed no. of individuals 
‘Exp’ is the expected no. of individuals and is calculated by ExpAA= n*p*p,  
ExpAa = 2n*p*q, Expaa = n*q*q, (p; is the wild type allele frequency, q; is the rare allele 
frequency) 
  χ2 = ∑       +   +    
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2. 2. 2. 15. 5. Linkage disequilibrium 
Linkage disequilibrium values for SNPs present in the same gene and for genes 
located on the same chromosome were calculated using the EH program (Ott, 
2006).  
2. 2. 2. 15. 6. Haplotype analysis 
Phase v 2.2.1.1 was used to estimate haplotype frequencies in cases and controls 
(Stephens & Donnelly, 2003). To test for haplotype-trait association, a generalized 
linear model (GLM) framework was used (haplo.glm). This model applies an 
iterative two-step expectation-maximization algorithm to estimate haplotype 
frequencies (Lake et al., 2003). The GLM framework was adjusted for age, gender, 
smoking and alcohol consumption.  
2. 2. 2. 15. 7. Gene-gene interaction 
Gene-gene interaction was computed for the genes working as a complex in the 
NER pathway. For those SNPs that exhibit association with cancer risk in the 
present study, a ‘risk score’ was assigned to each group thereby increasing the 
score with each additional risk allele. Correction for multiple testing was 
considered according to Bonferroni (Silicon Genetics, 2003). 
2. 2. 2. 15. 8. NER and cancer therapy 
Data were statistically analyzed in Excel 2007. ANOVA and t-test (two tailed) were 
used to investigate statistical differences between unexposed, solvent exposed and 
drug treated samples within cell lines. Furthermore NER proficient cell lines were 
compared to NER deficient cell lines using these tests. 
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3. Results, NER and cancer risk 
3. 1. Quality control of genotyping data 
3. 1. 1. Optimization of conditions for genotyping 
Conditions for genotyping were carefully optimized. Suitable annealing 
temperature for the primers was selected by performing PCR with a temperature 
gradient and analyzing the samples on agarose gel. Samples were genotyped in 
high throughput by real time PCR using SNP specific LCTM Hybridization probes 
(Hybprobes). Suitable concentration of primers and probes used for real time PCR 
are provided in Table.2.1 & 2.5. 
Optimized conditions were validated by genotyping 20 to 25 samples both by real 
time PCR on LC-480 and RFLP using SNP specific restriction enzymes. Genotypes 
obtained via both techniques were compared and a 100% concordance was found. 
Figure.3.1 presents an example for validation of optimized conditions for ERCC5 
Asp1104His of three samples (318, 319 and 320). Figure.3.1-a shows the melting 
peaks of the samples obtained by real time PCR. Probes having a matched 
underlying sequence melt at 60.5°C and represent the ‘G’ allele whereas the 
probes having an unmatched underlying sequence melt at 55°C and represent the 
‘C’ allele. The heterozygous samples carry a peak at both these temperatures. As 
the figure shows, the genotype of sample 318 is ‘GG’, sample 319 is ‘CC’ and 
sample 320 is ‘GC’. For RFLP (Figure.3.1-b) the samples (PCR product size = 172 bp) 
were digested using the restriction enzyme Nla111 (restriction site 5´…CATG…3´). 
The expected sizes after digestion were GG = 144, 28 bp, CC = 82, 62, 28 bp and GC 
= 144, 82, 62, 28 bp. As shown in the figure, sample 318 has a genotype ‘GG’, 
sample 319 is ‘CC’ and sample 320 is ‘GC’, validating the results obtained by real 
time PCR. 
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3. 1. 2. Genotyping by fluorescence-based real time PCR 
Genotyping assays were performed without knowledge of the clinical status. 
Genotyping data was checked by two investigators independently. Samples having 
ambiguous peaks were repeated. Melting temperatures (Table.3.1) of the probes 
were specific for matched and unmatched sequences and standards were used to 
analyze the melting peaks. 
3. 1. 2. 1. Multiplex Hybprobe assay 
In situations where two SNPs were analyzed in one reaction using multiplex 
Hybprobes, probes were labeled with different dyes. In case of ERCC6 SNPs, 
RED640 was used for Arg1230Pro and RED610 was used for Arg1213Gly. For the 
detection of ERCC2 Arg156Arg and ERCC5 His46His, Hybprobes were labeled with 
RED640 and RED670, respectively. Additionally, for ERCC2 Arg156Arg and ERCC5 
His46His, two separate pairs of primers having same annealing temperature and 
 a.                                                                                                          b. 
 
 
Figure.3.1. Genotyping results for ERCC5 Asp1104His of three samples (318, 319 and 320). 
a. Melting peaks obtained via real time PCR on LC-480. Matched sequence (60.5°C) 
represents the genotype ‘G’ and unmatched sequence (55°C) represents ‘C’. b. RFLP of the 
samples (PCR product size = 172 bp) using the restriction enzyme Nla111. Expected sizes 
after digestion were GG = 144, 28 bp, CC = 82, 62, 28 bp and GC = 144, 82, 62, 28 bp. M = 
pUC19 DNA/MspI M,23 (Fermentas) was used as size reference. 
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PCR conditions were used. The complex peaks obtained by multiplex assays were 
resolved by color compensation.  
3. 1. 3. Color compensation 
Color Compensation was used as a tool to calibrate the LightCycler® Instruments. It 
corrected for the spectral overlap of fluorescence channels in multiplex Hybprobe 
assays. During a calibration run, the LightCycler® Instrument measured the 
fluorescence of each dye in all channels and generated an instrument-specific color 
compensation object ‘CC Object’. In multiplex Hybprobe assays the CC Object was 
used to reassign the fluorescence in each channel to the appropriate dye. The net 
result is detection of only one dye signal in each channel. 
Figure.3.2 demonstrates the detection of ERCC6 Arg1230Pro and Arg1213Gly by 
using RED610 and RED640 in multiplex Hybprobe assay, with (Figure.3.2-b, d, & f) 
or without (Figure.3.2-a, c, & e) color compensation.  The melting peaks observed 
at a wavelength of 610 nm are simple (Figure.3.2-a) and are not affected by color 
compensation (Figure.3.2-b). The melting peaks observed at a wavelength of 640 
nm are complex (Figure.3.2-c) and following color compensation they get simplified 
(Figure.3.2-d). A similar effect was observed for samples in a 96 well plate 
(Figure.3.2-e & f). 
3. 1. 4. Validation of genotyping data 
3. 1. 4. 1. Restriction fragment length polymorphism (RFLP) 
10% of randomly selected samples were genotyped by a second method, RFLP. 
Results obtained were compared with the genotyping data by LC-480 by two 
investigators, independently. A 100% concordance was found.  
3. 1. 4. 2. Sequencing 
As ERCC2 Arg156Arg and ERCC5 His46His were genotyped in multiplex Hybprobe 
assay, they were further validated by sequencing. Six samples were selected, two 
of these were homozygous for wild type allele, two were heterozygous and two 
homozygous for variant allele of each SNP. The amplified PCR products of the two 
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genes were separated on agarose gel. DNA bands were cut out of the gel and 
samples were extracted. Samples were sequenced and results obtained were 100% 
concordant with the genotyping data. 
Table.3.1. Melting temperatures for Hybprobes used for genotype analysis 
Gene Polymorphism Probe Sequence (5´- 3´)a 
Melting temperature 
(°C) 
Matched 
sequence 
Unmatche
d sequence 
XPC Lys939Gln CTC AGC TCA CAG CTT CTC AAA TGG GAA CA
 FL-3´ 
5´LC- RED640-GTG GGA AGC TGC TGC TTT CTT TTC CCT TTT GG p 
67 62 
RAD23B Ala249Val TGA AGA CTG AGG AAC CCC A
 FL-3´ 
5´LC- RED640-CTA GCT GCT TGA GGG GGG TCA p 
58 51 
ERCC6 Arg1230Pro 
5´LC- RED610-GCT TCT GGT AAG GCC TTT TCT TC p 
CCT TGG CCT CAC TCT TGT TTT CAC TGT C FL-3´ 
65.5 60.5 
ERCC6 Arg1213Gly TGG CGT CTC CGC AAT GCT T
 FL-3´ 
5´LC- RED640-GAG TTC TTA GGC TTT TGC TTT GGT CTC AGA T p 
64 55 
ERCC2 Arg156Arg CGC AGT ACC AGC ATG ACA CCA GCC T
 FL-3´ 
5´LC- RED640-CCC CAC TGC CGC TTC TAT p 
65 54 
ERCC1 Asn118Asn CGC AAC GTG CCC TGG GAA T
 FL-3´ 
5´LC- RED640-TGG CGA CGT AAT TCC CGA CTA TGT GCT G p 
66.5 56.5 
ERCC1 C8092A GAC AAG AAG CGG AAG CAG CAG C
 FL-3´ 
5´LC- RED640-GCA GCA GCC TGT GTA GTC TGC CCC C p 
69 61 
ERCC1b IVS5+33 CCA CTG CAC AAC CTC AAA GCC CTG TGA GA
 FL-3´ 73 68.5 
ERCC4 Arg415Gln CAT GTT CGG TCA TCA CTT GC
 FL-3´ 
5´LC- RED610-CAA ATC AGT ACT TGA CCT GAA AAT AGA AAA CA p 
65.5 58 
ERCC5 Asp1104His TCA AGT GAA GAT GCT GAA AGT TC
 FL-3´ 
5´LC- RED640-CTT TAA TGA ATG TAC AAA GGA GAA CAG CTG p 
60.5 55 
ERCC5 His46His TCG CCA CGG GAA CTC AAT
 FL-3´ 
5´LC- RED670-GAA AAT CCT CAT CTT CTC ACT TTG TTT CAT CG p 
61.5 52 
a FL-3: probe is labeled with fluorescein at 3´position; 5´LC- RED**: probe is labeled with 
LightCycler-RedTM at 5´position; the position of polymorphism is underlined. 
b For ERCC1 IVS5+33 forward primer was labeled with LC-Red640 at 3´position. 
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Figure.3.2 Effect of color compensation on melting peaks in multiplex 
Hybprobe experiments. a, c and e are samples without color compensation. b, 
d and f are the same samples with color compensation. a) melting peak of three 
samples at a wavelength of 610 nm, b) effect of color compensation on melting 
peak of the samples at a wavelength of 610 nm, c) complex melting peaks of the 
same three samples as in a and b at 640 nm, d) simplified melting peaks of the 
three samples at 640 nm after color compensation, e) melting peaks of samples 
in a 96 well plate at 640 nm without color compensation f) melting peaks of 
samples in the same 96 well plate as in ‘e’ after color compensation. 
a.               b. 
 
 
 
 
 
 
 
 
 
c.               d. 
 
 
 
 
 
 
 
 
 
 
e.                f. 
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3. 2. Genotype analysis 
In this study, a total of 11 SNPs in seven NER genes were investigated for their 
effect on larynx cancer risk. These included XPC (Lys939Gln), RAD23B (Ala249Val), 
ERCC1 (Asn118Asn, C8092A and IVS5+33), ERCC2 (Arg156Arg), ERCC4 (Arg415Gln), 
ERCC5 (Asp1104His and His46His) and ERCC6 (Arg1230Pro and Arg1213Gly). 
3. 2. 1. Genotype frequency 
Figure.3.3 shows the rare allele frequencies of the SNPs in controls of the present 
study. For all the SNPs the allele frequencies were similar (≤ ± 5%) to those given 
for European Caucasian populations at the National Center for Biotechnology 
Information (NCBI).  
 
Figure.3.3. Rare allele frequency of each SNP in controls (red bars) compared with 
rare allele frequency of each SNP in European Caucasian population (gray bars) 
given at National Center for Biotechnology Information. 
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3. 2. 2. Genotype distribution 
The allele and genotype frequencies were tested for Hardy-Weinberg equilibrium. 
The Hardy–Weinberg principle states that both allele and genotype frequencies in a 
population remain in equilibrium, from generation to generation unless specific 
disturbing influences like non-random mating, mutations, selection, limited 
population size, random genetic drift and gene flow are introduced (Campbell et 
al., 2009). To test the allele and genotype frequencies for Hardy-Weinberg 
equilibrium, Chi-square test of goodness of fit with one degree of freedom was 
applied. The Tcritical for one degree of freedom is 3.84. Figure.3.4 demonstrates that 
the genotype distributions of all the SNPs were consistent with Hardy-Weinberg 
equilibrium except for RAD23B Ala249Val (χ2 = 6.28). For this SNP, all the 
genotyping data was rechecked, additional 5% samples were genotyped by RFLP, 
and some of the samples were also sequenced. Results were compared with the 
genotyping data and 100% concordance was obtained, thus ruling out any technical 
discrepancies.  
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Figure.3.4. Chi-square values of whole population. Red line indicates the Tcritical = 3.84 
for 1 degree of freedom A chi-square value below this line shows that the genotype 
distribution does not deviate from Hardy-Weinberg equilibrium. 
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3. 2. 3. Larynx cancer risk 
3. 2. 3. 1. Overall effect of genotype 
To find the association between larynx cancer risk and the SNPs in NER genes, data 
were statistically analyzed by multivariate conditional logistic regression analysis 
and odds ratios (OR) with 95% confidence intervals (CI), conditioned on age and 
gender and adjusted for smoking behavior, alcohol consumption and education, 
were computed. The potential confounders were differently distributed among 
cases and controls. The high frequency allele was taken as the reference genotype. 
For each SNP, the distribution of gene variants in cases and controls, the crude and 
adjusted ORs and 95 % CI for laryngeal cancer risk are provided in Table.3.2. 
An increased risk for larynx cancer was shown by the individuals homozygous for 
variant allele of XPC Lys939Gln (OR= 1.42, 95% CI 0.91 – 2.19), RAD23B Ala249Val 
(OR= 1.27, 95% CI 0.68 – 2.35) and ERCC6 Arg1213Gly (OR= 1.37, 95% CI 0.75 – 
2.51), where as individuals with at least one variant allele of ERCC4 Arg415Gln and 
ERCC5 His1104Asp exhibited an increased risk for the cancer (OR= 1.33, 95% CI 0.9 
– 1.98) and (OR= 1.24, 95% CI 0.92 – 1.68) respectively. Also a decrease in risk for 
larynx cancer was found in individuals carrying variant allele of ERCC2 Arg156Arg 
(OR= 0.74, 95% CI 0.48 – 1.15) and ERCC6 Arg1230Pro (OR= 0.55, 95% CI 0.12 – 
2.56), however these results did not reach a statistical significance. No change in 
OR was found for rest of the SNPs. 
As the study population differs in educational status, smoking and alcohol intake, 
ORs were adjusted for these factors (Table.3.2). Figure.3.5 demonstrates a highly 
significant reduction in risk for larynx cancer was associated with the heterozygous 
group of ERCC6 Arg1230Pro (OR=0.53, 95% CI 0.33 – 0.86) and in the Pro-allele 
carriers (OR=0.53, 95% CI 0.34 - 0.85). Heterozygote ERCC5 Asp1104His carriers 
exhibited a significantly increased risk (OR=1.40, 95% CI 1.0 – 2.10). Risk association 
was not detected in the homozygous variant group for both SNPs largely due to the 
small number of samples. No statistically significant association was found between 
the other SNPs and laryngeal cancer risk in the current study.  
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Figure.3.5. Overall effect of RAD23B Ala249Val, ERCC5 Asp1104His and ERCC6 
Arg1230Pro on Laryngeal cancer risk. Wild type homozygous genotype was 
considered as reference. Bullets represent the ‘OR’, and whiskers show the 
respective ‘95% Confidence interval’ obtained for the genotype. Results were 
stratified for age, gender and adjusted for education, smoking and alcohol 
intake. 
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Table.3.2. Genotype distribution and odds ratios (ORs) determined for larynx cancer cases and controls 
Genotype Cases  Controls  Crude odds ratio  
Adjusted odds 
ratioa 
  n (%)  n (%)  OR 95% CI  OR 95% CI 
Subjects analyzed 248 (100)  647 (100)       
XPC Lys939Gln            
Lys/Lys 83 (34)  230 (36)  1.0   1.0  
Lys/Gln 120 (48)  329 (51)  1.01 0.73 - 1.40  0.90 0.61 - 1.3 
Gln/Gln 45 (18)  88 (14)  1.42 0.91 - 2.19  1.30 0.76 - 2.1 
Gln carriers 165 (67)  417 (65)  1.10 0.80 - 1.49  0.98 0.68 - 1.4 
RAD23B Ala249Val            
Ala/Ala 152 (61)  422 (65)  1.0   1.0  
Ala/Val 80 (32)  190 (29)  1.17 0.84 - 1.61  1.30 0.89 - 1.9 
Val/Val 16 (7)  35 (5)  1.27 0.68 - 2.35  1.50 0.70 - 3.1 
Val carriers 96 (39)  225 (35)  1.18 0.88 - 1.60  1.30 0.92 - 1.9 
ERCC6 Arg1230Pro            
Arg/Arg 211 (85)  522 (81)  1.0   1.0  
Arg/Pro 35 (14)  116 (18)  0.75 0.49 - 1.12  0.53 0.33 - 0.86 
Pro/Pro 2 (1)  9 (1)  0.55 0.12 - 2.56  0.52 0.09 - 3.0 
Pro carriers 37 (15)  125 (19)  0.73 0.49 - 1.09  0.53 0.34 - 0.85 
ERCC6 Arg1213Gly            
Arg/Arg 152 (61)  383 (59)  1.0   1.0  
Arg/Gly 78 (32)  231 (36)  0.85 0.61 - 1.16  0.82 0.57 - 1.2 
Gly/Gly 18 (7)  33 (5)  1.37 0.75 - 2.51  1.20 0.59 - 2.5 
Gly carriers 96 (39)  264 (41)  0.92 0.68 - 1.24  0.87 0.61 - 1.2 
ERCC2 Arg156Arg            
CC 79 (32)  199 (31)  1.0   1.0  
CA 128 (52)  309 (48)  1.04 0.75 - 1.45  1.10 0.73 - 1.6 
AA 41 (17)  139 (22)  0.74 0.48 - 1.15  0.79 0.48 - 1.3 
A carriers 169 (68)  448 (69)  1.05 0.77 - 1.44  0.98 0.68 - 1.4 
ERCC1 Asn118Asn            
TT 103 (42)  272 (42)  1.0   1.0  
TC 114 (46)  289 (45)  1.04 0.76 - 1.43  0.88 0.61 - 1.3 
CC 31 (13)  86 (13)  0.95 0.59 - 1.52  0.65 0.37 - 1.1 
C carriers 145 (59)  375 (58)  1.02 0.759-1.374  0.83 0.58 - 1.2 
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Table.3.2. Genotype distribution and odds ratios (ORs) determined for larynx cancer cases and controls 
Genotype Cases  Controls  Crude odds ratio  
Adjusted odds 
ratioa 
  n (%)  n (%)  OR 95% CI  OR 95% CI 
Subjects analyzed 248 (100)  647 (100)       
ERCC1 C8092A            
CC 146 (59)  392 (61)  1.0   1.0  
CA 87 (35)  218 (34)  1.07 0.78 - 1.46  0.91 0.63 - 1.3 
AA 15 (6)  37 (6)  1.09 0.58 - 2.04  0.88 0.42 - 1.8 
A carriers 102 (41)  255 (39)  1.07 0.78 - 1.45  0.90 0.64 - 1.3 
ERCC1 IVS5+33A> C            
CC 194 (78)  498 (77)  1.0   1.0  
CA 50 (20)  135 (21)  0.95 0.66 - 1.37  0.78 0.51 - 1.2 
AA 4 (2)  14 (2)  0.73 0.24 - 2.26  0.64 0.16 - 2.6 
A carriers 54 (22)  149 (23)  0.93 0.65 - 1.32  0.77 0.51 - 1.2 
ERCC4 Arg415Gln            
Arg/Arg 203 (82)  554 (86)  1.0   1.0  
Arg/Gln 44 (18)  90 (14)  1.33 0.9 - 1.98  1.50 0.92 - 2.3 
Gln/Gln 1 (0)  3 (1)  0.91 0.09 - 8.79  0.60 0.05 - 6.7 
Gln carriers 45 (18)  93 (14)  1.32 0.89 - 1.95  1.40 0.89 - 2.2 
ERCC5 Asp1104His            
Asp/Asp 137 (55)  380 (59)  1.0   1.0  
Asp/His 103 (42)  230 (36)  1.24 0.92 - 1.68  1.40 1.0 - 2.1 
His/His 8 (3)  37 (6)  0.60 0.27 - 1.32  0.62 0.25 - 1.6 
His carriers 111 (45)  267 (41)  1.15 0.86 - 1.55  1.30 0.93 - 1.9 
ERCC5 His46His            
CC 78 (32)  212 (33)  1.0   1.0  
CT 127 (51)  320 (50)  1.08 0.77 - 1.50  1.10 0.75 - 1.6 
TT 43 (17)  115 (18)  1.02 0.66 - 1.57  1.30 0.80 - 2.2 
T carriers 170 (69)  435 (67)  1.06 0.78 - 1.45  1.20 0.80 - 1.7 
a Stratified for age, gender and adjusted for education, smoking and alcohol intake. 
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3. 2. 3. 2. Gene-environment interactions 
For evaluating gene-environment interactions by analysis of subgroups, the 
heterozygous individuals and the variant allele carriers (heterozygous + 
homozygous for variant allele) were regarded because for most SNPs the group of 
homozygous variants was too small for regression analysis.  
3. 2. 3. 2. 1. Effect of smoking and genotype on larynx cancer risk 
For estimating effect of smoking and genotype on larynx cancer risk, the population 
was divided into two subgroups, light smokers with ≤ 20 py and heavy smokers 
with > 20 py, where 1 py = 20 cigarettes/day for 1 year. Figure.3.6 and Table.3.3 
demonstrate that the stratified results for smoking status presented a significantly 
reduced risk in heavy smokers (>20py) for ERCC6 Arg1230Pro heterozygous 
individuals (OR=0.59, 95% CI 0.35-0.98) and for ERCC6 1230Pro carriers (OR=0.56, 
95% CI 0.34 – 0.93). The heterozygous group and the 249Val allele carriers of 
RAD23B displayed a significantly enhanced risk in heavy smokers (OR for 
heterozygosity = 1.70, 95% CI 1.1-2.7; OR for 249Val allele carriers = 1.60, 95% CI 
1.10 – 2.50). In addition, cancer risk was increased in heavy smokers heterozygous 
for the ERCC5 Asp1104His polymorphism (OR=1.7, 95% CI 1.1-2.5). There were no 
obvious effects of smoking on the association of other SNPs and larynx cancer risk 
(data not shown). 
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Figure.3.6. Smoking and different genotypes: Effect of RAD23B Ala249Val, 
ERCC5 Asp1104His and ERCC6 Arg1230Pro on Laryngeal cancer risk. Wild type 
homozygous genotype was considered as reference. Bullets represent the ‘OR’, 
and whiskers show the respective ‘95% Confidence interval’ obtained for the 
genotype. Results were stratified for age, gender and adjusted for education, 
and alcohol intake. 
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a Stratified for age, gender and adjusted for education and alcohol intake 
Table.3.3. Larynx cancer risk: genotype distribution and odds ratios (ORs) for larynx cancer cases and controls after stratification for smoking 
Genotype Light smokers: ≤ 20 pack-years  Heavy smokers: > 20 pack-years 
 Cases  Controls  Adjusted odds ratioa  Cases  Controls  Adjusted odds ratioa 
 n (%)  n (%)  OR 95% CI  n (%)  n (%)  OR 95% CI 
Subjects analyzed 42 (100)  429 (100)     206 (100)  218 (100)    
RAD23B Ala249Val              
Ala/Ala 28 (67)  270 (63)  1.0   124 (60)  152 (70)  1.0  
Ala/Val 9 (21)  136 (32)  0.70 0.31 - 1.6  71 (34)  54 (25)  1.70 1.1 - 2.7 
Val carriers 14 (33)  159 (37)  0.95 0.47 - 1.9  82 (40)  66 (30)  1.60 1.1 - 2.5 
ERCC6 Arg1230Pro              
Arg/Arg 37 (88)  356 (83)  1.0   174 (84)  166 (76)  1.0  
Arg/Pro 4 (10)  68 (16)  0.43 0.14 - 1.3  31 (15)  48 (22)  0.59 0.35 - 0.98 
Pro carriers 5 (12)  73 (17)  0.52 0.18 - 1.5  32 (16)  52 (24)  0.56 0.34 - 0.93 
ERCC5 Asp1104His              
Asp/Asp 25 (60)  243 (57)  1.0   112 (54)  137 (63)  1.0  
Asp/His 15 (36)  162 (38)  0.81 0.40 - 1.6  88 (43)  68 (31)  1.70 1.1 - 2.5 
His carriers 17 (40)  186 (43)  0.85 0.43 - 1.7  94 (46)  81 (37)  1.40 0.97 - 2.2 
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3. 2. 3. 2. 2. Effect of alcohol intake and genotype on larynx cancer risk 
For estimating effect of alcohol consumption and genotype on larynx cancer risk, 
the population was divided into three subgroups, less than 25 g of alcohol 
intake/day, between 25–50 g of alcohol intake/day and above 50 g of alcohol 
consumed/day. Figure.3.7 and Table.3.4 demonstrate, the heavy alcohol 
consumers (> 50g/day) exhibited a significantly reduced risk for the ERCC6 1230Pro 
carriers (OR=0.46, 95% CI 0.23 – 0.92). For RAD23B Ala249Val, a 2 fold significantly 
increased risk was observed with heterozygotes and with Val carriers in heavy 
alcohol consumers (> 50g/day; OR for heterozygosity = 2.00, 95% CI 1.1-3.6; OR for 
249Val carriers=2.00, 95% CI 1.10 – 3.40). There were no obvious effects of alcohol 
intake on the association of other SNPs and larynx cancer risk (data not shown). 
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Figure.3.7. Effect of alcohol consumption and RAD23B Ala249Val, ERCC5 Asp1104His 
and ERCC6 Arg1230Pro on Laryngeal cancer risk. Wild type homozygous genotype was 
considered as reference. Bullets represent the ‘OR’, and whiskers show the respective 
‘95% Confidence interval’ obtained for the genotype. Results were stratified for age, 
gender and adjusted for education and smoking. 
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a Stratified for age, gender and adjusted for education and smoking. 
 
Table.3.4. Larynx cancer risk: genotype distribution and odds ratios (ORs) determined for larynx cancer cases and controls after stratification for alcohol consumption 
Genotype ≤ 25g of ethanol / day  > 25g -50g of ethanol / day  > 50g of ethanol / day 
 Cases  Controls  Adjusted odds ratioa  Cases  Controls  Adjusted odds ratioa  Cases  Controls  Adjusted odds ratioa 
 n (%)  n (%)  OR 95% CI  n (%)  n (%)  OR 95% CI  n (%)  n (%)  OR 95% CI 
Subjects analyzed 66 (100)  295 (100)     53 (100)  149 (100)     129 (100)  203 (100)    
RAD23B Ala249Val                     
Ala/Ala 38 (58)  181 (61)  1.0   40 (75)  103 (69)  1.0   74 (57)  138 (68)  1.0  
Ala/Val 24 (36)  99 (34)  1.20 0.63 - 2.3  10 (19)  37 (25)  0.66 0.26 - 1.7  46 (36)  54 (27)  2.00 1.10 - 3.60 
Val carriers 28 (42)  114 (39)  1.20 0.64 - 2.2  13 (25)  46 (31)  0.85 0.36 - 2.0  55 (43)  65 (32)  2.00 1.10 - 3.40 
ERCC6 Arg1230Pro                     
Arg/Arg 62 (94)  239 (81)  1.0   39 (74)  121 (81)  1.0   110 (85)  162 (80)  1.0  
Arg/Pro 3 (5)  52 (18)  0.18 0.05 - 0.69  13 (25)  27 (18)  1.20 0.48 - 3.1  19 (15)  37 (18)  0.50 0.25 - 1.0 
Pro carriers 4 (6)  56 (19)  0.24 0.08 - 0.78  14 (26)  28 (19)  1.30 0.53 - 3.2  19 (15)  41 (20)  0.46 0.23 - 0.92 
ERCC5 Asp1104His                     
Asp/Asp 33 (50)  170 (58)  1.0   30 (57)  88 (59)  1.0   74 (57)  122 (60)  1.0  
Asp/His 29 (44)  112 (38)  1.40 0.72 - 2.6  21 (40)  48 (32)  2.20 0.96 - 5.3  53 (41)  70 (34)  1.20 0.71 - 2.1 
His carriers 33 (50)  125 (42)  1.40 0.76 - 2.6  23 (43)  61 (41)  1.80 0.79 - 4.0  55 (43)  81 (40)  1.10 0.64 - 1.8 
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3. 2. 3. 2. 3. Combined effect of smoking and alcohol intake and genotype on larynx 
cancer risk 
For analyzing the combined effect of smoking and alcohol intake the study 
population was categorized into three groups, as shown by Figure.3.8 and 
Table.3.5. For Pro-carriers of ERCC6 Arg1230Pro, a significant reduction in risk was 
observed at high exposure level (OR=0.47, 95% CI 0.22 - 0.98). His-heterozygotes 
for ERCC5 Asp1104His exhibited a significant enhanced risk associated with the 
cancer in medium exposed group (OR=1.8, 95% CI 1.0 - 3.1). The Val-carriers in 
RAD23B Ala249Val had a 2.6-fold highly significant enhanced risk for larynx cancer 
at high exposure (OR=2.6, 95% CI 1.3 - 4.9). Risk increase was still stronger in 
subjects heterozygous for this SNP (OR=2.9, 95% CI 1.4-5.8). There were no obvious 
effects of smoking and alcohol intake on the association of other SNPs and larynx 
cancer risk (data not shown). 
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Figure.3.8. Combined effect of smoking and alcohol intake and different 
Genotypes, RAD23B Ala249Val, ERCC5 Asp1104His and ERCC6 Arg1230Pro on 
Larynx cancer risk. Wild type homozygous genotype was considered as reference 
and set to 1. Bars represent the ‘OR’, and whiskers show the respective ‘95% 
Confidence interval’ obtained for the genotype. Results were stratified for age and 
gender, adjusted for education. 
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 a ≤ 20 pack-years of smoking & ≤ 50g ethanol per day, 
b ≤20 pack-years of smoking and >50g ethanol per day or > 20 pack-years of smoking and ≤ 50g ethanol per day, 
c > 20 pack-years of smoking and > 50g ethanol per day, 
d Stratified for age, gender and adjusted  for education. 
 
Table.3.5. Larynx cancer risk: genotype distribution and odds ratios (ORs) determined for combined effect of smoking and alcohol-intake in larynx cancer cases and controls 
Genotype Low exposure groupa  Medium exposure groupb  High exposure groupc 
 Cases  Controls  
Adjusted odds 
ratiod 
  Cases  Controls  Adjusted odds ratiod   Cases  
Control
s 
 
Adjusted odds 
ratiod 
 n (%)  n (%)  OR 95% CI  n (%)  n (%)  OR 95% CI  n (%)  n (%)  OR 95% CI 
Subjects analyzed 29 (100)  
320 
(100) 
    103 (100)  233 (100)     
116 
(100) 
 94 (100)    
RAD23B Ala249Val                     
Ala/Ala 18 (62)  201 (63)  1.0   70 (68)  152 (65)  1.0   64 (55)  69 (73)  1.0  
Ala/Val 7 (24)  101 (32)  0.73 0.27 - 2.0  29 (28)  70 (30)  1.00 0.58 - 1.8  44 (38)  19 (20)  2.90 1.4 - 5.8 
Val carriers 11 (38)  119 (37)  0.96 0.40 - 2.3  33 (32)  81 (35)  1.10 0.61 - 1.9  52 (45)  25 (27)  2.60 1.3 - 4.9 
ERCC6 Arg1230Pro                     
Arg/Arg 25 (86)  265 (83)  1.0   88 (85)  186 (80)  1.0   98 (85)  71 (76)  1.0  
Arg/Pro 3 (10)  52 (16)  0.56 0.16 - 2.0  14 (14)  43 (19)  0.5 0.26 - 1.1  18 (16)  21 (22)  0.52 0.24 - 1.1 
Pro carriers 4 (14)  55 (17)  0.69 0.22 - 2.2  15 (15)  47 (20)  0.6 0.27 - 1.1  18 (16)  23 (25)  0.47 
0.22 - 
0.98 
ERCC5 Asp1104His                     
Asp/Asp 17 (59)  179 (56)  1.0   54 (52)  143 (61)  1.0   66 (57)  58 (62)  1.0  
Asp/His 10 (35)  122 (38)  0.79 0.32 - 1.9  45 (44)  78 (34)  1.80 1.0 - 3.1  48 (41)  30 (32)  1.30 0.68 - 2.3 
His carriers 12 (41)  141 (44)  0.88 0.38 - 2.1  49 (48)  90 (39)  1.60 0.94 - 2.7  50 (43)  36 (38)  1.10 0.60 - 2.0 
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3. 2. 3. 3. Gene-Gene interactions 
SNPs in genes working as a complex in NER pathway (XPC-RAD23B and ERCC1-
ERCC4) and the genes showing an overall risk effect in the current study (RAD23B-
ERCC5-ERCC6) were tested for a multiplicative effect associated with larynx cancer 
risk (Table.3.3). It was observed that presence of three risk alleles of XPC Lys939Gln 
and RAD23B Ala249Val increased the cancer risk by 2.1 fold (OR=2.1, 95% CI 1.0 - 
4.3). Combined analysis of ERCC1-ERCC4 SNPs did not reveal any significant effects. 
Carriers of more than one allele of genes showing an overall effect on risk were 
compared, risk increased up to 2 fold but the estimates were not statistically 
significant. 
3. 2. 3. 4. Linkage analysis 
SNPs present in the same gene and genes present on the same chromosome were 
analyzed for linkage. For SNPs in ERCC1 (Asn118Asn, C8092A and IVS5+33), ERCC2 
(Arg156Arg, Lys751Gln and Asp312Asn) and ERCC5 (Asp1104His and His46His), a 
highly significant allelic association was found (P<0.0001 for both, larynx cancer 
cases and controls). The two SNPs present in ERCC6 (Arg1213Gly and Arg1230Pro) 
presented a high association in larynx cancer cases (P<0.0001), however weaker in 
controls (P=0.03). ERCC1 and ERCC2 are located in close proximity on chromosome 
19 and all the six SNPs from both these genes were strongly associated (P<0.0001 
for larynx cancer cases, controls). These results hint towards linkage 
disequilibrium. 
3. 2. 3. 5. Haplotype analysis 
Linked SNPs were analyzed for haplotype effects. For ERCC6 (Arg1213Gly and 
Arg1230Pro) the carriers of the 1213Arg-1230Pro haplotype had a significant 
reduction in laryngeal cancer risk (OR=0.57, 95% CI 0.37 – 0.87). We did not find a 
statistically significant association between the other haplotypes and laryngeal 
cancer risk in the current study (data not shown). 
 
Results NER and cancer risk 
94 
 
Table.3.3. Larynx cancer risk and presence of more than one ‘risk allele’. Combination 
of risk alleles from genes working as a complex in the NER pathway (XPC + RAD23B and 
ERCC1 + ERCC4) and the genes indicating larynx cancer risk when tested individually 
(RAD23B + ERCC5 + ERCC6) 
No. of risk 
alleles 
Cases  Controls  Crude odds ratio  
Adjusted odds 
ratioa 
 n (%)  n (%)  OR 95% CI  OR 95% CI 
Subjects 
analyzed 
248 (100) 
 
647 (100)  
  
 
  
XPC - Rad23B 
  
  
  
 
  
0 49 (20) 
 
158 (24)  1.0 
 
 1.0 
 
1 105 (42) 
 
263 (41)  1.30 0.87 - 1.9  1.30 0.81 - 2.1 
2 69 (28) 
 
181 (28)  1.23 0.80 - 1.9  1.30 0.76 - 2.1 
3 25 (10) 
 
45 ( 7)  1.80* 1.0 - 3.2  2.10* 1.0 - 4.3 
ERCC1 - ERCC4    
  
 
  
0 14 ( 6) 
 
31 ( 5)  1.0 
 
 1.0 
 
1 60 (24) 
 
159 (25)  0.84 0.42 - 1.7  1.20 0.50 - 2.7 
2 25 (10) 
 
65 (10)  0.85 0.4 - 1.9  0.84 0.32 - 2.2 
3 37 (15) 
 
93 (14)  0.90 0.42 - 1.8  0.98 0.40 - 2.4 
4 93 (37) 
 
258 (40)  0.80 0.41 - 1.6  1.30 0.55 - 2.8 
5 19 ( 8) 
 
41 ( 6)  1.03 0.45 - 2.4  1.40 0.52 - 3.9 
Rad23B - ERCC5 - ERCC6  
1 2 ( 1) 
 
8 ( 1)  1.0 
 
 1.0 
 
2 11 ( 4) 
 
27 ( 4)  1.63 0.3 - 8.9  1.60 0.19 - 13.7 
3 41 (17) 
 
118 (18)  1.39 0.28 - 6.8  2.10 0.28 - 14.8 
4 55 (22) 
 
144 (22)  1.53 0.31 - 7.4  2.40 0.34 - 17.6 
5 46 (19) 
 
122 (19)  1.51 0.31 - 7.4  2.10 0.29 - 15.2 
6 50 (20) 
 
113 (18)  1.77 0.36 - 8.6  2.50 0.35 - 18.2 
7 28 (11) 
 
74 (11)  1.51 0.30 - 7.6  2.00 0.28 - 15.2 
8 15 ( 6) 
 
41 ( 6)  1.46 0.28 - 7.7  2.40 0.30 - 18.4 
a Stratified for age, gender and adjusted for education, smoking and alcohol intake. 
*P < 0.05 (two tailed t-test) 
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4. Results, NER and cancer therapy 
In the current study 72 pure TCM compounds were screened for cytotoxicity against 
two NER deficient cell lines XP3BE (deficient in XPC) and GM10902 (deficient in 
ERCC6). As a control the normal cell line, GM01310 was included. Compounds 
differentially cytotoxic to NER deficient cells and not affecting normal cells were 
identified and selected ones were studied for their effects on cell cycle distribution 
and genotoxicity. The results obtained were validated for the strongest candidate in 
a second set of cell lines carrying XPC and ERCC6 deficiencies.  
4. 1. Cell models 
In our study, five cell lines were included (Table.2.7). Freshly grown cultures were 
tested for contaminations before starting any experiment and after six weeks. 
Table.4.1 provides the doubling times of the cell lines. 9 to 10 weeks old cultures 
were discarded and new cells were grown. 
 
 
Table.4.1. Doubling time of the cell lines included in the study 
Cell line / Coriell code Gene defect Doubling time (hrs) 
mean ± std.dev 
GM01310 Normal 48.4 ± 0.43 
GM10902 ERCC6 deficient, point mutation at C2282T 
(Colella et al., 2000) 
43.7 ± 1.44 
XP3BE / GM02248 XPC deficient cell line, 83bp insertion 
following codon Lys90, (Li et al., 1993). 
37.1 ± 3.38 
XP4PA / GM15983 XPC deficient cell line, dinucleotide (TG) 
deletion at 1483-1484 bp (Li et al., 1993) 
31.8 ± 2.01 
XP4PA-SE2 / GM16248 Fully corrected form of XP4PA by stable 
transfection using pXPC-3 plasmid 
(Legerski & Peterson, 1992) 
47.8 ± 5.07 
Results NER and cancer therapy 
96 
4. 1. 1. Mutation confirmation 
As a control, mutations reported for the cell lines were checked either by PCR 
amplification or sequencing. Presence of ERCC6 and XPC proteins was checked by 
western blotting. For GM01310 (Figure.4.1) no mutations were found and normal 
sized XPC (125 kDa) and ERCC6 (168 kDa) proteins were present. XP3BE is 
heterozygous for an 83 bp insertion at position 462 in cDNA leading to a frameshift 
mutation (Li et al., 1993). PCR amplification detected two PCR products (Figure.4.1-
a) a normal 254 bp band and a second, lighter band with the insertion. The cell line 
had only a very small amount of XPC protein and a normal sized ERCC6 protein 
(Figure.4.1-d & e). GM10902 harbors a point mutation at position C2282T in the 
cDNA (Colella et al., 2000). The region was sequenced and a G > A transition 
(Figure.4.1-b) was observed in the genomic DNA of GM10902. At protein level, only 
a week band of ERCC6 (Figure.4.1-e) was observed. The cell line had a normal sized 
XPC protein. XP4PA had no visible XPC protein but had a normal sized ERCC6 (168 
kDa) protein (Figure.4.1-c & e). XP4PA-SE2 is the fully corrected version of XP4PA, 
the cell line exhibits 90% of normal XPC expression and the protein is truncated by 
53 amino acids (Emmert et al., 2000). An XPC protein (Figure.4.1-c) slightly smaller 
in size than the normal XPC (125kDa; in GM01310) was detected. The cell line had 
normal sized ERCC6 protein (Figure.4.1-e). 
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Figure.4.1. Confirmation of the mutations reported in the NER deficient cell lines. a. PCR 
amplification of XPC cDNA around position 462 (carrying mutation in XP3BE) in GM01310, 
XP3BE and GM10902. PCR products were separated on 2% Agarose gel. Arrow indicates 83bp 
insertion in XP3BE.  b. Genomic DNA sequence of GM01310 and GM10902. Arrows indicate G > 
A transition at position C2282T. c. XPC protein in XP4PA, XP4PA-SE2 in comparison with 
GM01310. No protein is visible in XP4PA lane. XPC in XP4PA-SE2 is slightly smaller than 
GM01310. d. XPC protein in XP3BE and GM10902 in comparison with GM01310. A very weak 
band is visible in XP3BE lane. Varying amount of total cellular proteins was separated on the gel 
(see ß-actin). e. ERCC6 protein in XP4PA, XP4PA-SE2, GM01310, GM10902 and XP3BE. 
GM10902 has a weak band. XPC (125kDa) and ERCC6 (168kDa) proteins were detected by 
western blotting using gene specific antibodies and ß-actin (43kDa) was used as a reference. 
              
 
b. GM01310                          GM10902 
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4. 1. 2. P53 status of the cell lines 
Expression of P53 in the cell lines was checked by western blotting. Figure.4.2 
demonstrates that P53 expression was cell type specific. Overall the level of p53 in 
all cell lines was either undetectable or very low and p53/47 complex, and 
ubiquitinated forms of p53 were present. This profile is normal for resting cells (Yin 
et al., 2002; Maki, 1999) 
4. 1. 3. Sensitivity to UV exposure 
NER pathway is involved in the repair of bulky lesions produced by UV light. In case 
of a deficient NER cells are more sensitive to UV exposure than the normal cells. To 
examine the response of our cell lines to UV light exposure, cultures were exposed 
to different intensities of UVC and grown for 48 hrs at normal cell culture 
Figure.4.2. p53 expression in the cell lines included in the study. Proteins were 
detected by western blotting using gene specific antibodies and ß-Actin was used 
as a reference. 150 µg of total cellular proteins were separated on the gel. 
 
 
   M          XP4PA     XP4PA-SE2     GM01310      XP3BE     GM10902 
 
 XPC        -           +     +         -            + 
ERCC6        +           +     +         +             - 
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conditions. The percent viabilities relative to unexposed samples were measured by 
Calcein assay.  
Figure.4.3 demonstrates that GM01310 and XP4PA-SE2, the NER proficient cell lines 
had a better relative percent viability with increased UVC intensity. The IC50 values 
for GM01310 and XP4PA-SE2 were 41.09 J/m2 and 27.92 J/m2, respectively. NER 
deficient cell lines XP3BE, XP4PA and GM10902 had poor relative viabilities with 
increased UVC intensity. The IC50 value was 7.67 J/m
2 for XP3BE, 15.66 J/m2 for 
XP4PA and 16.22 J/m2 for GM10902. Exposure to 60 J/m2 UVC killed almost all the 
cell lines.  
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Figure.4.3. Viability curves. Sensitivity of the five cell lines to different dose of 
UVC (J/m2) exposure. After exposure cultures were grown for 48hrs and their 
percent growth (mean ± std.dev) relative to the unexposed samples was 
measured by Calcein assay. NER deficient cell lines (GM10902, XP3BE, XP4PA) 
are more sensitive to UVC. The results are from two experiments with three 
replicates each. 
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4. 2. Silencing of ERCC6 gene in XP4PA-SE2 cells 
ERCC6 was silenced in XP4PA-SE2 cells using ON-TARGETplus SMARTpool siRNA. 
Luciferase and GAPDH siRNA were used as negative and positive controls for 
knockdown, respectively. Transfection reagent treated and non transfected cells 
(NTC) were included as experimental controls. Before starting the knockdown 
experiments, certain conditions like plating densities, plating effects and suitable 
ratios of transfection reagent/siRNA were optimized. A plating density of 6 x 104 
cells/ml was considered as suitable for efficient gene silencing for up to 96hrs. 
4. 2. 1. Optimized conditions for transfection  
Two transfection reagents DharmaFECT-4 (DF4) and polyFECT were tested for their 
transfection efficiency. Exponentially growing cells were transfected with 
Fluorescein-siRNA (15 nM) by two concentrations of each reagent for 4 hrs. Cells 
(Figure.4.4-a) were counted using fluorescent microscope under blue (wavelength 
390 to 490 nm) and white light and the transfection efficiency was calculated. At 
DF4/siRNA-5:1 the transfection efficiency was 96% and at DF4/siRNA-10:1 it was 
75.76%. Both concentrations of polyFECT and the non treated cells did not show 
any fluorescent cells. 
To check the effect of the transfection reagent on cell viability and plating 
efficiency, exponentially growing cultures were incubated with the reagents for 24 
hrs in a normal 24-well plate and collagen coated plates which should offer better 
adhering. After 24 hrs, cells in the normal 24-well plate were floating whereas those 
incubated in collagen coated plates were still attached to the surface. When 
checked for cell viability (Figure.4.4-b) DF4 was cytotoxic to the cells. DF 4/siRNA-
5:1 samples growing in collagen coated culture plates had around 76% viable cells 
and cultures in normal plates had around 60% viability. At higher DF4 concentration 
the viability was very low. PolyFECT did not show any cytotoxicity to the cells. 
Clearly, DF4 transfected the cells with high efficiency but it was cytotoxic. This 
situation was not very ideal for experiments where we aim to see cytotoxicity and 
DNA damage caused by ascaridol in ERCC6-silenced cells. To reduce the cytotoxic 
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effects cells were grown in collagen-coated plates with lower concentrations of DF4. 
In addition, the transfection media was replaced by culture media after 24 hrs and 
cells were allowed to grow for another 48 hrs before any experiments were 
performed on them. 
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Figure.4.4. Optimization of conditions for transfection of XP4PA-SE2 cells with 
DF4/Fluorescein siRNA (5:1, 10:1) and polyFECT/Fluorescein siRNA (8:1, 16:1). a. 
Transfected cells (DF4/siRNA-5:1 and polyFECT/siRNA-8:1) observed under fluorescent 
microscope in blue (wavelength 390 to 490 nm) and white light after 4 hours of 
incubation. b. Percent viability of the cells grown in a normal 24-well plate and collagen 
coated 24-well plate after 24 hours of incubation. Viability (mean ± std.dev) as measured 
with trypan blue staining. Experiment included 3 replicates per treatment. 
b. 
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4. 2. 2. ERCC6 knockdown 
The ERCC6 gene was silenced in exponentially growing cultures of XP4PA-SE2 using 
the transfection conditions described above and ON-TARGETplus SMARTpool siRNA. 
The amount of DF4 is the same but the amount of siRNA was increased according to 
recommendations of manufacturer. Two concentrations of DF4/ERCC6 siRNA (0.88, 
1.76) were used to silence the gene. Luciferase and 
 GAPDH siRNA were included as negative and positive controls for knockdown, 
respectively. DF4 only and NTC were included as experimental controls. To analyze 
the knockdown, expression of ERCC6 gene was checked both at mRNA and protein 
level after 24, 48, 72 and 96 hrs. Relative quantification of mRNA levels was done by 
real time PCR on LightCycler 480 after reverse transcription and protein expression 
was checked by western blotting. Each experiment was performed twice with two 
replicates for each treatment. 
4. 2. 3. Gene expression at mRNA level 
Total RNA was extracted using RNeasy mini kit and cDNA was prepared using 
random hexamer primers and superscript III RT. Gene expression was quantified 
relative to HPRT expression (housekeeping gene) by LightCycler 480. Gene 
expression was calculated relative to expression in luciferase siRNA treated 
samples. Figure.4.5-a shows that expression of ERCC6 at DF4/siRNA-0.88 was 
reduced to 20% after 24 hrs but after 48 hrs expression levels resumed to normal. 
At DF4/siRNA-1.76 after 24 hrs expression levels were reduced to 18% and they 
remained below 50% even after 96 hrs of transfection. Silencing of GAPDH (positive 
control for knockdown) showed a gradual decrease in gene expression reaching to 
14% after 72 hrs. DF4 only and non-transfect cells had normal or high expression of 
ERCC6 gene. 
4. 2. 4. Gene expression at protein level 
Protein expression was analyzed by western blotting using gene specific antibodies, 
and compared to ß-actin expression. Results are provided in Figure.4.2-b. After 24 
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hrs, ERCC6 protein is still visible in all samples. In the DF4/siRNA-0.88 sample, a 
weak ERCC6 band is visible after 48 hrs and 72 hrs whereas it disappears after 96 
hrs (indicated by arrows). In DF4/siRNA-1.76 samples ERCC6 is not visible after 48, 
72 and 96 hrs. The protein is present in negative control and NTC. 
 
As DF4/siRNA-1.76 silenced the gene effectively, both at mRNA and protein level for 
longer periods of time, this concentration was used in further experiments. 
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Figure.4.5. ERCC6 knockdown in XP4PA-SE2 cells using ON-TARGETplus SMARTpool siRNA 
(Dharmacon) after 24, 48, 72 and 96hrs. Two concentrations of DF4/ERCC6 siRNA (0.88, 1.76) 
were used to silence ERCC6. Luciferase and GAPDH siRNA were included as negative and positive 
controls for knockdown, respectively. DF4 only and NTC (non transfected cells) were included as 
experimental controls. a. Relative quantification of ERCC6 and GAPDH expression at mRNA level 
by real time PCR. HPRT was used as reference. GAPDH indicates knockdown of GAPDH and 
expression of GAPDH was measured for these samples. Results are relative to ERCC6 or GAPDH 
expression in negative control. b. ERCC6 expression at protein level. ß-Actin was used as a 
reference. Arrows indicate no visible ERCC6 band. These are results of two experiments with two 
replicates each treatment. 
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4. 3. Viability / Cytotoxicity assay  
 In the present study fluorescence based ‘The LIVE/DEAD® Viability/Cytotoxicity 
assay’ (Invitrogen) was used to measure relative percentage of live and dead cells 
simultaneously. The assay comprises of two fluorescent dyes, Calcein AM 
(excitation: 485nm, emission: 520nm) for detecting live cells and Ethidium 
Homodimer (excitation: 520nm, emission: 620nm) for detection of dead cells. 
Table.4.2 gives the optimum concentrations of the dyes used for each cell line. 
Ethidium Homodimer could not be optimized for adherent cells (XP4PA and XP4PA-
SE2). A possible explanation is that washing step removed all the dead cells. For 
these cell lines relative viabilities were measured by Calcein AM only (Calcein assay). 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table.4.2. Optimized concentrations of dyes used for each cell line in 
LIVE/DEAD® Viability/Cytotoxicity assay 
Cell line 
Dye concentration 
Calcein AM (µM) 
Ethidium Homodimer 
(µM) 
GM01310 1 2 
XP3BE 2 2 
GM10902 3 2 
XP4PA 5 - 
XP4PA-SE2 5 - 
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4. 3. 1. Calibration of the assay 
To calibrate the assay, live and dead cells were mixed in different proportions and 
relative percent viability and relative percentage of dead cells was calculated 
according to LIVE/DEAD® Viability/Cytotoxicity assay. Figure.4.6 shows the 
calibration curves for GM01310. The assay permits a wide range of measurements 
in cultures with varying proportions of live and dead cells. The simultaneous 
determination of live and dead cells allows a bidirectional check in cytotoxicity 
screening. An average variation of 10% was observed between replicates. 
4. 4. Screening of TCM drugs for their differential cytotoxic effect on NER 
deficient cell lines 
In the current project a total of 72 drugs derived from TCM were screened for their 
activity against two NER deficient cell lines, XP3BE; an XPC deficient cell line and 
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Figure.4.6. Relative percentage of live ( ) and dead ( ) cells of GM01310 
measured in samples carrying different proportions of live and dead cells. 
Percentage of live cells was calculated relative to unexposed sample and 
percentage of dead cells was calculated relative to 100% dead culture. 
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GM10902; an ERCC6/CSB deficient cell line. As a control, the normal cell line 
GM01310 was used. After treatment with the drugs, relative percentage of live and 
dead cells was measured by LIVE/DEAD® Viability/Cytotoxicity assay and relative 
percent viabilities were considered as a measure of drug cytotoxicity.  
4. 4. 1. Determination of a suitable time for drug exposure – an experiment with 
arsenic trioxide 
To determine a suitable time for TCM exposure, exponentially growing cultures (> 
90% viability) of XP3BE, GM10902 and GM01310 were exposed to arsenic trioxide 
(10 µg/ml) for different time periods (10 min, 3, 6, 24 hrs) and their relative percent 
viabilities were determined. Figure.4.7 depicts that after 10 min of exposure, 
relative percentage of viable cells decreased to around 75% for the three cell lines, 
which remained stable after 3 hrs. After 6 hrs of incubation with the drug around 
Figure.4.7. Effect of arsenic trioxide (10 µg/ml) on relative percent viability of 
GM01310, XP3BE and GM10902 cells over a time period of 24 hrs. Exponentially 
growing cultures of the three cell lines were exposed to arsenic trioxide for different 
time points and samples were analyzed by LIVE/DEAD® Viability / Cytotoxicity Assay.  
Results are relative to unexposed samples. An ‘early effect’ of the drug was observed 
after 10 min exposure and a ‘later effect’ after 24 hrs. The results are from a single 
experiment with three replicates each treatment. 
 
Results NER and cancer therapy 
108 
55% of the cells from the three cell lines were dead and there was no significant 
difference between the cell lines. After 24 hrs, GM10902 had no viable cells, XP3BE 
had 13.9 ± 6.4% viable cells and the normal cells had a surviving proportion of 45.8 
± 2.1%.  
From these results ‘10 min exposure’ was considered as ideal for observing an ‘early 
effect’ of the drug and ‘24 hrs exposure’ as a time point where drugs show ‘later 
effect’ on the three cell lines. Based on this result we also found our first candidate 
drug differentially killing NER deficient cells. 
4. 4. 2. Screening of TCM drugs 
All the TCM compounds and their solvents were screened for cytotoxicity against 
GM01310, XP3BE and GM10902. Exponentially growing cultures (> 90% viability; 7.5 
X 105 cells / ml) were exposed to the saturated solutions of the compounds (1 µl / 
100 µl of the cell suspension) for 10 min and 24 hours and grown at normal culture 
conditions. Relative percent viabilities, a measure of drug cytotoxicity, were 
measured by LIVE/DEAD® Viability/Cytotoxicity assay. The screening experiment 
was performed twice with three replicates of each treatment. 
Drugs were categorized as having ‘no effect’ when the measured viability was ≥ 50% 
after 10 min or 24 hrs, having ‘Moderate effect’ when viability was between < 50% 
to ≥ 25 %, having ‘Strong effect’ when < 25 % to ≥ 5 % viability and having ‘Strongest 
effect’ when < 5 % viability was observed.  
The cytotoxicity screening revealed that most of the TCM drugs were active after 24 
hrs. Figure.4.8 demonstrates the overall results of the screening. Fifty three out of 
72 drugs (74%) had either ‘no’ or ‘comparable’ effects on the three cell lines . 6 
drugs  were highly cytotoxic, with a 100% killing effect on all the three cell lines 
whereas 13 drugs (18%) showed a differential activity against at least one of the 
mutant cell lines. Of these, 2 drugs (quercetin and scopoletin) were specifically 
active against XP3BE only, 1 drug (TCM-25-RAB) was active against GM10902 only 
and 10 of the 72 TCM drugs (14%; arsenic trioxide, ascaridol, isonardosinon, TCM-
22-RAB, TCM-23-RAB, TCM-44-RAB, TCM-47-RAB, TCM-48-RAB, TCM-50-RAB, TCM-
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Figure.4.8. Screening for cytotoxicity of TCM drugs to GM01310, XP3BE and 
GM10902 cells. Exponentially growing cultures were exposed to 1% of stock 
solution of the drugs and analyzed by LIVE/DEAD® Viability / Cytotoxicity Assay 
after 24 hrs. Unexposed and solvent exposed samples were included as 
controls. The results are from two independent experiments with three 
replicates for each treatment. 
54-RAB) were killing the two NER deficient cell lines more efficiently when 
compared with the normal cells (Table.4.3).  
Depending on the amount available, 6 of these drugs (Table.4.4; arsenic trioxide, 
ascaridol, isonardosinon, TCM-25-RAB, quercetin and scopoletin) were picked for 
further analyses. 
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Table.4.3. TCM drugs having differential cytotoxic effects on NER deficient cell 
lines. 
no. 
Effective 
compound 
Cell lines 
GM01310 GM10902 XP3BE 
    Early effect2 
Later 
effect2 
Early 
effect 
Later 
effect 
Early 
effect 
Later 
effect 
1 Arsenic trioxide1 - - - +3 - ++ 
2 Ascaridol - - - ++ - ++ 
3 Isonardosinon - - - ++ - ++ 
4 TCM-22-RAB - - - ++ - ++ 
5 TCM-25-RAB - - - + - - 
6 TCM-23-RAB - + - ++ - ++ 
7 TCM-44-RAB - + - ++ - ++ 
8 TCM-47-RAB - + - +++ + ++ 
9 TCM-48-RAB - + + +++ ++ +++ 
10 TCM-50-RAB - + - +++ - +++ 
11 TCM-54-RAB - - - +++ - +++ 
12 Quercetin - - - - - ++ 
13 Scopoletin - - - - - ++ 
1 Red color indicates the drugs were selected for further analysis, 
2 Early effect; 10 min exposure to the compound, later effect; 24 hour exposure,  
3 +, ≤ 50 % viability; ++, ≤ 25 %; +++, ≤ 5 % and -, no effect. 
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4. 5. Analysis of the selected drugs 
Table.4.4 provides some details of the selected drugs. Arsenic trioxide and 
quercetin are established cytostatic drugs. Arsenic trioxide was selected as a 
positive control for our experiments as the drug is known to cause DNA damage and 
to effect cell cycle. Furthermore as we were blessed with plenty of this drug, it was 
also used to optimize conditions for different experiments.  
Table.4.4. Details of the TCM drugs selected after screening experiments. 
name Structure 
mole mass 
(g/mol) 
CAS-no. Information available 
Arsenic 
trioxide 
 
197.841 1327-53-3 Well studied compound 
(Gazitt & Akay, 2005; Miller 
et al., 2002), used in 
treatment of acute 
promyelocytic leukemia 
(APL) (Shen et al., 1997). 
Isonardosinon 
 
250.0 -   
Quercetin 
 
338.0 117-39-5 Potential anti-cancer drug 
(van Erk et al., 2005). 
Ascaridol 
 
168.23 512-85-6 It is an antihelmintic 
(Vanfleteren & Roets, 1972), 
has anti-malarial properties 
(Pollack et al., 1990) and is a 
potential anti-cancer drug. 
Scopoletin  
 
192.6 92-61-5 Scopoletin is an antioxidant 
(Shaw et al., 2003) and it 
induces apoptosis in 
promyelocytic cells (Kim et 
al., 2005). 
TCM-25-RAB Under investigation   
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4. 5. 1. Determination of IC50 values 
To determine IC50 values of the selected drugs, exponentially growing cultures (> 
90% viability; 7.5 X 105 cells/ml) of GM01310, XP3BE and GM10902 were exposed to 
different concentrations of the drugs for 24 hrs and relative % viabilities were 
measured. Relative viability curves (Figure.4.9) were generated against drug 
concentrations and IC50 values of the drugs for each cell line were calculated. As a 
control, solvent exposed and unexposed samples were included. 
Ascaridol (Figure.4.9-a) did not kill 50% of GM01310 cells (IC50 = > 30 µg/ml) at 
concentrations upto 30 µg/ml. As the drug was available only as a solution in DMSO, 
testing at higher concentrations would have increased DMSO to intolerable levels. 
NER deficient cell lines were very sensitive to the drug with an IC50 of 0.025 µg/ml 
and 0.03 µg/ml for GM10902 and XP3BE, respectively. A difference of more than 
1000 fold in resistance was observed between normal and NER deficient cells.  
Arsenic trioxide (Figure.4.9-b) had an IC50 of 2.2 µg/ml for GM01310, 0.4 µg/ml for 
GM10902 and 0.7 µg/ml for XP3BE. Normal cells were 3 to 5.5 times resistant to 
arsenic trioxide exposure when compared with NER deficient cells. 
Isonardosinon (Figure.4.9-c) was active against both the NER deficient cell lines. It 
had an IC50 of 30 µg/ml for the GM01310, 2.6 µg/ml for GM10902 and 1.6 µg/ml for 
XP3BE cells. 
Quercetin (Figure.4.9-d) and Scopoletin (Figure.4.9-e) specifically affected XP3BE. 
For these cells quercetin and scopoletin had an IC50 value of 0.5 µg/ml and 14.7 
µg/ml, respectively. Quercetin exposure did not kill 50% of GM01310 and GM10902 
cells even at highest concentrations (60 µg/ml) used in our experiments. Scopoletin 
had an IC50 value of 24.9 µg/ml for GM01310 and 22.1 µg/ml for GM10902 cells. 
TCM-25-RAB (Figure.4.9-f) was specifically active against GM10902 (IC50 = 8.9 
µg/ml). However it also showed toxicity to XP3BE cells (IC50 = 15.4 µg/ml). Its IC50 
value for GM01310 was 21.3 µg/ml. 
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Figure.4.9. Determination of IC50 values for 6 TCM compounds in GM01310, GM10902 
and XP3BE. Exponentially growing cultures were exposed to serial dilutions of the 
drugs (µg/ml) for 24hrs and relative % viabilities (mean ± std.dev) were measured using 
LIVE/DEAD® Viability/Cytotoxicity Assay. a. Ascaridol, b. Arsenic trioxide, c. 
Isonardosinon, d. Quercetin, e. Scopoletin and f. TCM-25-RAB. 
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4. 5. 2. Cell cycle analysis  
Analysis of cell cycle distribution by flow cytometry was used as a tool for 
characterization of the selected TCM drugs. In flow cytometry DNA content of cells 
was measured and propidium iodide (PI) was used as DNA dye. The DNA content of 
a cell can provide a great deal of information about the cell cycle and consequently 
the effect of external exposure e.g., drug treatment, on the cell cycle. Figure.2.3 
demonstrates four different cell cycle phases as observed by flow cytometry. G1 
phase comprises diploid (2n) cells, S phase is comprised of cells replicating their 
DNA content and generally lie between G1 and G2/M phase, G2/M phase consists 
of tetraploid (4n) cells, and subG1 phase includes apoptotic cells having DNA less 
than diploid cells. 
The influence of the selected TCM drugs on a specific cell cycle phase, such as cell 
cycle arrests was studied. An increase in the SubG1 peak was considered as cell 
killing by apoptosis. 
4. 5. 2. 1. Determination of a suitable time for observation of TCM effects on cell 
cycle distribution – an experiment with arsenic trioxide 
Before starting experiments with the selected drugs, a suitable time to observe a 
clear effect of a given drug on cell cycle distribution was determined by exposing 
GM01310 cells to different arsenic trioxide (0.73, 2.2 µg/ml) concentrations for 4 
hrs, 8 hrs and 24 hrs.  Samples were fixed in 70% ice cold ethanol, stained with 
propidium iodide for 30 min and analyzed on a FACScalibur using the ‘CellQuestPro’ 
software.  
The Figure.4.10 demonstrates that exposure to arsenic trioxide (0.73, 2.2 µg/ml) 
had no effect on the cells after 4 hrs. After 8 hrs exposure, minor effects of 0.73 
µg/ml arsenic trioxide were observed and 2.2 µg/ml arsenic trioxide caused a 
decrease in G2/M peak and an increase in subG1 peak. Exposure to 0.73 µg/ml 
arsenic trioxide for 24 hrs increases the G2/M peak indicating G2/M arrest. At 2.2 
µg/ml and after 24 hrs, a sharp decrease in G2/M peak and increase in subG1 peak 
is observed indicating that cells arrested in G2/M at lower arsenic trioxide 
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concentration undergo apoptosis at the higher concentration. As maximum drug 
effect for the concentrations used in the experiment was observed after 24 hrs, this 
time point was considered suitable for further experiments. 
 
 
 
 
 
 
 
 
 
 
4. 5. 2. 2. Effect of the selected TCM drugs on cell cycle progression 
To investigate the effect of the selected drugs on cell cycle distribution 
exponentially growing cells of XP3BE, GM10902 and GM01310 were exposed to 
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Figure.4.10. Cell cycle analysis of GM01310 cells after arsenic trioxide (0.73, 2.2 
µg/ml) treatment after 4, 8 and 24 hours. Red arrow indicates increase in G2/M 
phase at 0.73 µg/ml arsenic trioxide and boxed data show a sharp decrease in 
G2/M and increase in subG1 at 2.2 µg/ml after 24 hrs indicating G2/M arrest at 
the lower arsenic trioxide concentration and cells arrested in G2/M undergoing 
apoptosis at higher concentration. 
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different concentrations of the drugs for 24 hrs and samples were handled as 
explained in the previous section. 
4. 5. 2. 2. 1. Ascaridol 
Ascaridol (Figure.4.11 and Table.4.5) caused a significant decrease of cells in G1 
phase in all three cell lines at different concentrations (0.05, 0.1, 0.5 and 1.0 µg/ml) 
tested. In GM10902, an increase in G2/M peak was observed at 0.05 and 0.1 µg/ml. 
This peak decreased at higher concentrations (0.5, 1.0 µg/ml). In XP3BE cells, a 
decrease in G2/M phase was observed at 0.5 and 1.0 µg/ml of ascaridol. In normal 
cells (GM01310), a decrease in height of G2/M peak was observed at 0.5 and 1.0 
µg/ml ascaridol but the overall percentage of cells in this phase remains unchanged. 
In GM01310, a significant increase in S phase was also observed at all 
concentrations of ascaridol.  
At all the concentrations ascaridol produced 13 to 20% subG1 phase in GM01310. 
GM10902 showed a dose-dependent increase in subG1, reaching up to 28% at 1.0 
µg/ml and XP3BE had around 27% subG1 at all the concentrations. This indicates, in 
comparison to NER proficient cells, a higher number of NER deficient cells undergo 
apoptosis when exposed to same concentration of ascaridol. 
4. 5. 2. 2. 2. Arsenic trioxide 
Arsenic trioxide produced G2/M phase arrest in all three cell lines (Figure.4.12 and 
Table.4.5). This arrest was achieved in normal cells at 0.73 µg/ml whereas 0.22 
µg/ml of arsenic trioxide produced the same effect in GM10902 and XP3BE cells. At 
2.2 µg/ml the G2/M phase peak disappears in GM10902 and XP3BE whereas it was 
still present in GM01310. 
A significant increase in subG1 phase was observed in GM10902 and XP3BE cells at 
0.73 µg/ml. At 2.2 µg/ml, 21.6 ± 0.8 % of GM01310, 49.1 ± 3.0 % of GM10902 and 
36.2 ± 0.8 % of XP3BE cell were in subG1 phase, indicating, in comparison to NER 
proficient cells, a higher number of NER deficient cells undergo apoptosis when 
exposed to same concentration of arsenic trioxide. 
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4. 5. 2. 2. 3. Other drugs 
Results for TCM-25-RAB, Quercetin, Scopoletin and Isonardosinon are given in 
Table.4.6. TCM-25-RAB (10 μg/ml) caused a slight increase in G1 phase in GM10902 
cells. It also increased subG1 phase by 20%. Quercetin (10 μg/ml) decreased ‘S 
phase’ in XP3BE cells and significantly increased the subG1 phase, whereas 
Scopoletin (20 μg/ml) exposure caused an increase in G1 phase in GM01310 and 
XP3BE cells. Isonardosinon did not affect the cell cycle. 
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Figure.4.11. Cell cycle analysis of GM01310, GM10902 and XP3BE cells after 
Ascaridol (0.05, 0.1, 0.5, 1.0 µg/ml) treatment for 24 hours. The arrows indicate 
G2/M peak disappears in XP3BE (at 0.1 µg/ml), in GM10902 (at 0.5 µg/ml) and in 
GM01310 (at 0.5 µg/ml). 
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Figure.4.12. Cell cycle distribution of GM01310, GM10902 and XP3BE cells after 
arsenic trioxide (0.07, 0.22, 0.73, 2.2 µg/ml) treatment for 24 hours. Arrows 
indicate a clear reduction of G2/M peak at 2.2 µg/ml in GM10902 and XP3BE 
cells. 
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Table.4.5. Effect of Ascaridol and Arsenic trioxide on cell cycle distribution of GM01310, GM10902 and XP3BE. 
Cell line GM01310 GM10902 XP3BE 
Cell cycle phases subG1 G1 S G2/M subG1 G1 S G2/M subG1 G1 S G2/M 
Un-exposed 4.5 ± 0.4 50.6 ± 0.7 23 ± 0.7 22.3 ± 0.9 3.5 ± 0.8 43.4 ± 1 34.7 ± 0.9 18.9 ± 1.1 9.4 ± 1.4 38.5 ± 0.6 32.3 ± 1.2 20 ± 1.3 
Ascaridol  
           
0.05 µg/ml 20.5 ± 1.62 34.4 ± 1.12 25 ± 0.92 20.9 ± 0.9 17.6 ± 1.62 32.4 ± 1.12 23.6 ± 0.42 27.3 ± 2.22 28.3 ± 1.62 23.9 ± 1.12 29.3 ± 0.51 19.3 ± 1.1 
0.10 µg/ml 16.2 ± 1.32 34.7 ± 1.32 29.6 ± 1.82 20.7 ± 1.1 19 ± 1.32 26.9 ± 0.62 27.9 ± 1.11 27.2 ± 0.62 27.3 ± 1.12 17.8 ± 0.72 34.1 ± 1.4 21.9 ± 0.6 
0.50 µg/ml 13.9 ± 0.62 36.4 ± 1.22 29.6 ± 1.72 21.3 ± 0.4 24.2 ± 2.12 29.8 ± 0.82 30.8 ± 0.7 16.2 ± 1 27.9 ± 2.22 21.9 ± 4.92 34.5 ± 2.7 16.7 ± 4.5 
1.00 µg/ml 15.4 ± 0.52 37.8 ± 0.52 27.8 ± 0.62 20.1 ± 0.4 28.7 ± 0.72 30.1 ± 1.22 30.6 ± 0.5 11.8 ± 0.42 26.4 ± 22 25.1 ± 4.11 34.9 ± 1.31 14.7 ± 1.51 
 DMSO control 7.5 ± 1.3 51.3 ± 1 22.3 ± 1.2 19.6 ± 0.9 4 ± 0.4 51.2 ± 0.8 29.2 ± 1.3 16.3 ± 0.6 13.9 ± 4.8 37.4 ± 1.6 29.7 ± 1.4 19.7 ± 2 
Arsenic trioxide 
            
0.07 µg/ml 1 ± 0.3 55.3 ± 0.8 26 ± 1.11 18.3 ± 1.7 4.9 ± 0.51 55.8 ± 0.92 24.2 ± 0.92 15.6 ± 1.3 11.1 ± 2 46.1 ± 0.62 27.8 ± 1.22 15.6 ± 1 
0.22 µg/ml 1.1 ± 0.2 56.7 ± 2.4 21.6 ± 0.82 21.2 ± 2.1 6 ± 0.62 56.6 ± 0.72 20.6 ± 0.72 17.4 ± 0.7 10.7 ± 0.52 45.6 ± 0.72 25.2 ± 0.52 19 ± 0.8 
0.73 µg/ml 2.5 ± 0.4 60.9 ± 0.72 10.7 ± 0.62 26.5 ± 0.72 13.5 ± 0.32 46.1 ± 0.82 17.1 ± 0.62 23.7 ± 0.52 19.2 ± 0.82 30.6 ± 1.12 27.1 ± 1.52 23.7 ± 0.81 
2.2 µg/ml 21.6 ± 0.82 44.5 ± 1.32 18.9 ± 0.92 15.6 ± 0.52 49.1 ± 32 29.1 ± 1.12 15.1 ± 1.82 7.3 ± 0.62 36.2 ± 0.82 25.2 ± 0.82 31.9 ± 0.5 7.4 ± 0.52 
PBS control 1.2 ± 0.3 50.5 ± 0.8 24.6 ± 0.5 24.2 ± 0.4 3.6 ± 0.4 50.3 ± 1.2 31.9 ± 1.3 14.8 ± 0.6 8.5 ± 1 39.1 ± 1.3 33.6 ± 1.3 19.4 ± 3 
1Significantly different from unexposed sample (P < 0.05, two tailed t-test) 
2Significantly different from unexposed sample (P < 0.001, two tailed t-test) 
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Table.4.6. Effect of TCM-25-RAB, Quercetin, Scopoletin and Isonardosinon on cell cycle distribution of GM01310, GM10902 and XP3BE. 
Cell line GM01310 GM10902 XP3BE 
Cell cycle phases subG1 G1 S G2/M subG1 G1 S G2/M subG1 G1 S G2/M 
Un-exposed 4.5 ± 0.4 50.6 ± 0.7 23 ± 0.7 22.3 ± 0.9 3.5 ± 0.8 43.4 ± 1 34.7 ± 0.9 18.9 ± 1.1 9.4 ± 1.4 38.5 ± 0.6 32.3 ± 1.2 20 ± 1.3 
TCM-25-RAB  
           10 µg/ml 15 ± 3.1 52.6 ± 3 15.6 ± 0.4 17.2 ± 0.9 18.7 ± 41 45.7 ± 5.41 24.6 ± 2.1 13.1 ± 1.1 16.7 ± 0.3 44.2 ± 0.3 23.7 ± 0.3 16 ± 0.4 
 DMSO (solvent) 7.5 ± 1.3 51.3 ± 1 22.3 ± 1.2 19.6 ± 0.9 4 ± 0.4 51.2 ± 0.8 29.2 ± 1.3 16.3 ± 0.6 13.9 ± 4.8 37.4 ± 1.6 29.7 ± 1.4 19.7 ± 2 
Quercetin  
            0.5 µg/ml 3.6 ± 0.4 51.8 ± 0.5 22.7 ± 0.4 22.4 ± 0.7 10.5 ± 2.3 48.1 ± 1.8 32.3 ± 1.1 9.8 ± 0.5 13.7 ± 1.6 37.6 ± 1.4 28.4 ± 0.6 20.8 ± 2.1 
1.0 µg/ml 4.1 ± 0.9 52.1 ± 0.6 23.4 ± 1.4 21 ± 1.9 8.3 ± 2.8 48.6 ± 1.2 34.2 ± 2 9.6 ± 0.9 11.2 ± 1.8 37.7 ± 1.4 30.1 ± 0.9 21.5 ± 1.9 
5 µg/ml 4.1 ± 0.8 52.8 ± 0.9 22.8 ± 0.4 20.7 ± 1.6 7.1 ± 0.6 48.3 ± 0.8 35 ± 0.8 10.2 ± 1.2 13.9 ± 2.2 37.6 ± 1 28.8 ± 1.3 20.3 ± 1.1 
10 µg/ml 4.2 ± 0.4 51.4 ± 0.6 22.4 ± 0.6 22.5 ± 0.8 8.8 ± 1.3 47 ± 0.8 33.8 ± 1.3 11 ± 0.6 21.6 ± 1.41 36.7 ± 0.7 24.3 ± 1.21 17.8 ± 1.3 
10% NaOH (solvent) 3.7 ± 0.5 53.5 ± 0.9 22.4 ± 0.7 20.9 ± 0.7 6.2 ± 1.6 46.8 ± 0.7 36.7 ± 1.4 10.9 ± 0.6 13 ± 1.6 38.1 ± 0.8 29.2 ± 1.3 20.2 ± 0.8 
Scopoletin 
            20 µg/ml 8.9 ± 4.2 61.4 ± 3.81 15 ± 3.5 15 ± 3 3.4 ± 0.4 51.6 ± 0.5 23.1 ± 0.7 22.4 ± 1.1 11.6 ± 1 42.3 ± 0.81 26.2 ± 0.7 20.4 ± 1.6 
Isonardosinon  
           5 µg/ml 6 ± 0.1 50 ± 0.8 22 ± 0.5 22 ± 0.9 1.9 ± 0.3 38.4 ± 1.1 35.2 ± 0.6 25.2 ± 1.5 9.7 ± 1.7 35.7 ± 1.5 31.1 ± 1.6 24 ± 2.1 
10 µg/ml 8 ± 0.2 48 ± 1.1 23 ± 0.4 21 ± 1.1 1.8 ± 0.1 38.3 ± 0.6 34.1 ± 1.5 26.4 ± 1.3 10 ± 1.3 36.6 ± 1 30.1 ± 0.8 23.8 ± 1.8 
10% EthOH (solvent) 1.1 ± 0.1 52.5 ± 0.5 24.3 ± 0.9 22.5 ± 1 3.8 ± 0.7 39 ± 0.7 33 ± 0.9 24 ± 1 13.9 ± 4.8 37.4 ± 1.6 29.7 ± 1.4 19.7 ± 2 
1Significantly different from unexposed sample (P < 0.05, two tailed t-test) 
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4. 5. 3. Single cell gel electrophoresis  
The genotoxic effects of the selected drugs were quantified by alkaline comet 
assay. Exponentially growing cells were treated with different drug concentrations 
for one hour and embedded in low melting agarose gel. Samples were spotted on 
comet slides, lysed and electrophorized. As DNA is a charged molecule, during 
electrophoresis the fragmented DNA moves out of the nucleus and runs towards 
anode giving the cells a comet like shape. At higher DNA damage, more DNA 
fragments will migrate in the tail region. Slides were stained with SYBR-green and 
comets produced by each treatment were analyzed with ‘Komet 4’ (a semi-
automated system). An olive tail moment was calculated for each comet and tail 
moments relative to unexposed samples were used as a measure of DNA damage. 
The average tail moment of unexposed samples in all experiments was GM01310 
0.86 ± 0.37, GM10902 0.54 ± 0.33, and XP3BE 0.54 ± 0.28, respectively. 
4. 5. 3. 1. Ascaridol 
DNA damage caused by ascaridol was tested at three different doses (0.1, 0.5 and 
1.0 µg/ml). Exposure to 1.0 µg/ml ascaridol produced a relative tail moment of 3.38 
± 0.74 in GM01310, 6.88 ± 0.78 in GM10902 and 6.5 ± 0.34 in XP3BE. 
Ascaridol produced DNA damage in a dose-dependent manner (Figure.4.13). NER 
deficient cells were highly sensitive to ascaridol even at the lowest dose (0.1 µg/ml) 
used in the experiments. A significant increase in DNA damage was observed for 
GM10902 (4.41± 0.14) and XP3BE (4.63 ± 1.3) where as GM01310 (1.57 ± 0.41) did 
not show any significant DNA damage at this concentration. The difference was 
around three times, thus ascaridol produced DNA damage in NER deficient cells at 
a dose not genotoxic to the normal cells. 
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4. 5. 3. 2. Arsenic trioxide 
DNA damage caused by arsenic trioxide was tested at three different doses (0.22, 
0.73, 2.2 µg/ml). Exposure to 2.2 µg/ml of arsenic trioxide produced a relative tail 
moment of 2.66 ± 0.38 in GM01310, 6.19 ± 0.41 in GM10902 and 5.17 ± 0.46 in 
XP3BE. 
An increase in DNA damage was observed in the three cell lines even at the low 
dose (0.22 µg/ml) of arsenic trioxide (Figure.4.14). In GM10902 and XP3BE, arsenic 
trioxide produced DNA damage in a dose-dependent manner. In GM01310, the 
increased DNA damage remained stable at higher doses of arsenic trioxide. 0.22 
µg/ml arsenic trioxide produced significantly higher DNA damage in GM10902 
Treatment 
Figure.4.13. DNA damage in GM1310, GM10902 and XP3BE samples after 
treatment with ascaridol (0.1, 0.5, 1.0 µg/ml) and measured by comet assay. 
Exponentially growing cells were treated with the respective drug 
concentrations for one hour. Unexposed and DMSO (solvent) exposed 
samples were included as controls. Tail moment (median ± std error) relative 
to unexposed samples was used as a measure of DNA damage. *P < 0.05, **P 
< 0.01 (two tailed t-test). 
* ** 
* 
* 
* 
** 
** 
Results NER and cancer therapy 
124 
0
2
4
6
8
Unexposed PBS 0.22 0.73 2.2
Re
la
ti
ve
 T
ai
lm
om
en
t
Arsenic trioxide (µg / ml)
GM01310
XP3BE
GM10902
when compared to GM01310. At higher doses difference between GM01310 and 
NER deficient cell lines was even stronger. 
4. 5. 3. 3. TCM-25-RAB 
DNA damage caused by TCM-25-RAB was tested at two different doses (5, 10 
µg/ml). At 10 µg/ml TCM-25-RAB produced a relative tail moment of 5.37 ± 0.51 in 
GM10902 and 3.13 ± 1.08 in XP3BE whereas GM01310 had a relative tail moment 
of 1.58 ± 0.11. TCM-25-RAB (Figure.4.15-a) produced DNA damage in a dose-
dependent manner. A significant increase in DNA damage was observed in drug 
treated GM10902 and XP3BE samples, producing more damage to GM10902 cells. 
GM01310 did not show any significant DNA damage at any concentration.  
Treatment 
Figure.4.14. DNA damage in GM1310, GM10902 and XP3BE samples after 
treatment with Arsenic trioxide (0.22, 0.73, 2.2 µg/ml) as measured by 
alkaline comet assay. Unexposed and PBS (solvent) exposed samples were 
included as controls. Tail moment (median ± std error) relative to unexposed 
samples was taken as a measure of DNA damage. *P < 0.05, **P < 0.01 (two 
tailed t-test). 
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Figure.4.15. DNA damage in GM01310 ( ), XP3BE ( ) and GM10902 ( ) after treatment with different TCM drugs and measured by 
comet assay. Tail moment relative to unexposed samples was used as a measure of DNA damage. a. Isonardosinon, b. Quercetin, c. 
Scopoletin and d. TCM-25-RAB. *P < 0.05, **P < 0.01 (two tailed t-test). 
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4. 5. 3. 4. Quercetin, Scopoletin and isonardosinon 
Quercetin (Figure.4.15-b) was tested for its genotoxic effects at two different doses 
(5, 10 µg/ml). 5 µg/ml quercetin had a similar effect on all the three cell lines. At 
10µg/ml, GM01310 cells showed significantly higher DNA damage than XP3BE and 
GM10902.  
DNA damage caused by scopoletin (Figure.4.15-c) was tested at two different doses 
(10, 20 µg/ml). 10 µg/ml of scopoletin caused a significant increase in DNA damage 
in XP3BE as well as GM10902 cells however at 20 µg/ml scopoletin the three cell 
lines did not have a significant difference. 
Isonardosinon (Figure.4.15-d) caused a slight increase in DNA damage in the three 
cell lines, but there was no significant difference between the cell lines. 
  
In summary, these results show that ascaridol, arsenic trioxide and TCM-25-RAB 
induce significant DNA damage. This DNA damage is higher in NER deficient cells 
(GM10902, XP3BE) than NER proficient cells (GM01310). 
4. 5. 4. Quantification of AP sites (Arp assay)  
Next step was to investigate the type of DNA damage these drugs induce. 
Regarding the chemical formulas of drugs (Table.4.4), oxidative DNA damage would 
be probable. One method to measure oxidative damage is by counting apurinic / 
apyrimidinic (AP) sites in the samples after treatment. AP sites are one of the major 
types of lesions in DNA.  These sites can generate either spontaneously or as an 
intermediate in base excision repair (Boiteux & Guillet, 2004). 
Exponentially growing cultures were treated with drugs and their solvents for 
24hrs, cells were harvested and their DNA was extracted. AP sites in the DNA 
samples were counted by using the ‘DNA damage quantification assay-AP site 
counting’. It is an ELISA-like assay that uses avidin-biotin complex conjugated with 
horseradish peroxidase as an indicator enzyme for the detection of AP sites. The 
assay constitutes of ARP (aldehyde reactive probe) reagent that specifically tags the 
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aldehyde group in the ring opened AP site with a biotin residue. The number of AP 
sites (per 105 base pairs) was quantified by using standard ARP labeled DNA 
solutions and AP sites in the drug exposed samples were measured relative to the 
solvent control. The standard has a known amount of AP sites, ranging from 0 to 40 
per 1 × 105 base pairs of calf thymus DNA. Each experiment was performed twice 
with two independent replicates. 
Results are given in Figure.4.16. Treatment with Arsenic trioxide (2.2 µg/ml), 
ascaridol (0.1 µg/ml) and TCM-25-RAB (5 µg/ml) did not cause significant increase 
(p > 0.05) in AP sites in GM01310, GM10902 and XP3BE. Scopoletin (10 µg/ml) and 
Quercetin (1 µg/ml) exposure produced increased amount of AP sites but because 
of large variations, results were not significant. 
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Figure.4.16. Number of AP sites / 105 base pairs caused by selected TCM drugs in 
GM01310, GM10902 and XP3BE. Results shown are relative to the solvent control of 
each drug. PBS is the solvent for Arsenic trioxide, 0.1M NaOH for quercetin, 1% DMSO for 
Ascaridol, scopoletin and TCM-25-RAB. Number of AP sites in solvents: PBS 4.19 ± 0.59, 
3.051 ± 0.733 and 3.732 ± 0.321, 0.1M NaOH 5.317 ± 0.392, 4.952 ± 0.539 and 4.422 ± 
0.608, 1% DMSO 4.377 ± 0.373, 2.843 ± 0.169 and 3.086 ± 0.157, in GM01310, GM10902 
and XP3BE cells respectively. The results are from two experiments with duplicate 
samples for each treatment. 
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4. 6. Validation of results obtained for ascaridol 
Ascaridol was the most promising TCM compound in our study. The drug killed NER 
deficient cells very efficiently and at doses that were apparently nontoxic to the 
normal cells. To prove that the results obtained in the previous experiments are 
because of NER (XPC and ERCC6) deficiencies, cytotoxicity and DNA damage caused 
by ascaridol were measured in a different cell model. As a model for XPC mutation 
a pair of XPC cell lines (XP4PA and XP4PA-SE2) was picked. The pair has the same 
genetic background but XP4PA is deficient in XPC whereas XP4PA-SE2 is the fully 
corrected version of the cell line by stable transfection using pXPC-3 plasmid 
(Legerski & Peterson, 2002). As a model for ERCC6 mutation, the gene was silenced 
in XP4PA-SE2 cells using ON-TARGETplus SMARTpool siRNA and the Luciferase 
siRNA exposed cultures (negative control for gene silencing) were considered as 
repair competent control.  
4. 6. 1. Determination of IC50 values 
To determine IC50 value of ascaridol, confluent cultures of XP4PA, XP4PA-SE2, and 
ERCC6-silenced XP4PA-SE2 cells and Luciferase siRNA exposed cultures were 
exposed to different concentrations of the drug for 24 hours and relative % 
viabilities were measured.  
For the measurement of relative % viabilities, conditions for ‘The LIVE/DEAD® 
Viability/Cytotoxicity assay’ (Invitrogen) were optimized. The assay comprises of 
two fluorescent dyes, Calcein AM (excitation: 485nm, emission: 520nm) and 
Ethidium Homodimer (excitation: 520nm, emission: 620nm) for detecting live cells 
and dead cells, respectively. Ethidium Homodimer could not be optimized for these 
cell lines. A possible explanation is that XP4PA and XP4PA-SE2 are adherent cells 
and washing step removed all the dead cells from the culture. For these cell lines 
relative viabilities were measured by Calcein AM only (Calcein assay). Table.4.2 
gives the optimum concentrations of the dyes used for the cell lines. 
Relative viability curves were generated by plotting relative viability (%) against 
drug concentrations and IC50 values were calculated. As a control, solvent exposed 
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and unexposed samples were included. Experiments were performed twice with 
three replicates for each treatment. 
4. 6. 1. 1. Effect of ascaridol on paired XPC cell lines 
As the Figure.4.17 demonstrates, XP4PA (XPC-deficient) cells (IC50 = 0.013 µg/ml) 
were very sensitive to ascaridol exposure. At 0.01 µg/ml ascaridol exposure, 
relative viability was only 53.3 ± 6.7 % and 1 µg/ml ascaridol killed all the cells. 
XP4PA-SE2 (XPC-proficient) cells (IC50 = 2.19 µg/ml) were not as sensitive as XP4PA. 
There was a 165 fold difference in the sensitivity of the two cell lines to ascaridol 
exposure. The result confirms our previous finding ‘XPC deficient cells are more 
sensitive to ascaridol exposure’. 
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Figure.4.17. Determination of IC50 values for ascaridol in XP4PA and XP4PA-SE2. 
Exponentially growing cells were exposed to different concentrations of ascaridol 
for 24 hrs and percent viability (mean ± std.dev) relative to the unexposed 
sample as calculated by Calcein assay. The IC50 values for XP4PA = 0.013 µg/ml 
and XP4PA-SE2 = 2.19 µg/ml. Mean values of two independent experiments with 
three replicates for each treatment are shown. 
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4. 6. 1. 2. Effect of ascaridol on ERCC6 silenced cells 
As Figure.4.18 demonstrates, ERCC6 silenced cells (IC50 = 0.095 µg/ml) were more 
sensitive to ascaridol exposure than Luciferase siRNA exposed cells (IC50 = 3.0 
µg/ml). There was a difference of 32 folds in the sensitivity of the two cell types to 
ascaridol exposure. This confirms our previous finding that ERCC6 deficient cells are 
more sensitive to ascaridol exposure. Moreover, the Luciferase siRNA exposed cells 
(IC50 = 3.0 µg/ml) have similar sensitivity as XP4PA-SE2 (IC50 = 2.19 µg/ml). 
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Figure.4.18. Viability curves. Relative resistance to ascaridol determined in 
ERCC6 silenced and Luciferase siRNA exposed (negative control) cells. 
Exponentially growing cells were exposed to different concentrations of ascaridol 
for 24hrs and percent viabilities (mean ± std.dev) relative to the unexposed 
sample were calculated by Calcein assay. The IC50 values are ERCC6 silenced cells 
= 0.095 µg/ml and Luciferase siRNA exposed cells = 3.0 µg/ml. Mean values of 
two independent experiments with three replicates for each treatment are 
shown. 
 
Results NER and cancer therapy 
131 
4. 6. 2. Single cell gel electrophoresis  
4. 6. 2. 1. Genotoxic effects of Ascaridol on paired XPC cell lines 
DNA damage caused by ascaridol was tested at three different doses (0.1, 0.5 1.0 
µg/ml). The average tail moment of unexposed samples was XP4PA = 2.94 ± 0.67 
and XP4PA-SE2 = 2.95 ± 1.33. Figure.4.19 demonstrates that ascaridol produced 
DNA damage in XP4PA and XP4PA-SE2 in a dose-dependent manner. 0.1 µg/ml 
ascaridol caused a very strong effect on XP4PA (relative tail moment = 12.95 ± 1.29) 
compared with XP4PA (relative tail moment = 6.79 ± 1.41). Exposure to 1 µg/ml 
ascaridol produced a relative tail moment of 15.40 ± 0.85 in XP4PA and 11.63 ± 
1.50 in XP4PA-SE2. XP4PA cells had higher DNA damage compared to XP4PA-SE2 at 
all concentrations.  
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Figure.4.19. DNA damage caused by Ascaridol (0.1, 0.5, 1.0 µg/ml) in XP4PA and 
XP4PA-SE2 cells as measured by alkaline comet assay.  Exponentially growing 
cells were treated with the respective drug concentrations for one hour.  
Unexposed and DMSO (solvent) exposed samples were included as controls. Tail 
moment (median ± std error) relative to unexposed samples was used as a 
measure of DNA damage. *P < 0.05, **P < 0.01 (two tailed t-test).  
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4. 6. 2. 2. Genotoxic effects of Ascaridol on ERCC6 silenced cells 
DNA damage caused by ascaridol was tested at three different doses (0.1, 0.5, 1.0 
µg/ml). The average tail moment of unexposed samples in ERCC6 silenced cells was 
5.73 ± 0.49 and in the Luciferase siRNA exposed cells was 6.76 ± 1.66. Figure.4.20 
shows that ascaridol produced DNA damage in ERCC6 silenced cells in a dose-
dependent manner.  
At higher doses the effect was stronger and exposure to 1 µg/ml ascaridol 
produced a relative tail moment of 6.30 ± 0.22 in ERCC6 silenced cells and 2.28 ± 
0.40 in Luciferase siRNA exposed cells. ERCC6 silenced cells accumulated more DNA 
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Figure.4.20. DNA damage caused by Ascaridol (0.1, 0.5, 1.0 µg/ml) in ERCC6 
silenced XP4PA-SE2 cells and negative control as measured by alkaline comet 
assay.  Exponentially growing cells were treated with the respective drug 
concentrations for one hour.  Unexposed and DMSO (solvent) exposed samples 
were included as controls. Tail moment (median ± std error) relative to 
unexposed samples was used as a measure of DNA damage. Negative control is 
Luciferase siRNA treated XP4PA-SE2 cells.*P < 0.05, **P < 0.001 (two tailed t-
test). 
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damage compared to repair competent cells. 
XP4PA-SE2 cells were more sensitive to ascaridol compared with Luciferase siRNA 
exposed cells. As the results are from different experiments and involve 
electrophoresis, high background in paired XPC cell lines can be attributed as 
experimental variation. 
4. 7. Mode of action of Ascaridol 
Although ascaridol was the first peroxide discovered and has been used a as 
medicine for centuries (Dembitsky, 2008), yet little is known about its mode of 
action. Our data show that the drug produces DNA damage, this damage is higher 
in NER deficient cells when compared to NER proficient cells. As the structure 
(Table.4.4) suggests, the drug contains an endoperoxide bridge and therefore may 
produce oxidative damage. ARP assay performed earlier did not reveal much 
information, therefore more direct methods like the production of reactive oxygen 
species by ascaridol and quantification of 8-oxodG sites by Fpg-modified comet 
assay were used to investigate how the drug actually works. 
4. 7. 1. 2´,7´-dichlorofluorescein diacetate (H2DCFDA) assay 
The intracellular production of ROS after ascaridol treatment was measured by 
H2DCFDA assay. H2DCFDA was added to XP4PA and XP4PA-SE2 cells growing in 96 
well plates and samples were treated with different concentrations of ascaridol 
(0.1, 0.5, 1 µg/ml) and DMSO. Two concentrations of H2O2 were included as 
positive controls for ROS production. The RateRos in the cells was measured by 
CytoFlour multi well plate reader, series 4000 at Ex / Em : 485 / 520 nm. The RRRos 
was calculated with reference to the unexposed samples. 
Figure.4.21 demonstrates that the unexposed XP4PA cells (RateROS = 5.3 ± 0.52) had 
a significantly higher (P < 0.001) intracellular peroxide levels compared to XP4PA-
SE2 cells (RateROS = 3.2 ± 0.45). A dose-dependent significant (P < 0.001) increase in 
intracellular peroxide levels was observed in ascaridol treated cells. Although 
XP4PA had higher basal intracellular peroxide levels compared to XP4PA-SE2, the 
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RRRos after treatment did not differ in both the cell lines. RRRos was 1.75 ± 0.30, 1.98 
± 0.44, 3.05 ± 0.92 and 1.73 ± 0.35, 2.04 ± 0.23, 2.57 ± 0.54 at 0.1, 0.5, 1 µg/ml in 
XP4PA and XP4PA-SE2 cells, respectively. 1% DMSO exposure had no significant 
effect on ROS production in our cells (XP4PA RRROS = 0.8 ± 0.13, and XP4PA-SE2 
RRROS = 0.94 ± 0.15).  
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Figure.4.21. Production of reactive oxygen species (ROS) after ascaridol (0.1, 0.5, 
1 µg/ml) treatment in ( ) XP4PA and ( ) XP4PA-SE2 cells measured by H2DCFDA 
(25 µM) assay. Exponentially growing cultures were treated with ascaridol and 
fluorescence was measured for 40 min starting immediately. Samples treated with 
H2O2 (0.5, 1 µM) were included as positive controls. a. Rate of ROS (AFU/min) 
production. b. Relative Rate of ROS (relative AFU/min) production (RateROS in 
unexposed XP4PA = 5.3 ± 0.52 and XP4PA-SE2 = 3.2 ± 0.45). The results are from 
two independent experiments with three replicates per treatment. AFU = arbitrary 
fluorescence units. *P < 0.05, **P < 0.001 (two tailed t-test) 
b. 
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4. 7. 2. Quantification of 8-oxodG sites by Fpg-modified comet assay 
Exponentially growing cell cultures were treated with different concentrations of 
ascaridol and DMSO for one hour, cells were harvested and embedded in agarose 
and spotted on comet slides. After lysis overnight samples were treated with Fpg 
enzyme or NEBuffer 1 for 50 min. Samples were electrophorized and comets 
produced were scored with Komet 4. Olive tail moments were taken as a measure 
of DMA damage. To differentiate the oxidized bases from single strand breaks, 
olive tail moment of buffer treated samples representing single strand breaks and 
alkali-labile sites was subtracted from Fpg treated sample (enzyme induced 
breaks). 
4. 7. 2. 1. Effect of ascaridol on XPC deficient and proficient cell line 
Oxidative DNA damage caused by ascaridol was tested at three different doses (0.1, 
0.5 1.0 µg/ml). For XP4PA, the average tail moment of NEBuffer 1 treated-
unexposed samples was 17.69 ± 0.80 and Fpg treated-unexposed samples was 
15.62 ± 0.64. For XP4PA-SE2, the NEBuffer 1 treated-unexposed sample was 
missing and the average tail moment of Fpg treated-unexposed samples was 7.31 ± 
0.36. Figure.4.22-a demonstrates that ascaridol (1 µg/ml) produced a highly 
significant increase in oxidized bases in XP4PA (Fpg sensitive lesions 13.78 ± 1.72, p 
= < 0.0001) cells. XP4PA-SE2 did not show such an increase. 
4. 7. 2. 2. Effect of ascaridol on ERCC6 silenced and Luciferase siRNA exposed (repair 
competent control) cells  
Oxidative DNA damage caused by ascaridol was tested at three different doses (0.1, 
0.5 1.0 µg/ml). For ERCC6 silenced cells, the average tail moment of NEBuffer 1 
treated-unexposed samples was 16.69 ± 0.87 and Fpg treated-unexposed samples 
was 17.54 ± 1.37. For Luciferase siRNA exposed cells, the average tail moment of 
NEBuffer 1 treated-unexposed samples was 15.46 ± 1.28 and Fpg treated-
unexposed samples was 16.53 ± 0.90. Figure.4.22-b demonstrates that ascaridol 
produced a highly significant increase in oxidized bases in ERCC6 silenced cells (Fpg 
sensitive lesions 19.84 ± 1.1 and 19.33 ± 1.2 at 0.5 and 1 µg / ml, respectively, p = < 
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0.0001) after ascaridol treatment. Such an increase was not observed in Luciferase 
siRNA exposed cells. 
These results show that ascaridol is mediating DNA damage by oxidative stress and 
NER deficient cells are sensitive to oxidative damage compared to NER proficient 
cells.
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Figure.4.22. Oxidative DNA damage. Fpg sensitive lesions (mean ± std error) 
after treatment with different concentrations of ascaridol. Unexposed and 
DMSO exposed samples were included as experimental controls. a. XP4PA and 
XP4PA-SE2 cells b. ERCC6 silenced XP4PA-SE2 cells and negative control 
(luciferase siRNA treated) samples. 153 cells were scored for each treatment. *P < 
0.05, **P < 0.0001 (two tailed t-test) 
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5. Discussion, NER and cancer Risk 
5. 1. Genotype analysis 
We investigated 11 SNPs present in seven NER genes (XPC, ERCC1, ERCC2, ERCC4, 
ERCC5, ERCC6 and RAD23B) in a cohort of laryngeal cancer patients and matched 
controls. Allele frequencies observed were similar to frequencies given for the 
European Caucasian population reported by the NCBI Reference Assembly (NCBI, 
2007). Using multivariate logistic regression analysis, three of the investigated 
SNPs, ERCC6 Arg1230Pro, ERCC5 Asp1104His, and RAD23B Ala249Val, showed a 
significant association with laryngeal cancer risk in the overall population and in 
individuals with high tobacco and/or alcohol consumption. For all other SNPs, no 
significant associations were determined. 
Some of the 11 SNPs were also investigated in two further studies in patients with 
squamous cell carcinoma of the head and neck. Studies included a separate 
analysis for laryngeal cancer in 157 non-Hispanic, white patients (An et al., 2007) 
and in 326 Europeans (Hall et al., 2007). Both studies did not find a statistically 
significant association for any of the SNPs and laryngeal cancer, even when 
considering smoking and alcohol consumption in the regression model. 
5. 2. ERCC6 
The ERCC6/CSB protein is part of the damage recognition complex of the 
transcription-coupled branch of the NER pathway (Fousteri & Mullenders, 2008). 
Larynx cancer risk of the ERCC6 1230Pro allele carriers was found to be only half as 
high as the risk of carriers of the more frequent wild type allele. As the 
polymorphism is encoding an amino acid change, we suggest that the 1230Pro 
variant strengthens the ERCC6 protein or enhances its function, and thus protects 
against larynx cancer. Cockayne syndrome was not found to be a cancer 
predisposing condition, which could be explained by the fact that the Cockayne 
syndrome cells are especially sensitive to apoptosis, thereby preventing them from 
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tumorigenesis. However, it has been shown that ERCC6-disrupted mice had an 
increased susceptibility to skin cancer (van der Horst et al., 1997). To our best 
knowledge, data on laryngeal cancer risk are missing for this ERCC6 1230Pro SNP. In 
breast, bladder or colon cancer patients, no statistically significant associations 
were reported (Berndt et al., 2006; Garcia-Closas et al., 2006; Huang et al., 2006; 
Mechanic et al., 2006).  
5. 3. ERCC5 
ERCC5 encodes the 3'-endonuclease XPG involved in the excision step of NER. Our 
data indicate that the ERCC5 1104His allele might contribute to laryngeal cancer 
risk in heterozygous patients. This result is not supported by other studies on 
laryngeal or head and neck cancer which did not report a significant association for 
this SNP (An et al., 2007; Cui et al., 2006). The mixed ethnicities in one study and 
the small sample size (90 and 152 patients) could be reasons for this result. 
Regarding other cancer types, Kumar et al., (2003) found an increase in risk in 
breast cancer patients for His allele carriers whereas Sanyal et al., (2004) reported 
a protective effect of this allele (homozygous His) in bladder cancer. Studies on 
bladder, breast, endometrial or colorectal cancer did not find an association for the 
ERCC5 Asp1104His SNP in Caucasian populations (Berndt et al., 2006; Garcia-Closas 
et al., 2006; Huang et al., 2006; Mechanic et al., 2006; Weiss et al., 2005).  
5. 4. Exogenic risk factors for larynx cancer and NER genotypes 
Smoking and alcohol consumption are among the major exogenic risk factors of 
laryngeal cancer (Hashibe et al., 2007; IARC, 2002; La et al., 2008; Ramroth et al., 
2004; Talamini et al., 2002). Both exposures cause DNA damage such as bulky DNA 
adducts and oxidation products. This DNA damage has to be repaired to preserve 
genomic stability, and NER is one of the main pathways involved. The repair gene 
polymorphisms studied here were selected because of their believed effects on 
protein function. For assessing their contribution to cancer risk, it must, however, 
be noted that the tested polymorphisms are defined as low penetrance variations 
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that might alter the protein functions only slightly. But even a slight reduction of 
repair capacity might still be sufficient for complete repair with low exposure 
conditions. With high and longer exposure, however, DNA repair might not be 
sufficient any more. Thus, effects of repair gene polymorphisms should 
preferentially become perceptible in individuals with strong exposure to DNA 
damaging agents from smoking and alcohol. 
We therefore stratified our data for light and heavy tobacco and alcohol 
consumption and analyzed the risk modifying effect of the genotype in both 
groups. These analyses reflected the protective effect of the ERCC6 1230Pro allele 
found in the overall evaluation in individuals with strong tobacco or/and alcohol 
consumption. In patients with low tobacco exposure, this protective association 
was already observed, despite no statistical significance. As a whole, this finding 
seems to strengthen the role of the ERCC6 1230Pro allele in the etiology of larynx 
cancer. The stratified analysis revealed further a moderately increased risk for 
ERCC5 Asp1104His heterozygotes in heavy smokers, and a more than two fold risk 
increase in these individuals with medium alcohol intake which was also visible in 
the medium exposure group when both exposures were considered. Although 
statistically not significant, these data might indicate an increasing risk effect of the 
allele in exposed individuals.  
We could not establish a dose-response effect for alcohol consumption. The 
strongest effects were detected in the group with an intermediate exposure of 25-
50 g alcohol per day. A possible explanation could be that our risk estimates could 
be biased by the fact that our data on alcohol as well as tobacco consumption were 
derived from a questionnaire. Self-reports on lifestyle factors are subject to a 
different recall bias for cases and controls, although we tried to thwart this bias by 
trained interviewers for data acquisition. Nevertheless, our results support the 
results of the overall analysis and underline that gene-smoking and gene-alcohol 
interactions may modify laryngeal cancer risk.  
Furthermore, an exposure dependent risk effect of the RAD23B 249Val 
polymorphism was found which was not apparent in the overall analysis. Regarding 
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the combined exposure with smoking and alcohol, 249Val carriers showed no risk 
effect in the low exposure group but a 2.6 fold increase in risk with high exposure. 
The contribution of the RAD23B 249Val variant to laryngeal cancer risk was 
reflected in the gene-gene interaction analysis, an effect similar to those reported 
previously by Shen et al., (2005) in lung cancer. The RAD23B and XPC proteins work 
together as a complex in DNA damage identification in the GGR pathway. The 
presence of three risk alleles resulted in a 2.1 fold increased risk of larynx cancer, a 
level much higher than that conferred by the individual genetic variants. 
Interestingly, the genetic variants of ERCC6/CSB and RAD23B are both located in 
genes encoding proteins involved in damage recognition, ERCC6/CSB in 
transcription coupled NER and RAD23B/XPC in global genome repair (Shuck et al., 
2008; Fousteri & Mullenders, 2008). DNA lesions not correctly recognized cannot 
be processed in time suggesting that this early step in NER might be rate-limiting 
and that a variant protein with reduced function at this critical step of the pathway 
might confer genomic instability and cancer.  
5. 5. Limitations of our study 
Our study is limited by its relatively small number of cases. Especially the analysis of 
gene-environment and gene-gene interactions was restricted by limited statistical 
power. Further analyses regarding occupational exposure or important clinical 
markers (such as location of the tumor in relation to the glottis) were not possible. 
However, in comparison to lung or breast cancer, laryngeal cancer is a rare disease 
and establishing large cohorts is a time-consuming and expensive task. Therefore, 
we improved the power of our study by increasing the number and quality of 
controls, and established a population-based case-control study with three healthy 
controls matched for age and gender for each case. As to be expected considering 
the strong risk factors for this type of cancer, a matching for the high risk factors 
smoking and alcohol consumption was not possible. As these habits are correlated 
with educational status, cases and controls also differed in this feature. The 
enrolled controls showed a higher education profile than the larynx cancer cases. It 
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could thus be hypothesized that controls probably had a healthier lifestyle and 
higher health standards (higher pattern of fruits and vegetables consumption, 
physical activity, attendance to health services, or health-related practices). This 
might also influence enzymatic mechanisms, such as DNA repair. Therefore, we 
cannot exclude that our data analysis, even after adjusting for education, could 
reflect such overall differences among cases and controls. At present, our study is 
among the larger studies published involving European laryngeal cancer patients 
(Hopkins et al., 2008). Further validation of our results in larger populations is 
however required. 
We cannot rule out the possibility of false-positive associations. When correcting 
our estimates for multiple testing according to Bonferroni (Silicon Genetics, 2003), 
a very low P value is required for statistical significance since a large number of 
comparisons were made. Using this stringent criterion, no odds ratio, even of the 
ERCC6 Arg1230Pro SNP, would show significance in the overall analysis. The 
contribution of the ERCC6 Arg1230Pro polymorphism to laryngeal cancer risk is 
nevertheless supported by haplotype analysis which showed a significant 
association for the 1213Arg-1230Pro haplotype. We can, however, not exclude that 
there are still other variants linked with this gene which actually determine genetic 
susceptibility. However, the three gene variants which we have identified to 
contribute to laryngeal cancer risk show their effects in more than one test, the 
overall analysis and the gene-environment or the gene-gene interaction analysis. 
Most of the associations found in our study are additionally supported by 
associations with cancer risk described in other studies although a clear functional 
impact of the polymorphisms was not shown up to now.  
5. 6. Conclusion 
In conclusion, our results suggest that the presence of ‘risk alleles’ of ERCC6, 
ERCC5, and RAD23B may result in compromised damage recognition and repair of 
smoking and alcohol induced DNA bulky adducts, leading to more DNA damage and 
higher laryngeal cancer risk. This risk modification is especially observed in 
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individuals that are exposed to heavy smoking or high alcohol intake. As we do not 
know about the biological impact of these polymorphisms, additional studies 
evaluating their functional significance are needed. 
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6. Discussion, NER and cancer therapy 
Seventy two TCM drugs were screened for their cytotoxic effects on NER deficient 
cell lines, XP3BE and GM10902, and a normal cell line GM01310. XP3BE is deficient 
in XPC and GM10902 is deficient in ERCC6. Thirteen of the 72 drugs (18%) showed a 
differential activity against at least one of the mutant cell lines. Of these quercetin 
and scopoletin were specifically active against XP3BE only, TCM-25-RAB was active 
against GM10902 only and 10 drugs (14%) including arsenic trioxide, ascaridol, 
isonardosinon, TCM-22-RAB, TCM-23-RAB, TCM-44-RAB, TCM-47-RAB, TCM-48-
RAB, TCM-50-RAB and TCM-54-RAB killed the two NER deficient cell lines more 
efficiently when compared with the normal cells, whereas a majority of the TCM 
drugs had no differential effect on the three cell lines. Depending on the amount 
available, 6 of these drugs; ascaridol, arsenic trioxide, isonardosinon, TCM-25-RAB, 
quercetin and scopoletin were picked for further analyses. Selected drugs were 
studied for their effects on cell cycle distribution and genotoxicity. 
6. 1. Cell models 
XPC with a molecular weight of 125 kDa has 940 amino acids (Masutani et al., 
1994). The XP3BE / GM02248 cell line is deficient in XPC and carries an 83bp 
insertion following codon Lys90. This generates a pre-mature stop codon and a 
truncated protein (Li et al., 1993). In our experiments we confirmed the mutation 
reported for the cell line by PCR amplification and detected a very low amount of 
the XPC protein. XPC has a HR23B binding domain (amino acid 495 to 734) at the C-
terminal end that overlaps with the DNA binding domain (amino acid 606 to 742) of 
XPC (Bernardes de Jesus et al., 2008; Park & Choi, 2006). The very end of the C-
terminus of XPC carries a TFIIH interaction domain (amino acid 816 to 940). XPC 
interacts with TFIIH through ERCC3 and p62 subunits (Uchida et al., 2002). All these 
domains are missing in our cells. We could show that the cell line had a normal p53 
expression and was more sensitive to UV exposure then normal cells. The cells are 
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also reported to be much more sensitive to UV light and repair DNA damage much 
slower than normal cells (Chavanne et al., 2000). 
ERCC6 is a member of SW12/SNF2-family of DNA-dependent ATPases. It has a 
molecular weight of 168 kDa and 1493 amino acids (Stevnsner et al., 2008; Wong et 
al., 2007). ERCC6 has an acidic domain, a glycine-rich region, two putative nuclear 
localization signal (NLS) sequences and 7 ATPase motifs. GM10902 cells harbor a 
point mutation (C2282T) in ERCC6 gene in ATPase domain IV, generating a pre-
mature stop codon and a truncated protein (734 amino acids) (Colella et al., 2000). 
The resulting protein lacks ATPase domains V and VI and one putative nuclear 
localization signal (NLS) sequence. We could confirm the mutation reported for the 
cell line by sequencing. Low amounts of the ERCC6 protein and normal levels of p53 
expression were detected in the cells. The cell line was found to be more sensitive 
to UV exposure than normal cells. The result is supported by other studies as well 
(Itoh et al., 1995; Greenhaw et al., 1992). After UV exposure cells show a reduced 
level of RNA synthesis but normal levels of unscheduled DNA synthesis (Itoh et al., 
1996; Greenhaw et al., 1992). GM10902 cells are defect in transcription (Kim et al., 
1997). 
6. 2. Ascaridol 
Ascaridol (also known as ascaridole, ascarisin, 1,4-epidioxy-p-menth-2-ene) is a 
bicyclic monoterpene that has an unusual bridging peroxide functional group 
(Dembitsky et al., 2008). Our data showed that ascaridol was highly cytotoxic to 
NER deficient cells. GM10902 and XP3BE cells were over 1000 times more sensitive 
to the drug compared to GM01310 cells. Ascaridol was apparently non-toxic to 
normal cells. No data was found in the literature regarding the cytotoxicity of 
ascaridol in the NER deficient cells. Efferth et al., (2002b) reported its 
antineoplastic activity as it is active against multi drug resistant cancer cell lines. 
Recently Bezerra et al., (2009) showed ascaridol exhibits antitumor activity in 
leukemia (HL-60), melanoma (MDA-MB-435), brain (SF-295) and colon (HCT-8) 
cancer cell lines and in a sarcoma 180 murine model. However ascaridol did not 
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show any bioactivity in NCI in vivo antitumor screening (pubchem.ncbi.nlm.nih.gov, 
2008). Cell cycle analysis showed a remarkable specificity for the effect of ascaridol. 
The G1 phase decreased in all three cell lines at concentrations between 0.05 to 1.0 
µg/ml. In GM10902 cells, the G2/M phase increased at 0.05 and 0.1 µg/ml and then 
decreased at 0.5, 1.0 µg/ml. In XP3BE cells, The G2/M phase remained unchanged 
at 0.05 and 0.1 µg/ml and decreased at 0.5 and 1.0 µg/ml of ascaridol. In normal 
cells (GM01310), G2/M phase remained unchanged. In GM01310, an increase in S 
phase was also observed at all the concentrations. Ascaridol also caused an 
increase in the apoptotic peak (sub-G1 phase) in the three cell lines.  GM10902 
showed a dose-dependent increase in subG1, reaching up to 28% at 1.0 µg/ml and 
XP3BE had around 27% subG1 at all the concentrations. At all the concentrations, 
ascaridol produced 13 to 20% subG1 phase in GM01310. Ascaridol induced DNA 
damage in a dose-dependent manner and produced two to three times more DNA 
damage in NER deficient cells compared to the normal cells. Data regarding the 
effect of ascaridol on cell cycle distribution and induction of DNA damage are not 
available in literature. 
Ascaridol is a naturally occurring compound and is a component of many plants 
(Holm et al., 1993; Johnson & Croteau, 1984; Jardim et al., 2008). Ascaridol is 
commercially available as a mixture of herbs (www.ghchealth.com, 2009) and also 
as a pure compound by some Chinese companies (www.chemexper.com, 2008). 
Since long ascaridol has been used as an anti-helminth drug and nematicide 
(Vanfleteren & Roets, 1972). The drug has also shown anti-malarial (Pollack et al., 
1990), antifungal (Jardim et al., 2008) and trypanocidal (Kiuchi et al., 2002) 
activities. Overdose of ascaridol can lead to death (DeStefano, 2001). However it 
did not show any toxic side effects, at the concentrations tested by Bezerra et al., 
(2009). In a recent study (Tietze & Blomeke, 2008) aimed at dendritic cells and skin 
sensitization by contact allergens, ascaridol augmented expression of CD86 in 
monocyte leukemia cell line THP-1 and monocyte-derived dendritic cells. 
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6. 3. Arsenic trioxide 
Arsenic trioxide is an established cytostatic drug. It has been used as a medicine for 
thousands of years and is known to induce cell apoptosis, DNA damage and to 
affect cell cycle. As it is a well studied compound (Gazitt & Akay, 2005; Miller, Jr. et 
al., 2002), arsenic trioxide was selected as a positive control for our experiments. 
Our data showed that arsenic trioxide was 3 to 5.5 times more effective on NER 
deficient cells than the normal cells. Flow cytometry data showed arsenic trioxide 
treatment blocked cells from all the three cell lines at G2/M phase. Lower 
concentration (0.22 µg/ml) of the drug was required to induce this blockade in 
GM10902 and XP3BE cells compared to the normal cells (0.73 µg/ml). We 
measured sub-G1 phase as marker for DNA decay and apoptosis and found that 
0.22 µg/ml of arsenic trioxide caused twice as much of NER deficient cells to enter 
this phase compared to normal cells. A lot of data on apoptosis caused by arsenic 
trioxide is available in literature. Zhu et al., (1999) reported apoptosis and growth 
inhibition in malignant lymphocytes after treatment with arsenic trioxide at 
clinically achievable concentrations. Low concentrations (0.25 – 2.0 µM) of arsenic 
trioxide inhibit growth of human leukemia/lymphoma cell lines HL-60, RL and K562 
by inducing apoptosis (Zhu, 2003). Shao et al., (2005) reported that arsenic trioxide 
treatment induces apoptosis and cell cycle arrest at G2/M phase in human gastric 
cancer cells. It also induces apoptosis and inhibits cellular growth in cisplatin 
sensitive and resistant ovarian cancer (Kong et al., 2005) and colon cancer cells 
(Nakagawa et al., 2002). Arsenic trioxide induces apoptosis in acute promyelocytic 
leukemia cells (Shao et al., 1998) and is used in treatment of acute promyelocytic 
leukemia (Shen et al., 1997; Soignet et al., 1998). These studies provide support to 
our findings. Data from comet assay shows that arsenic trioxide leads to around 
three times more DNA damage in GM10902 and XP3BE than GM01310 cells. Similar 
findings were reported by Yedjou & Tchounwou, (2007) in human leukemia (HL-60) 
cells. 
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6. 4. Other TCM drugs 
Quercetin and scopoletin are used as antioxidants (Shaw et al., 2003; Lamson & 
Brignall, 2000). Our data showed that both these drugs were specifically cytotoxic 
to XP3BE cells only with little or no effect on GM10902 and GM01310 cells. Both 
these compounds exhibit cancer chemopreventive properties (Jang et al., 2004) 
and are potential anti-cancer drugs (van Erk et al., 2005; Bhattacharyya et al., 
2009). Quercetin (10 μg/ml) caused a decrease in S phase in XP3BE cells and an 
increase in the subG1 phase. However literature shows Quercetin caused a G0/G1 
phase arrest in colon (Ranelletti et al., 1992), bladder (Ma et al., 2006) and breast 
cancer cells (Jeong et al., 2009) whereas Yang et al., (2006) reported G2/M phase 
arrest and apoptosis in lung cancer cells. Different cell types could be a reason for 
this result. We did not find a significant effect of quercetin on DNA damage in our 
cells. Scopoletin (20 μg/ml) exposure caused an increase in G1 phase in GM01310 
and XP3BE cells. Kim et al., (2005) reports that scopoletin induces apoptosis in 
promyelocytic cells. We also found a significant increase in DNA damage in XP3BE 
as well as GM10902 cells at lower concentration of scopoletin (10 µg/ml), however 
at a higher concentration (20 µg/ml), the three cell lines did not have a significant 
difference. 
TCM-25-RAB is so far an unidentified TCM drug. It killed GM10902 cells more 
specifically then XP3BE and GM01310 cells. TCM-25-RAB slightly increased the G1 
phase in GM10902 cells. It also increased subG1 phase by 20% in these cells but did 
not have any effect on cell cycle distribution of the other two cell lines. TCM-25-
RAB induced dose-dependent DNA damage in GM10902 cells. This was twice as 
much as in XP3BE and 5 times as in GM01310. The drug did not cause any 
significant DNA damage in GM01310 cells at the concentrations tested. 
Isonardosinon was active against both the NER deficient cell lines. It was around 10 
to 15 times more cytotoxic to NER deficient cells than normal cells. Isonardosinon 
did not cause any significant effect on DNA damage and cell cycle distribution.  
Discussion NER and cancer therapy 
150 
6. 5. Validation of results 
Ascaridol was the most promising compound in our study. Results obtained for 
ascaridol were validated in a second cell model carrying XPC and ERCC6 
deficiencies. As a model for XPC mutation a pair of XPC cell lines, XP4PA and XP4PA-
SE2 was picked. XP4PA cells harbor a dinucleotide (TG) deletion at position 1483-
1484 of XPC causing a frameshift at codon Val431 and a premature stop codon (Li 
et al., 1993) whereas XP4PA-SE2 is the fully corrected version of the cell line by 
stable transfection using pXPC-3 plasmid (Emmert et al., 2000; Legerski & Peterson, 
1992). As a model for ERCC6 mutation, the gene was silenced in XP4PA-SE2 cells 
using ON-TARGETplus SMARTpool siRNA and the Luciferase siRNA exposed cultures 
(negative control for gene silencing) were considered as repair competent control.  
The cytotoxicity screening revealed XP4PA cells were 165 times more sensitive to 
ascaridol exposure than XP4PA-SE2 cells and ERCC6 silenced cells were 32 times 
more sensitive to ascaridol exposure than Luciferase siRNA exposed cells. Ascaridol 
caused DNA damage in these cells in a dose-dependent manner. At 1 µg/ml 
ascaridol exposure, XP4PA cells gathered around 1.5 times more DNA damage than 
XP4PA-SE2. The ERCC6 silenced cells accumulated around 3 times more DNA 
damage than Luciferase siRNA exposed cells. These results confirm our previous 
findings that following ascaridol treatment, NER deficient cells have higher DNA 
damage compared to repair proficient cells.  
6. 6. Mode of action of ascaridol 
How ascaridol exactly works is not well understood. Ascaridol undergoes a 
concerted dissociative reduction by a nonadiabatic electron transfer of the O-O 
bond (Donkers & Workentin, 2001). Monzote et al., (2009) showed that ascaridol 
formed carbon-centered radicals in the presence of Fe2+ and reduced hemin. This 
mechanism is very similar to another endoperoxide artemisinin, which is another 
anti-malarial and potent anticancer drug (Efferth et al., 2002b; Golenser et al., 
2006; Balint, 2001). From these descriptions, we speculated that ascaridol creates 
oxidative stress and investigated the production of reactive oxygen species by 
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ascaridol. Furthermore, we quantified 8-oxodG sites by the Fpg-modified comet 
assay. 
The production of reactive oxygen species by ascaridol in XP4PA and XP4PA-SE2 
cells was measured by the 2´,7´-dichlorofluorescein diacetate (H2DCFDA) assay. 
Overall XP4PA cells had higher intracellular peroxide levels compared to XP4PA-SE2 
cells. A dose-dependent increase in intracellular peroxide levels was observed in 
ascaridol treated cells. The RRRos after treatment did not differ in both the cell lines. 
Quantification of 8-oxodG sites by Fpg-modified comet assay showed that XP4PA 
cells exhibit a strong increase in oxidized bases than XP4PA-SE2 cells, after 
treatment with 1 µg/ml ascaridol. Similarly, ERCC6 silenced cells exhibit a highly 
significant increase in Fpg sensitive lesions compared to luciferase siRNA exposed 
cells after ascaridol treatment. All of these findings are consistent with a role of 
ascaridol in mediating DNA damage by oxidative stress. 
6. 7. Role of NER proteins in the repair of oxidative damage 
The main pathway for the repair of oxidative DNA damage is BER (Mitra et al., 
1997; Seeberg et al., 1995). However recent studies have identified proteins which 
are involved in repair of oxidative DNA damage but which belong to other repair 
pathways especially the NER pathway. NER is involved in the removal of 8-oxodG 
(Reardon et al., 1997). Langie et al., (2007) reported an increase in expression of 
NER genes including XPC in the presence of oxidative stress after H2O2 exposure. 
Mutations in XPC disturb both NER and BER (Bernardes de Jesus et al., 2008). 
D’Errico et al., (2006) reported that XPC deficient keratinocytes and fibroblasts 
were hypersensitive to DNA-oxidizing agents and re-introduction of XPC in these 
cells reduced their sensitivity. In the absence of XPC, a decrease in repair of 8-
oxodG was observed. XPC-HR23B complex acted as a cofactor for repair of 8-oxodG 
by stimulating Ogg1. An XPC protein completely lacking its C-terminus does not 
stimulate the glycosylase activity of Ogg1 while wild type XPC shows this activity. 
Mutations in the N-terminal part of XPC also reduced the XPC-Ogg1 interaction, 
leading to reduced BER activity (Bernardes de Jesus et al., 2008). Okamoto et al., 
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(2008) found a significantly increased accumulation of 8-oxodG adducts in the liver 
of XPC-knockout mice. 
ERCC6 also plays a role in the repair of oxidative DNA damage. The ATPase domains 
V and VI of ERCC6 are important for the repair of 8-oxodG lesions (Tuo et al., 2001) 
and ATPase domain VI is important for the repair of 8-oxoA lesions (Tuo et al., 
2002a). ERCC6 Protein in GM10902 cells lacks both these domains. In ERCC6 
mutated cells, hOgg1 is down-regulated, causing accumulation of 8-oxodG (Dianov 
et al., 1999; Tuo et al., 2002b). The same authors (Tuo et al., 2003) report 
accumulation of oxidative damage in ERCC6 deficient cells. The unrepaired 8-oxodG 
blocks transcription by stalling RNA pol II and ERCC6 may start TCR at this site 
(Slupphaug et al., 2003). Sensitivity of XPC and ERCC6 deficient cells to oxidative 
damaging agents observed in our study also highlights the involvement of these 
genes in oxidative damage repair. 
6. 8. Other possible mechanisms  
Overall, the data support the role of oxidative DNA damage as the underlying 
reason for the anticancer effect of ascaridol. The fact that this drug is active 
towards NER deficient cells at much lower concentrations than the concentrations 
required for normal cells hints for the involvement of other possible mechanisms. 
6. 8. 1. Formation of DNA adducts 
One possible mechanism is, ascaridol may bind to DNA strands leading to DNA 
adducts that are directly repaired by NER. Deficiency of the pathway leads to 
excessive DNA damage and cell death. However nothing is known about it. 
6. 8. 2. Synthetic lethal interactions 
Another possibility is that ascaridol targets other repair-specific gene or gene 
products, thus causing a synthetic lethal effect. Synthetic lethal interaction 
between two genes is defined as a situation when absence of either gene has no 
effect but when both the genes are missing, the condition becomes fatal 
(Dobzhansky, 1946). Ascaridol might be targeting a gene having synthetic lethal 
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interactions with XPC and/or ERCC6. So far such interactions of NER genes are not 
known (Helleday et al., 2008). The concept of synthetic lethal interactions has been 
implicated in cancer therapy (Ashworth, 2008; Kaelin, Jr., 2005). One such example 
is the interaction of poly (ADP-ribose) polymerase and BRCA1 and BRCA2 genes 
(Drew & Calvert, 2008). PARP is an enzyme involved in base excision repair and 
BRCA1 and BRCA2 are important for double strand break repair (Hoeijmakers, 
2001b). PARP inhibitors selectively kill BRCA1/2 deficient cancer cells but are not 
toxic to normal cells (Bryant et al., 2005; Farmer et al., 2005). Currently clinical 
studies testing PARP inhibitors as single agents in BRCA1/2 deficient tumors are 
ongoing (Fong et al., 2009; Drew & Calvert, 2008). ERCC6 deficient cell lines also 
demonstrate hypersensitivity to PARP-1 inhibition (Thorslund et al., 2005). ERCC6 
and PARP-1 bind and relocate to the damaged site both in vitro as well as in vivo, in 
response to oxidative stress (Lan et al., 2004). The concept of synthetic lethal 
interactions in cancer therapy is fairly new yet it provides a novel basis for cancer 
treatment. The exact mechanism by which ascaridol causes DNA damage and cell 
death needs therefore to be further explored. 
6. 9. Limitations of the study 
Although we controlled our experiments carefully, our study is limited by the fact 
that it was conducted in vitro. Although in vitro characterization of the potential 
drug helps forecast its activity in vivo (Jayat & Ratinaud, 1993), yet experiments in 
animal models are required. The cell lines included in the study were checked for 
the reported mutations and cultures were tested for contaminations at regular 
intervals. Each experiment included solvent exposed and unexposed samples. 
Multiple replicates for each treatment were included and experiments were 
performed at least twice. 
6. 10. Conclusion 
There is no question that the ability for improved cancer therapy by targeting DNA 
repair defects is extremely attractive, as many tumors show defects in DNA repair 
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genes such as those involved in NER. NER defects in tumors can be exploited 
intelligently.  
We identified 13 out of 72 TCM drugs that are selectively killing NER deficient cells. 
Ascaridol was the most efficient TCM drug targeting the NER deficient cells. 
Ascaridol was up to 1000 fold more active in NER deficient cells compared to 
normal cells. Exquisitely high sensitivity of NER deficient cells to ascaridol is novel. 
We also show, for the first time that ascaridol in mediating DNA damage by 
oxidative stress. DNA-damaging agents still represent the most effective drugs for a 
large fraction of human malignancies. The growing knowledge on cell response to 
DNA damage and DNA repair is providing the rationale for the development of new 
therapies. Our data demonstrates the sensitivity of XPC and ERCC6 cells to 
ascaridol. Defects in both these genes affect the early damage recognition steps. As 
most of the other NER genes are involved in both of the NER sub-pathways (GGR 
and TCR), we suggest that cells / tumors deficient in other NER genes are also 
sensitive to ascaridol. We suggest it can be used for treating NER deficient tumors 
and provide a rationale for the development of new therapies. Elucidation of 
involved mechanisms in tumor models in vivo is still needed. 
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8. Appendix 
8.1. Genotypes of the larynx cancer case-control study participants 
 
Table.8.1. Genotypes of the larynx cancer case-control study participants 
Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
            
1 CT CA CC AC GG GG TC AA GG CC AC 
2 CC AA CC CC GG GG TC AA GG CC CC 
3 CT CA CC CC GA GC CC AA GG CT AC 
4 CC AA CC CC GG GG CC AA GG CC CC 
5 CT CA CC CC GG GG CC AA GG CC AC 
6 CT CC CA AC GG GG CC AG GG CC AC 
7 CT CC CA AC GG GC CC AG GG CC CC 
8 CT CC CA AC GG GC TC AA GG CC AC 
9 CT CA CC CC GG GG TC AG GG CC AC 
10 TT CC CC AC GG GG CC AG GG CC CC 
11 TT CC CC CC GG GG CC AA GG CC AA 
12 TT CC CC AC GA GG CC AA GC CC CC 
13 CT CC CA AC GG GC TC AA GG CC AC 
14 TT CC CC AC GG GG TT AA GG CT AA 
15 TT CC CC CC GG GG CC AA GG CC AC 
16 CT CA CC CC GG GC TC AG GG CT AC 
18 CT CC CA CC GG GG TC AG GG CC CC 
19 CT CC CA AC GG GG TC AA GG CC AC 
20 CT CC CA CC GA GG TC AG GG CT AC 
21 CT CA CC AC GA GC CC AA GG CT AC 
22 CC CA CA AC GA GC TC AG GG TT AC 
23 CC AA CC AC GG GG CC AG GG CT AA 
24 TT CC CC AC GG GG CC AA GC CT AC 
25 CC AA CC AC GG GG TC AA GG CC AC 
26 CC AA CC AA GG GG TC AA GC CT AC 
27 CT CA CC CC GG GC TT AG GG CC AC 
28 CT CC CA AC GG GG CC AA GG CC AC 
30 TT CC CC CC GA GC TT AG GG CT AA 
31 TT CC CC AC GG GG TC AA GG CC CC 
32 TT CC CC AC GG GG TC AG GG CC CC 
33 CT CA CC AC GG GC CC AG GG CT AC 
34 CT CA CC AC GG GG CC AA GG CC AA 
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Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
35 TT CC CC AA GA GG CC AA GG CT AC 
36 CT CC CC AA GG GG CC AA GG CT CC 
37 CT CA CC AC GG GG CC AG GC CT AC 
39 CT CC CA AC GA GG TC GG GG CC AC 
40 CT CA CC AC GA GG TC AA GG CT CC 
41 CC AA CC CC GG GG CC AA GG CC AC 
42 CT CA CC AC GA GG TC AA GG CC AA 
43 TT CC CC AC GG GC TC AA GG CT AA 
44 TT CC CC AA GG GC TC AA GC CC AA 
45 TT CC CC AC GG GG CC AG GG CC AA 
46 TT CC CC AC GG GG TC AA GG CC AC 
47 CT CA CC AC GG GG CC AG GC CC AC 
48 CC CC AA CC GG GC CC AA GG CC AC 
49 CC AA CC CC GG GG CC AA GG CC AA 
50 CT CC CA CC GG GG CC AA GG CC AC 
51 CT CC CA AC GG GC TC AG GG CT AC 
52 TT CC CC CC GG GC CC AA GG CC AA 
53 CC AA CC CC GG GG TC AA GG CC AC 
54 CC CC AA CC GG GC TT AA GG CT AC 
55 TT CC CC AA GG GG CC AA GG CC AA 
56 CT CA CC AC GG GC TC AG GG CT AC 
57 TT CC CC AA GG GC TT AG GG CC AC 
58 CT CA CC AC GG GG CC GG GG CC AC 
59 TT CC CC AC GG GG CC AA GG TT AC 
60 CC CC AA CC GG GG CC AA GG CC AC 
62 TT CC CC AC GG GC TC AA GG CC AA 
63 TT CC CC AC GG GC TC AA GG CC AC 
64 CT CA CC AA GA GC TC AA GG CC AC 
65 CT CC CA AC GG GC TC AA GG CC AA 
67 TT CC CC AC GG GC TC AA GG CT AC 
68 CT CC CA AA GG GG TC AG GC CT AC 
69 CT CA CC AC GG GG CC AG GG CC AA 
70 TT CC CC AC GG GG TC AG GG CC AA 
71 TT CC CC AA GG GG TC AG GG CC AA 
72 TT CC CC AC GG GG CC AA GG CC AC 
73 CC CA CA CC GG GG CC AA GG CC AC 
76 TT CC CC AA GG GC TT AG GG CC CC 
77 CT CA CC AC GG GC TT AA GG CC AC 
78 CT CA CC AC GG GC TC AA GG CC AA 
79 CT CC CA CC GG GG CC AA GC CC CC 
80 CT CA CC AC GG GG TC AG GG CC CC 
82 CT CA CC CC GG GG CC AG GG CT AC 
83 CT CA CC AA GG GC TT AG GG CC AA 
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Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
84 TT CC CC AA GG GC TC AG GG CC AC 
85 CT CA CA CC GG GC TT AG GG CC AA 
86 CT CC CA AC GG GG TC AA GG CT CC 
87 CT CC CA CC GG GC TC AG GG CT AC 
88 CT CA CC CC GG GC TC AA GG TT AA 
89 TT CC CC AC GG GG TC AA GC CC AA 
90 TT CC CC AC GG GG CC AG GG CC AC 
91 CT CA CC AC GG GC CC AA GG CC AC 
92 CT CC CA CC GG GC TC AA GG CC AC 
93 TT CC CC AC GG GG CC AA GG CT AA 
94 TT CC CC AA GG GC TC AA GG CC AC 
95 TT CC CC AC GG GG TC AG GG CC AC 
96 CC CC AA AC GA GG TC AA CC CC AA 
97 CT CA CC CC GG GC TT AA GG CC AC 
98 TT CC CC AC GG GG TT AA GG CC AC 
99 CT CC CA CC GG GG CC AA GG CT AC 
100 CC AA CC CC GG GG TC AG GG CC CC 
101 TT CC CC AC GG CC TC AG GC CT AA 
102 CC CA CA CC GG GG TC AG GC CC AA 
103 CC CA CA CC GG GG CC AG GG CT AC 
104 TT CC CC AC GG GG TC AA GG CC AC 
105 CT CA CC AC GG GG CC AA GC CC AC 
106 CC AA CC AC GG GG TC AG GG CT AC 
107 CT CA CC AC GG GG TC AA GG CT CC 
108 CT CC CA AC GG GG TC AG GG CT AC 
109 CT CA CC AA GG GG TC AA GG CT AA 
111 CT CC CA AC GG GG CC AA GG CC AC 
113 TT CC CC CC GG GC TC AA GC CT AA 
114 CT CA CC AA GG GC TC AG GG CC CC 
115 CT CC CA AC GA GC TC AG GG CC AC 
116 CT CA CC AC GG GG TT AA GC TT CC 
117 TT CC CC CC GA GC TT AA GG CC AC 
118 CT CA CC AC GG GG CC AA GG CT AC 
119 TT CC CC AC GA GG CC AG GC CC AC 
120 TT CC CC CC GG GG CC AA GC CC AC 
122 TT CC CC AA GG GG CC AG GC CC AC 
124 CT CC CA CC GA GG TC AA GG CC AC 
125 TT CC CC CC GG GC TC AA GG CT AA 
126 CT CA CC CC GG GC TT AG GG CT AC 
128 CT CA CC AC GG GG TC AG GG CC AC 
129 CC CA CC CC GG GC TC AG GG CC AC 
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Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
130 TT CC CC AC GG GC TC AA GG CC AC 
131 CC AA CC CC GG GG TT AA GC CC AA 
132 TT CC CC AC GG GC TT AG GG CC AC 
133 TT CC CC AA GA GC CC GG GG TT AC 
134 TT CC CC AC GG GG TC GG GG CC AC 
135 CT CA CC AC GG GG TC AA GG CC AC 
136 TT CC CC AA GA GG CC AG GG CC AC 
138 TT CC CC AC GG GG TC AG GC CC AA 
139 TT CA CC CC GG GG TC AA GG CC AC 
140 CT CC CA CC GG GG TC AG GG CC AC 
141 TT CC CC AC GG GC TC AA GG CC AC 
142 TT CC CC AC GG GG CC GG GG CC CC 
143 CT CC CA CC GG GC TC AA GG CC AC 
144 CT CA CC AC GG GC TC AG GG CC CC 
145 CT CA CC AC GG GG CC AA GG CT AC 
146 CT CC CA AC GG GC TT AA GG CC CC 
147 CT CC CA AA GG GG TC GG GG CC AC 
148 CC AA CC CC GA GG CC AG GG CC AC 
149 CT CA CC AC GG GG TT AA GG CC AA 
151 CT CC CA CC GG GC TT AA GC CC AC 
152 TT CC CC AC GG GG TC AA CC TT AC 
153 CT CC CA CC GG GG CC AA GG CT AC 
154 CC AA CC AC GA GG CC AA GG CC AA 
155 TT CC CC AC GG CC TT AA GG CC AA 
156 CT CC CA AC GA GC TC AA GG CT AC 
157 TT CC CC CC GG GG CC AG GG CT AC 
159 CT CC CA AC GG GC TC AA GC CT AA 
160 TT CC CC AC GG GG CC AG GG CC CC 
161 CT CA CC AC GG GC TC GG GG CT AA 
162 CT CC CA CC GA GG TC AA GG CT AA 
163 CT CC CC AA GG GG CC AG GG CC CC 
165 TT CC CC AA GA GG TC AA GG CC AA 
166 CT CA CC AC GA CC TT AA GG CC AC 
167 CT CA CC CC GG GG CC AG GG CC AC 
168 CC CA CA CC GG GC TC AA GG CT AC 
170 CC AA CC AC GG GG CC AG GG CT AC 
171 CC AA CC CC GG GC TC AA GG CT AC 
174 TT CC CC AC GG GC TT AA GG CC AA 
175 TT CC CC AA GG GG CC AG GC CT AC 
176 TT CC CC AC GG GG CC AA GG CC AC 
177 CC CA CA CC GG GC CC AA GG CT AC 
178 TT CC CC AC GG GC TC AA GG CC CC 
179 CC AA CC AC GG GC TC AG GG CC AC 
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Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
180 TT CC CC CC GG GG TT AA GG CC AA 
181 CT CA CC AC GG GG TC AG GG CC AC 
182 TT CC CC AC GG CC CC AA GG CC AC 
183 CT CA CC AA GG GG TC AG GG CC AC 
184 CC AA CC AC GG GC TC AA GG CC AC 
185 CT CA CC CC GG GC TC AA GC TT AA 
186 CT CC CA CC GG GG CC AG GG CC AC 
187 CT CA CC CC GG GG CC AG GG CT AA 
189 TT CC CC AC GG CC TT AA GG CC AC 
190 TT CC CC AC GG GG TC AA GC CC AC 
191 CC AA CC CC GG GG CC AG GG CC AC 
192 CT CC CA CC GG CC TT GG GG CC AA 
193 TT CC CC AC GG CC TT AA GG CC CC 
194 TT CC CC AC GG GC TC AG GC CC AA 
195 TT CC CC AC GG GC TT AG GG CC AA 
196 TT CC CC AA GG GC TT AG GG CC CC 
197 CT CA CC CC GG GG TT AG GC TT AA 
198 TT CC CC CC GG GG CC AG GG CT AC 
199 TT CC CC CC GG GG CC AG GG CT AC 
200 TT CC CC AA GG GG TC AA GG CT AA 
201 TT CC CC AC GG GG TC AA GC CT AC 
202 CT CC CA AA GG GG TC AA GG CC AC 
203 CT CA CC AC GA GC CC AA GG CT AC 
204 CT CA CC AC GG GG CC AA GG CT AC 
205 CT CA CC AC GG GG TC AG GG TT AC 
206 CT CA CC AC GG GG TC AG GG CC AA 
207 CT CA CC CC GA GG CC AG GG CC AA 
209 TT CC CC AC GG GG TT AA GC TT AA 
211 TT CC CC AA GG GC TT AG GG CC AA 
212 CC AA CC AC GG GG TC AA GG CC CC 
213 TT CC CC AA GG GC TC AA GG CC AC 
214 TT CC CC AA GG GG TC AG GG CT AA 
215 CT CA CC AC AA GG CC AA GC CC AC 
216 CC CA CA CC GG GC TC AA GG CT AC 
218 TT CC CC CC GG GG TC AA GG CT AC 
219 CT CC CA CC GA GC TT AA GG CT AC 
220 CT CA CC AC GG GG CC AA GC CC CC 
222 CC AA CC AC GG GG TC AA GG CC CC 
223 CT CA CC AC GG GC TT AA GG CT AC 
224 TT CC CC AC GG GC TC AA GG CC CC 
225 TT CC CC CC GG GC TC AG GG CT AA 
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Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
226 CT CA CC AC GG GC TT AG GG TT AA 
227 TT CC CC AC GG GG TC AG GG CC CC 
228 TT CC CC CC GG GC TC AA GG CT CC 
229 TT CC CC AA GA GG CC AA GG CT CC 
230 CT CC CC CC GA GC TC AA GC CC AC 
231 CT CC CA AC GG CC TT AG GG CC AC 
232 TT CC CC AC GG GG CC AG GC CC CC 
233 CT CA CC AC GG GG TC AG GC CT AC 
234 CT CC CA AC GA GG CC AA GG CC AC 
235 TT CC CC AC GG GC CC GG GG CC AC 
236 CT CC CA CC GG GC TC AG GG CC AC 
237 CT CA CC AC GG GG CC AA GC CT AA 
238 CT CA CC AC GG GC TC AA GC CC AA 
239 TT CC CC AA GG GC CC AA GG CC AC 
240 CT CA CC CC GG GG TC AA GC CT AC 
241 CT CA CC AA GG GC TC AA GG CC CC 
242 CT CA CC AA GG GC TC AG GG CC AC 
243 TT CC CC AC GG GG CC AA GG CC AC 
244 TT CC CC AA GG GC TC AA GC CC CC 
246 TT CC CC CC GG GG TT AG GG CC AC 
247 TT CC CC AA GG CC TC AA GG TT AC 
248 CT CA CC AC GG GG CC AA GG CC AC 
249 CT CC CA AC GG GG CC AA GG CT AC 
250 CT CA CC AC GG GG TT AA GG CC AA 
251 TT CC CC AC GG GG CC AA GC CC CC 
252 CT CA CC CC GG GC TC AA GG TT AC 
253 CT CC CA AA GG GG TT AA GG CC AA 
254 TT CC CC AC GG GG TC AA GG CT CC 
255 TT CC CC AC GG GC TT AA GG CC AC 
257 TT CC CC AC GA GG CC AA GG CC AA 
258 CC CA CA AC GG GG TC AA GG CC AA 
259 TT CC CC CC GA GC TC AA GG CC AA 
260 CT CA CC CC GG GG TC AA GG CC CC 
261 CT CC CA CC GG GC TT GG GG CC AA 
262 CC CA CA CC GA GG TT AG GG CC AC 
264 CT CA CC CC GA GG CC AG GG CT AA 
265 TT CC CC AC GG GG CC AA GG CT AA 
266 TT CC CC CC GG GC TC AA GG CC AC 
267 CT CA CC AC GG GG TT AA GC CC AA 
268 CT CA CC CC GG GG CC AA GG CC AA 
269 TT CC CC AC GG GG CC AG GG CC AA 
270 CT CC CA AC GG GC TC AA GG CC AC 
271 TT CC CC AC GG GC TC AA GG CC AC 
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Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
272 TT CC CC AC GG GG CC AA GG CC AC 
274 TT CC CC AA GA GG TC AA GG CC AA 
275 TT CC CC CC GG GG TC AA GC TT AA 
276 CT CC CA AA GG GG TC AG GG CC CC 
278 CT CA CC AC GG GG TC AA GC CC CC 
280 TT CC CC CC GG GG CC AA GG CT AA 
282 TT CC CC AC GA CC TT AA GG CC AC 
283 CC CA CA AC GA GC TC AA GG CC AC 
285 TT CC CC AC GG GG TT AA GG CT AA 
286 CT CA CC AA GG GG CC AA GG CC AC 
287 TT CC CC AA GG GG TC AG GG CC AA 
289 TT CC CC CC GG GG CC AA GG CC AA 
290 CT CA CC AA GG GC TC GG GG CT CC 
291 TT CC CC AC GG GC TT AA GC CC AA 
292 TT CC CC CC GA GG CC AG GG CT CC 
293 CT CA CC CC GA GC TC AA GG CC AA 
294 TT CC CC AC GG GG CC AA GG CT AC 
295 CT CA CC AC GG GG CC AG GG CC AC 
296 CT CA CC CC GG GG TC AG GG CT AC 
297 CT CA CC AC GG GG TC AA GG CT CC 
298 TT CC CC AC GG GG TC AG GG CT AC 
299 CT CA CC CC GG GG TC AG GG CT CC 
301 CC AA CC CC GG CC TT AA GG CT AC 
302 TT CC CC AC GA GC TC AA GG CT AA 
303 CT CC CA AC GG GG TC GG GG CC AC 
304 CT CC CA AA GG GG TT AA GG CT AA 
305 CT CC CC CC GG GC CC AA GG CC CC 
306 TT CC CC CC GG GG CC AG GG CC CC 
307 TT CC CC AA GG GG CC AG GG CC AC 
308 CT CA CC CC GG GC TC AG GG CT CC 
309 TT CC CC AA GA GC CC AA GG CT AC 
310 TT CC CC AC GG GG TC AG GG CT CC 
311 TT CC CC AC GG GC TC AA GG CC AA 
312 TT CC CC CC GG GG CC AA CC CT AA 
313 CC AA CC AC GA CC TT AG GG CC AC 
314 TT CC CC AC GG GC TC AA GG CC AC 
315 TT CC CC AC GG GC TC AA GC CC AC 
316 CT CC CA AC GG CC TT AA GC CC AC 
318 TT CC CC AA GG GG TC AA GG CT AA 
319 CC CA CA CC GG CC TC AA GG CC AA 
320 TT CC CC AC GG GC TC AA GG CC AA 
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Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
323 TT CA CC CC GG GG CC AA GG CC AA 
326 CT CA CC AC GG CC TT AA GG CC AC 
329 TT CC CC CC GG GG TC GG GG CC AA 
330 CT CC CC AC GG GG CC AA GG CC AA 
331 CC AA CC AC GG GG TC AA GC CC AC 
332 TT CC CC AA GG GC TC AG GG CC CC 
333 CT CC CA CC GG GG TC AG GG CC CC 
334 CT CC CA CC GG GC TC AG GG CC AA 
335 TT CC CC AA GG GG CC AA GG CT AC 
336 TT CC CC AC GG GC TC AA GG TT AC 
337 TT CC CC AA GG GG CC GG GG CC AC 
338 CT CC CA CC GG GG CC AA GG CT AC 
339 TT CC CC AA GG GC TC AG GG CC AC 
340 CC CA CA CC GG GC TC AA GG CT AC 
341 CC CA CA CC GG GG TC AA GG CC AA 
342 TT CC CC AA GG GG CC GG GG CC AA 
343 CT CA CC AA GG GG TC AA GG TT AA 
344 CC CA CC CC GA GG TC AG GG TT AC 
345 TT CC CC AA GG GG TC AA GC CC AA 
346 TT CC CC AA GG GG TC AA GG CC AC 
347 TT CC CC AC GA GG TC AG GG CT AC 
348 TT CC CC CC GA GC TC AA GC CC AC 
349 CT CC CA AC GA GG CC AG GG CT AC 
350 CT CA CC AC GG GG CC AG GG CC AA 
352 TT CC CC AA GG GG TC AA GC CC AC 
353 CT CC CA AC GG GC TC AA GG CC AA 
354 TT CC CC AC GG GC TT AA GG CC AA 
355 TT CC CC AA GA GC TC AA GC CC AA 
356 TT CC CC AC GG GC CC AG GC CT AC 
357 CC CA CA AC GG GG TT AA GG CC AC 
359 CT CA CC AC GG GC CC AG GG CC AC 
360 TT CA CC AC GG GC TC AA GG CC AC 
361 CT CC CA CC GG GC TT GG GG CT AC 
362 CT CA CC AC GA GG TC AA GG CT AC 
364 CT CC CA AC GG GG CC AG GC CC CC 
365 TT CC CC CC GG GG CC AA GG CC AC 
366 TT CC CC AC GA GG CC AG GG CT AC 
367 CT CC CA AC GG GC TC AA GG CT AA 
368 TT CC CC CC GG GG CC AA GG CC AC 
370 TT CC CC AC GG GG CC AA GG CT AA 
371 CT CA CC AA AA GC TC AA GG CC CC 
373 CT CC CA AC GG GG TT AA GG CT AA 
374 CT CC CA CC GG GG CC AG GC CT AA 
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Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
375 TT CC CC AC GA GG CC AG GG CT CC 
376 CT CA CC AC GG GC TT AA GG CC AA 
377 TT CC CC AA GG GG TC AG GG CC CC 
378 TT CC CC AC GA GC TC AA GG CC AC 
379 TT CC CC AC GG GG CC AA GG CC AA 
382 TT CC CC AC GG GC TC AG GG CC AA 
383 CT CC CA AC GG GC TT AG GG CT AA 
384 CT CA CC AC GG GC TC AA GG TT AC 
385 CT CA CC CC GG GG CC AG GG CT AC 
387 CC AA CC AA GG GG CC AG GG CT AA 
388 TT CC CC CC GG GG TC AG GG CC CC 
389 TT CC CC CC GG GG CC AA GG CC AC 
390 TT CC CC AC GA GG CC AA GC CT AA 
391 CC CA CA AC GG GG TC AA GC CC CC 
392 CT CA CC CC GG GG TC AA GC CT AA 
393 TT CC CC AC GG GG CC AG GG CC AA 
394 TT CC CC AA GG GG TC AG GG CC AC 
395 CT CA CC AC GG CC TC AA GG CC AC 
396 TT CC CC AA GG GG CC AA GC CC AA 
397 CT CA CC AC GG GC TC GG GG TT AC 
398 TT CC CC AC GA GC TC AA GC CT AC 
399 TT CC CC AC GG GG CC AA GC CC AA 
400 TT CC CC CC GG GG TT AG GG CT AC 
401 TT CC CC CC GG GC CC AA GG CC AA 
402 CT CA CC CC GG GC TC AG GG CC AC 
404 CT CC CC AA GG GG CC AA GG CC AA 
405 TT CC CC CC GG GG TT AA GG CC AA 
407 CT CC CA CC GA GG TC AA GC CC AA 
408 CT CA CC AC GA GG TC AG GG CC AA 
410 CC CA CC CC GG GC TT AG GG CC AC 
411 TT CC CC AC GG GG TC AA GG CC AA 
412 CT CC CA CC GG GC TT AA GG CC AC 
414 CC AA CC CC GA CC TT AG GG CC CC 
415 TT CC CC AC GG GC TT AG GG CC AC 
416 CT CA CC CC GG GG CC AG GG CC CC 
417 CT CA CC CC GG CC TC AA GG CC CC 
418 TT CC CC AC GG GG CC AG GC CT AA 
420 CT CA CC AA GG GG TC AA GG CT AC 
421 CT CC CA AC GA GG CC AG GG CC CC 
422 CT CC CA AA GG GG TC AG GG CT AA 
423 TT CC CC AA GG GG TC AA GG CT AC 
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Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
424 CT CC CA CC GG GG CC AA GC CC AC 
425 CT CC CC CC GG GG TC GG GG CC AC 
426 TT CC CC AC GG GG CC GG GG CC AC 
427 TT CC CC AA GG GG TC AG GG CT AA 
428 CC AA CC CC GG GG CC AG GG CC AA 
429 CC AA CC AC GG GG TT AA GG CT CC 
431 TT CC CC AA GA GG CC AA GG CC AC 
432 CT CA CC CC GG GC TC GG GG CC AA 
434 TT CC CC AA GG GG CC AA GG TT AA 
435 TT CC CC AA GG GG CC AG GC CC CC 
437 CT CA CC AC GG GC TC AG GG CC AA 
438 TT CC CC AC GG GG CC AA GG CC AA 
439 CT CA CC AC GG GG CC AA GC CC AC 
440 TT CC CC AA GG GC TC AG GG CT AC 
441 TT CC CC CC GG GG CC GG GG CC CC 
442 CT CC CA CC GG GC TC AG GG CC AA 
443 TT CC CC CC GG GG TC AG GG CC AA 
444 TT CC CC AA GG GC TT AG GG CT AC 
445 CT CA CC CC GG GG TT AG GG CC CC 
447 CT CA CC AC GG GC TC AA GG CC AC 
448 TT CC CC AA GG GG CC AA GG TT CC 
449 CT CA CC AA GG GC TC AA GG CC AC 
450 TT CC CC AC GG GG TT AG GG CC AA 
451 CT CA CC CC GG GG TT AA GG CT AA 
453 TT CC CC CC GG GG TC AA GG CC AC 
454 CT CA CC AC GA GG TC AA GG CC AA 
455 CC AA CC AA GG GG CC GG GG CC AC 
456 CT CA CC AC GG GG TT AA GC CT AA 
457 CC AA CC CC GG GG CC AG GG CC AA 
458 TT CC CC AA GG GG CC AA GG CC AC 
459 CT CA CC AA GA GG TC AA GG CT CC 
460 CT CA CC CC GG GC TC AA GG CC AC 
461 TT CC CC AC GG GG CC GG GG CC AC 
462 TT CC CC CC GG GG CC AA GG CT AC 
463 CT CC CA CC GG GG CC AG GG CC AA 
464 TT CC CC AA GG GG CC AG GG CC AC 
465 CT CC CA AC GA GG CC AA GG CC AA 
467 CC CC AA CC GG GC TC AA GG CT AC 
468 TT CC CC AC GG GC TC AA GG CC AA 
469 TT CA CC AC GG GC CC AG GG CC CC 
470 CT CC CA AC GG GG TC AA GG CC AC 
471 CT CC CA AC GG GG TC AG GG CC AC 
472 CT CA CC AC GG GC TC AA GG CT AA 
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Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
473 CT CA CC AC GG GC TC AA GC CT AC 
474 CT CA CC CC GG GG TC AA GG CT AC 
475 TT CC CC AA GG GC TC AA GG CC AC 
476 TT CC CC CC GG CC TC AA GG CC AA 
477 CT CC CA CC GG GG CC AA GG CT AA 
478 CT CA CC CC GG GG TC AA GG CC AC 
479 TT CC CC AC GG GC TC AA CC CC AA 
481 CC CC AA AC GG GG CC AA GC CT AA 
482 CC CC AA AC GG GG CC AA GG CC AA 
483 CT CA CC CC GG GG CC AA GC CC CC 
484 TT CC CC AC GG GG TC AA GG CC AC 
486 TT CC CC AC GG GC CC AA GG CC AA 
487 CT CC CA AC GG GC TC AA GC CC AC 
489 CT CC CA AA GG GG CC AG GG CC AC 
490 CC CC AA AA GG GC TT AA GG CT AC 
491 CC CA CA AC GG GG TC AA GG CC AA 
492 CT CA CC AA GG GG TC AA GG TT AA 
495 CT CA CC AC GA GC TT GG GG CT CC 
496 CC CA CA CC GG GC TC AG GG CC AA 
498 TT CC CC AA GG GG TC AA GG CC AC 
499 TT CC CC AC GG GC TC GG GG CC AA 
500 CT CC CA AA GG GC TC AA GG CT AC 
501 TT CC CC AC GG GG TC AA GG CC AC 
502 TT CC CC AA GG GG TC AA GC CT AC 
504 CT CC CA AA GG GG CC AA GG CT AA 
505 CT CA CC AA GG GC TT AG GC CC AA 
506 TT CC CC AC GA GC TT AA GG CC AC 
507 CT CA CC AC GG GC TC AA GG CC AC 
508 CC AA CC CC GG GC TC AA GG TT AC 
509 TT CC CC AC GG GG TC AG GG CT AC 
510 TT CC CC CC GA GC TC AA GC CC AA 
511 CT CA CC AC GG GG CC AG GG CT AA 
512 CT CA CC CC GG GG CC AA GG CC AC 
513 TT CC CC CC GA GG TC AA GG CC AC 
514 TT CC CC CC GA GG CC AA GG TT CC 
515 CC AA CC AC GG GG TC AA GC CC AC 
516 CC CA CA CC GG GG CC AA GG CC AA 
517 TT CC CC CC GG GG TT AG GG CC AA 
518 TT CC CC CC GG GC TT AA GG CC CC 
519 CT CA CC AC GA GG TT AA GC CC AC 
520 TT CC CC AC GG GG TT AA GG CC AC 
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Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
521 CC CC AA CC GG GG TT AA GG CC CC 
522 CC AA CC CC GG GG CC AA GG CC CC 
523 TT CC CC AC GG GG CC AG GG CC AC 
524 CT CC CC AC AA GC TC AA GG CT AC 
526 TT CC CC AA GG GC TC AA GG CC AA 
527 TT CC CC AC GG GG TC AA GC CC AA 
528 TT CC CC AC GG GC CC AA GC CT CC 
529 CT CA CC AC GG GC CC AA GC CT AA 
530 TT CC CC AC GG GG CC AG GG TT AA 
532 TT CC CC AA GG GG TC AG GG CC AA 
533 CT CC CA CC GG GG CC AA GG CC AC 
534 TT CC CC AC GG GC TC AA CC CC AA 
535 TT CC CC AC GG GC TC AA GG CT CC 
536 TT CC CC AC GA GG CC GG GG CT AC 
537 CT CC CC AC GG GG CC AG GG CT AC 
538 CT CA CC AA GG GC TT AA GG CT AA 
541 CT CC CA AC GG GC TC AA GC CC AC 
542 CT CA CC CC GG GG CC AA GG CC AC 
543 CC CC AA CC GG GG CC AA GG CT AC 
544 TT CC CC AC GG GG CC AA GG CC AC 
545 TT CC CC AC GG GC TC AG GG CT AA 
546 CT CA CC AC GG GC TC AG GC TT CC 
547 TT CC CC AC GG GC TT AA GC CT AC 
548 TT CC CC AA GA GG CC GG GG CT AA 
549 TT CC CC AC GG GG TC AA GG CT AA 
550 CT CC CA AA GG GG TC AG GG CT AC 
551 CT CC CA CC GG GC CC AG GG CC AA 
552 CT CA CC AA GG GG TT AG GG CT AC 
554 TT CC CC AC GG GC TT AG GG CC AC 
555 TT CC CC AC GG GG TC AA GC CC AA 
556 TT CC CC AC GG GC TT AG GG CT AA 
557 CT CC CA CC GG GC TC AG GG CC AC 
558 CT CA CC CC GG GG CC AG GG CC AC 
559 TT CC CC AA GG GG TC AA GG CC AA 
560 TT CC CC CC GA GG TC AG GC CC AA 
561 CT CC CC AC GG GC TC AA GC CT AA 
562 CC AA CC AA GG GC TC AG GG TT AC 
564 TT CC CC AA GG GG CC AA GG CC AC 
565 CC CA CA AC GG GG TC AG GG CC AC 
566 CT CC CA AC GA GG TC AA GG CT AC 
567 TT CC CC AC GG GG TC AG GG CC AC 
568 TT CC CC AC GG GC TT AA GG CC AA 
569 TT CC CC AA GG GC TC AA GG CT AC 
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Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
570 CT CA CC AC GG CC TT AA GG CT AC 
572 TT CC CC AC GG CC CC AA GG CC AC 
574 CT CA CC AC GG GC TT GG GG CT AC 
575 TT CC CC AC GA CC TT AG GG TT AC 
576 TT CC CC CC GG GG CC AA GG CT AC 
577 CT CA CC AC GG GC TT AA GG TT AC 
578 TT CC CC AA GG CC TT AA GG CC AC 
580 CC AA CC CC GA GG TC AG GG CC AA 
582 CC AA CC CC GG GG CC AA GG CC AA 
583 CT CC CA AA GG GG CC AA GG CC AA 
584 CT CA CA AA GG GG TC AG GG CT AC 
585 CT CA CC CC GG GG TC AA GG CC AC 
586 TT CC CC AC GG GC TC GG GG CC AC 
589 CT CA CC AC GG GG CC AG GG CC AC 
590 TT CC CC AC GG GC TT AA GG CC AA 
591 TT CC CC AA GG GC TT AG GG CT AA 
592 CT CC CA AC GG GG TC GG GG CT AA 
593 CT CA CC AC GG GG CC GG GG CC AA 
594 CT CA CC AC GA GC TC AA GG CC AC 
595 CT CC CA AC GG GC CC AG GG CC AC 
596 CT CA CA CC GG GG CC AA GG CC AA 
597 CT CA CC AC GA GC TT AA GG CT CC 
598 CT CC CA AC GA GC TC AA CC CC AA 
599 TT CC CC AA GG GC TC AG GG CC AA 
600 TT CC CC AA GG GG TC AA GG CC AC 
601 CC CC AA AC GG GC TC AA GC CT AA 
602 TT CC CC CC GG GG TT AG GG CC AC 
603 TT CC CC AC GG GG TC AA GG TT AC 
604 TT CC CC AA GG GG TC AA GG CC AA 
605 TT CC CC AC GG GC TT AA GG CC AA 
606 CT CC CA AC GA GC TC AG GG CC AC 
607 TT CC CC AA GG GG TC AG GG CC CC 
608 CT CA CC CC GG GG CC AG GC CC AC 
609 CT CC CA AA GG GG TC AA GC CT AC 
610 TT CC CC CC GG GC TT AG GC CC AC 
611 CT CC CA AC GG GG TC AA GG CC AA 
612 TT CC CC AC GG GC TC AG GG CT AC 
613 CT CC CA AC GG GG CC AG GG CC AA 
615 CT CA CC AA GG GG CC AG GG CT AC 
616 CC CA CA CC GG GG TT AA GG CC AC 
617 CT CC CA AC GG CC TT AA GC CC AC 
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Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
619 CT CA CC AC GG GC TT AA GG CT AC 
620 CT CC CA AC GG GG CC AG GG CT AA 
621 TT CC CC AC GG GG TT AG GG CT AC 
622 CT CA CC AC GG GC TC AA GG CT CC 
623 CT CA CC CC GG GG TT AA GG CC AA 
624 CT CA CC CC GG GC TC AA GG CT AA 
625 TT CC CC AA GG GG TC AA GG CC AC 
626 TT CC CC AA GG GG TC AA GG TT AC 
628 TT CC CC AC GG GC TC GG GG CC AC 
629 CT CA CC CC GG GG CC AA GG CC CC 
630 TT CC CC AC GG GC TC GG GG CT AA 
631 TT CC CC AC GG GC TC AA GG CC AC 
632 TT CA CC AC GG GC TC AG GG CT AC 
633 CT CA CC AA GG GC TT AA GG CC AA 
634 CT CA CC AC GG GC TT AG GG CC AC 
635 CT CC CA AC GG GC TC AG GG TT AC 
637 CT CC CA AC GG GG TC AA GG CC AC 
638 CT CA CC AC GG GC TC AG GC CC AC 
639 TT CC CC AC GA GC TT AA GC CC AA 
642 CT CA CC AC GG GG TC AG GG CC AC 
643 CT CC CA AA GG GC TC AG GC CC AA 
645 CT CA CC AC GG GG CC AA GG CC AC 
646 CT CC CA AC GG GG TC AA GG CT AC 
647 CT CA CC AC GG GC TT AA GG CC AA 
648 CT CC CA AC GG GG CC AA GG CC AC 
649 CC CC AA CC GG GC TC AA GG CC AA 
650 CT CA CC AC GA GG TC AA GG CC AC 
652 TT CC CC AC GA CC TT AA GG CT AC 
653 CT CA CC CC GA GG TC AA GG CC AC 
655 CC AA CC CC GG GG TC AG GG CT AA 
656 TT CC CC CC GA GG TC AA GG CC AA 
657 TT CC CC AC GG GC TC AG GG CC AA 
658 CT CC CA AC GG GG CC AA GG CC AC 
659 TT CC CC CC GG GG CC AA GG CT AA 
661 TT CC CC AC GG GC TC AG GC CT AC 
662 TT CC CC AC GA GG CC AA GC CC CC 
663 CT CC CA AC GG CC TT AG GG CC AA 
664 CC CA CA AC GG GC TC AG GC CC AC 
665 CC CA CA CC GG GG TC AA GC CT AA 
666 TT CC CC CC GG GG TC AG GG CC AC 
668 CT CA CC AA GG GG TC GG GG CC AC 
669 CT CC CA CC GG GC TC AA GC CT AA 
670 TT CC CC AC GA GC TC AA GG CC AA 
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Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
671 CT CC CA AC GA GG CC AA GG CC AC 
672 TT CC CC AA GG GG CC AA GG CC AA 
673 CT CA CC AA GG GG CC AA GC CC CC 
674 CC AA CC CC GG GG TC AG GC CC AA 
675 TT CC CC CC GG GG CC AA GG CT AA 
678 CT CA CC AA GG GG TC AA GG TT CC 
679 CC CA CA AC GG GG TC AA GG CC AC 
680 CT CA CC CC GG GG TT AG GG CC CC 
681 CT CA CC AA GG GG TC GG GG CC AA 
682 TT CC CC AC GA GG TC AG GC CC AC 
683 CT CC CA AC GG GG TC AG GG TT CC 
684 TT CC CC CC GA CC TC AA GC CT AC 
685 TT CC CC AC GG GC TC GG GG CC AC 
686 CT CA CC AC GG GG TC AA CC CC AA 
687 TT CC CC AA GG GG TC AG GG CT AC 
688 TT CC CC CC GG GG TT AG GG CC AA 
689 TT CC CC AC GG GG TC AG GG CC AA 
690 CT CC CA AA GG GG TC AA GG CC CC 
692 CT CA CC AA GG GC TC AA GG TT CC 
693 TT CC CC CC GG GC TC AG GG CC AC 
694 CC AA CC CC GG GC TT AA GC CC AA 
695 TT CC CC AC GG GG TT AA GG CC CC 
696 CT CC CA AA GG GC TC AG GG CC AC 
697 TT CC CC AC GG GG CC GG GG CT CC 
698 CT CA CC CC GG GG CC GG GG CC AA 
699 CT CA CC CC GG GC TC AG GG CC AA 
700 TT CC CC AC GG GG CC AG GG CC AA 
701 TT CC CC AC GG GG CC AA GG CC AC 
702 TT CC CC AA GG GG CC AG GG TT AC 
705 CT CC CC AC GG GC TC AA GG CC AC 
706 CT CC CA CC GG GG CC AA GG CC CC 
707 CT CC CA AA GG GC TT AG GG CC AC 
708 CT CA CC CC GA GC CC AA GG CC AA 
710 CT CA CC CC GG GG CC AG GG CT AC 
711 CC CC AA CC GG GC TC AA CC CC AA 
712 TT CC CC AC GG GC TC AG GG CC AA 
713 TT CC CC CC GG GG TC AG GG CT AC 
714 TT CC CC AA GG GG TC AA GC CC AC 
715 CC CA CA AC GG GG TC AA GC CT AC 
716 CC CA CA AC GG GG TC AA GG CC AA 
717 CC CA CC AC GA GG TT AA GG CT AA 
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Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
718 CT CA CC AA GG GG CC AG GG CC AC 
720 CT CA CC AC GG GG CC AA GG CT AC 
721 TT CC CC AC GG GG CC AG GG CC CC 
722 CC CC AA CC GG GG CC AA GC CC AC 
723 CT CA CC AA GG GG CC AA GG CT AA 
726 CT CA CC CC GA GC TC GG GG CC AC 
728 TT CC CC AA GG GG TC AA GG TT AC 
729 CT CA CC AC GG GG CC AA GG CT AC 
730 TT CC CC AC GG GC TC AA GG CT AA 
731 TT CC CC CC GG GG CC AG GG CC CC 
732 CT CA CC CC GG GG TC AG GG CC AC 
734 CT CA CC AC GG GC TT AG GG CC AA 
736 CC CA CA CC GG GC TT AA GG CT CC 
738 CT CA CC CC GG GG TT AG GC CT AA 
739 CT CA CC AC GG GC TT AA GG CC AC 
740 CT CA CC AA GG GG TT AA GC CC CC 
741 TT CC CC CC GG GG CC AA GG CC AC 
742 CT CA CC CC GG GG CC AA GG CC AA 
743 CC CC AA AC GG GG TC AA GG CT AC 
744 TT CC CC AC GG GG TC AA GC CC AC 
745 CC CA CA CC GG GC TC AA GG CC AC 
746 CT CA CC AA GG GG CC AA GG CC AA 
747 CT CA CC CC GG GC TC AA GG CC AA 
748 CT CA CC AC GG CC TT AG GG CT AC 
749 TT CC CC AC GA CC TC AA GC CC AA 
750 CT CA CC AC GA GG CC AG GG CC AC 
751 TT CC CC AC GA GC TC AA GG CC AC 
752 CT CC CA CC GG GG TC AG GG CC AC 
753 CT CA CC AC GG GC TC AG GG CC CC 
754 TT CC CC AC GG GG CC AA GG CC AC 
757 TT CC CC AA GG GG TC AA GG CC AA 
758 CT CC CA CC GG GG CC AA GG CC AA 
760 TT CC CC AA GG GC TC GG GG CC AC 
761 TT CC CC AC GA GC TC AA GG CT AC 
762 CC AA CC AC GG GC TC AG GG CT CC 
763 CT CA CC AC GG CC TC AG GG CC AC 
765 TT CC CC AA GA GC CC AA GC CT AC 
766 TT CC CC AC GA GG CC AA CC CC CC 
767 TT CC CC AC GA GG CC AA GG TT AC 
769 CT CA CC AC GA GC TC AG GG CT CC 
772 CC AA CC CC GG GC TC AA GC CC AA 
774 TT CC CC AA GG GG CC AA GG CT AA 
775 CT CA CC CC GG GG TC AA GG CC AC 
Appendix 
193 
 
Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
776 TT CC CC AC GG GC TC AA GG CC AC 
777 CT CC CA AA GG GC TT AA GG CT CC 
778 CT CA CC AC GG GC TT AA GG CT AA 
779 TT CC CC AC GG GG TC AA GG CT AC 
780 CT CC CA AC GG GG TC GG GG CT AC 
781 CT CA CC CC GG GG TC AG GG CC AC 
782 CT CC CA AC GG GG TC AA GG CC AC 
783 TT CC CC AA GG GG CC GG GG CC AA 
784 CT CA CC AC GG GC TT AG GC CT AC 
785 TT CC CC AC GG GC TC AA GC CT AC 
786 TT CC CC AA GG GC TT AA GG CC AA 
788 TT CC CC CC GG GG CC AG GG CC AC 
789 CT CC CA AC GA GG CC AA GG CC AA 
791 CT CA CC CC GG CC TC AG GG CT AA 
792 CT CA CC AC GG GC TC AA GG CC CC 
793 TT CC CC CC GG GG TC AA GG CC AA 
794 CT CC CA AA GG GG TT AG GG CC AA 
795 TT CC CC CC GA GC TC AA GG CC AC 
796 CC CA CA CC GG GC TC GG GG CT AA 
797 CT CA CC AC GG CC TT AA GG CC AC 
798 CC CA CA AC GA GC CC AA GG CT AC 
802 TT CC CC AA GG GG TC AG GG CC AC 
803 CT CA CC AA GG CC TT AA GG CT AC 
804 CC AA CC AC GA GG CC AG GG CC AA 
805 CT CA CC CC GA GC TC AG GG TT AC 
807 TT CC CC CC GG GG TC AA GG CT AC 
808 TT CC CC AA GA GG CC AG GG CC AC 
809 TT CC CC CC GG GG CC AG GG CC AC 
810 TT CC CC AC GG GG TC AG GG CT AA 
812 CT CC CA AC GG GC TT AA GC CT AC 
813 TT CC CC AC GG GG CC AA GG CC AC 
814 CT CA CC CC GG CC TT AA GC CC AA 
816 TT CC CC CC GG GC TT AG GG CC CC 
818 CT CC CA AC GA CC TT AA GC CT AC 
819 TT CC CC AA GG GG CC AG GG CT AA 
821 TT CC CC AA GG GC TC AA GG CC AA 
822 CT CA CC AC GG GG TC AA GG CC AA 
823 CT CC CA AA GG GC CC AG GG CT AC 
824 CC AA CC CC GG GC CC AG GG CT AA 
826 TT CC CC AA GG GC TC AA GG CC AA 
827 CT CC CA AC GG GC TC AA GG CC CC 
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Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
829 CC CA CA CC GG CC TT AA GC CC AC 
830 CT CC CA CC GG GC TC AA GG CC AC 
831 TT CC CC AA AA GC TT AG GG CC AA 
833 CT CA CC AA GG GC CC AG GG CC AC 
834 CT CC CA AA GG GC CC AA GG CC AC 
835 CT CC CA AC GA GC TC AG GG CC AC 
842 CC CA CA CC GG GG CC AG GG CC AA 
843 CC CA CA CC GG GG TC AA GG CC CC 
844 CT CA CC AC GG GG CC AG GG CC AC 
845 TT CC CC AC GG GG TC AA GG CC AC 
846 CT CA CC AC GG GG TC AA GC CT AA 
847 TT CC CC CC GG GC TC AA GG CC AA 
848 CT CA CC AC GG GG CC AA GG CT AC 
849 CT CA CC AC GG GG CC AA GG CC AC 
850 TT CC CC CC GG GG TT GG GG CC AC 
852 CT CA CC CC GG GG CC AA GC CT AA 
853 TT CC CC CC GG GG CC AG GG TT AC 
854 TT CC CC CC GG GG CC AG GC CT AA 
855 CT CC CA AC GG GG TC AA GG TT AC 
856 CT CC CA AA GG GG CC GG GG CC AA 
857 TT CC CC AC GG GC TC AA GG CC AA 
861 TT CC CC AA GG GG CC AG GG CT AA 
863 CT CA CC AA GA GG TC AG GC CC AC 
864 CT CA CC AA GG GC TT AA GG CC AC 
865 TT CC CC AA GG GG TC AA GC CC AC 
866 CT CC CA CC GG GG TC AA GG CT AC 
867 TT CC CC AC GG GC TT AG GC CC AC 
868 CT CC CA AC GG GC TC AA GG CT CC 
870 TT CA CC CC GG GG TC AG GG CC AC 
871 TT CC CC AC GG GG CC AG GG TT AA 
873 TT CC CC CC GG GG CC AG GG CC AC 
875 TT CC CC AC GG GG TC AA GG CC AC 
876 CT CA CC AC GG GC TC AA GC CT AC 
877 CT CA CC AA GG GG TC GG GG CC CC 
878 CT CA CC CC GA GG TC AA GG CC AA 
879 CT CA CC AC GA GG TC AA GG CC AC 
881 CT CC CA AC GG GG CC AA GC CT AA 
882 TT CC CC AC GG GC TC GG GG CC AA 
883 TT CC CC AA GG GC TC AA GG CT AC 
884 CC AA CC AC GG GG CC GG GG CC AA 
885 CT CA CC AA GG GC TC AA GG CC AA 
886 TT CC CC AC GG GG CC AA GG CT AC 
887 CT CA CC AC GG GC TC AA GG CC CC 
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Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
888 TT CC CC AC GG GG CC AG GG CT AC 
889 TT CC CC CC GG GC TC AA GG CC AA 
891 CT CC CA AC GA GG TC AA GG CT CC 
892 TT CC CC AC GG GG TC AA GC CT AC 
893 CT CA CC AC GG GC TC AA GC CT AC 
894 CC AA CC CC GA GG TC AA GC CC AC 
895 CC CA CA CC GG GC CC AG GC CT AC 
897 CT CC CA CC GG GG CC AG GG CC AC 
898 CT CA CC AC GG GC TT AG GG TT AC 
902 TT CC CC AC GG GC TC AA GG CC AC 
904 TT CC CC CC GG GC TC AG GG CC AC 
905 CT CA CC CC GG GC TC AG GG CC CC 
906 TT CC CC AA GG GG CC AG GG CC CC 
907 CT CC CC AC GG GG TC AA GC CC AC 
908 CT CA CC AC GG GG CC AA GG CT AA 
909 TT CC CC CC GG GG TC AG GG CC CC 
910 CT CA CC CC GG GC CC AA GG CC AA 
911 TT CC CC AA GG CC TT AA GG CC AC 
912 TT CC CC AA GG GC TC AG GC CC AC 
913 TT CC CC AA GG GG TT AG GG CT CC 
914 TT CC CC AA GG GG TT AA GG CC AA 
915 TT CA CC AC GG GG CC AA GG CT AA 
916 TT CC CC CC GA GG CC AA CC CC AA 
917 TT CC CC AC GG GC TT AG GG CT AC 
918 TT CC CC AC GG GC TC AA GG CT AC 
919 CC CA CA CC GG GC TC GG GG CT AC 
920 TT CC CC AA GG GC TT AA GG CT AC 
921 TT CC CC CC GG GG TC AA GG CT AA 
922 TT CC CC AC GG GG TC AG GG CC AA 
923 TT CC CC CC GG GG TT AG GG CC AC 
924 CT CA CC AC GG GC TC AA GG CC AA 
926 CT CA CC AA GG GG CC AA GG CC AA 
927 CT CA CC AA GG GG TT AG GG CC AA 
928 CC AA CC AC GG GG TC AA GG CC AC 
929 CT CA CC AC GA GC TC GG GG CC AA 
931 CT CA CC AC GG GC TC AA GG CC AC 
932 TT CC CC AC GG GG TC AG GG CT AA 
933 TT CC CC AA GG GG CC AG GG CC AA 
934 CC CA CA AC GG GC TC AA GG CC AC 
935 CC AA CC CC GG GG TC AA GG CC AC 
936 CT CA CC AC GG GG CC AG GG CC AC 
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Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
937 CT CC CC CC GG GG CC AA GG CT AA 
939 CT CC CA AA GA GG TT AA GG CT AC 
940 TT CC CC CC GG GC TC AG GG CT AC 
941 CT CA CC AC GG CC TT AG GC CC AC 
942 CC AA CC AC GG GC TC AG GG CT AA 
943 CT CA CC AC GG GC TC AA GC CT AA 
944 TT CC CC AC GG GC TC AA GG CC CC 
945 CT CA CC AC GG GC TC AG GG CT CC 
946 CT CA CC AC GG GC TT AG GC TT CC 
947 CT CA CC AC GG GG CC AA GG CC AA 
949 TT CC CC AA GG GG TC AA GG CC AA 
950 CC CA CA CC GG GC TC AA GG CT AA 
954 CT CA CC AC GG GC TC AG GG CC CC 
955 CT CA CC CC GG GG TC AA GG CC AA 
956 CT CA CC CC GA GC TC AG GG CT AA 
961 CT CC CA AC GG CC TT AA GG CC AC 
962 TT CC CC AA GA GC TT AA GG CC AC 
963 CT CA CC AC GG GC TC AA GG CC AA 
966 TT CC CC AC GG GG TC AG GG CC CC 
969 CT CC CA AC GA GG TC AG GG CT AA 
970 CT CA CC AC GG GG CC AA GG CT AA 
971 TT CC CC AC GG GC TC AA GG CC AC 
972 TT CC CC CC GG GC TC AG GC CC AC 
973 CT CA CC CC GG GC TC AA GG CC AA 
974 TT CC CC AC GA GC TC AG GC CT AC 
975 CT CA CC AC GG GC CC AG GG CC AA 
976 TT CC CC AC GG GG CC AA GG CC AA 
978 CC CA CA AC GG CC TT AA GG CC AC 
981 CT CA CC AC GA CC TT AA GC CC AA 
982 TT CC CC AA GG GC TC AA GG CT CC 
983 CC AA CC CC GG GG CC AA GC CC AC 
984 CT CA CC AC GG CC CC AA GG CC CC 
986 TT CC CC AC GA GG CC AA GG CC AC 
987 CT CA CC CC GG CC TT AG GG CC AA 
988 TT CC CC AC GG GG CC AA GC CT AC 
989 TT CC CC AC GG GG CC AA GG TT CC 
990 CC AA CC CC GG GC TC AA GC CC AC 
991 CT CA CC AC GG GC TC AA GG CC AA 
992 CT CA CC CC GG GG TC AG GG CT AA 
993 CC CC AA AC GG CC TT AA GG CC CC 
994 TT CC CC AA GG GG TC AA GC CC AA 
995 TT CC CC AC GA GC TC AA GG CC CC 
996 CT CA CC AA GG GG CC AA GG TT AC 
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Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
997 CT CA CC AC GG GG TC AA GG CC AC 
998 CT CA CC CC GA GC TT AA GG CC CC 
999 CT CC CA AC GG GG TC AA GC CT AC 
1000 TT CA CC AC GG GG CC AG GG CT AC 
1001 CT CC CA CC GG GG CC AA GG CT AC 
1002 CC CA CA CC GA GC TT AA GG CC AA 
1003 TT CC CC AA GG GC TC AA GG CC AA 
1004 CT CA CC AC GG GG TC AA GG CT CC 
1005 CT CA CC CC GG GC TC AG GC TT AC 
1006 CT CC CA AC GG GC TC AA GG CC AA 
1008 CT CC CA AC GG GC CC AA GG CT AC 
1009 CT CA CC AC GG GG TC GG GG CC AA 
1010 CT CA CC AA GG GC CC AA GG CT AC 
1011 TT CC CC CC GG GC TC AG GG CC CC 
1012 TT CC CC CC GG GC TC AA GG CT AA 
1013 CC CC AA CC GA CC TC AA GG CT AC 
1014 CT CC CC AC GG GG TT AG GG CC CC 
1015 TT CC CC AC GA GG TC AG GC CC AC 
1016 CT CC CA AC GG GC TC AA GG CT AC 
1017 TT CC CC AC GG GG CC AG GG CT AC 
1018 CT CA CC AC GG GG CC AG GG CT AA 
1019 CT CA CC AC GG GG CC AA GC CC AA 
1020 CT CC CA AC GG GC TC AA GG CC AA 
1022 CC AA CC AC GG GG TC AA GG CT AC 
1023 TT CC CC AC GG GG TC AG GG TT AC 
1024 CC CA CA AA GG GG CC AA GG CC AC 
1025 TT CC CC AC GG GG CC AG GG CC AA 
1026 CT CC CA CC GG GG CC AA GG CC AC 
1027 CT CA CC AA GA GC TC AA GG CC AC 
1028 CT CA CC AC GG GG CC AG GG CC AA 
1029 CC CA CA CC GG GG TC AA GG CT AA 
1031 CT CA CC AC GG GG CC AA GG CC AC 
1032 TT CC CC CC GA GC TC AG GC CC AC 
1033 CT CA CC CC GG GG CC AA GC TT AA 
1034 CT CC CA AA GG GG TC AG GG CT AC 
1035 CT CA CC CC GG GG CC AA CC CC CC 
1036 TT CC CC AA GG GC TC AA GG CC AC 
1037 TT CC CC CC GG GC TC AG GC CC AA 
1038 CT CA CC AC GG GG CC AG GG CC AA 
1039 CT CC CA AA GG GG TT AA GC CC CC 
1040 TT CC CC AC GG GG TC AA GG TT AC 
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Lab ERCC1 ERCC1 ERCC1 ERCC2 ERCC4 ERCC5 ERCC5 ERCC6 ERCC6 RAD23B XPC 
no. Asn118Asn C8092A IVS5+33 Arg156Arg Arg415Gln Asp1104His His46His Arg1213Gly Arg1230Pro Ala249Val Lys939Gln 
1041 CC CA CA AC GG GG CC AA GG CC AA 
1042 TT CC CC AC GG GC TC AA GG CC AA 
1043 TT CC CC AA GA GC TC AG GG CC AC 
1044 CC AA CC CC GG GG TC AA GC CC CC 
1045 CT CA CC AA GA GG CC AA GG CC CC 
1048 TT CC CC AC GG GC TC AA GG CC AA 
1050 CC CC AA CC GG GG CC AG GG CT AC 
1051 CT CA CC CC GG GC TT AA GC CC AC 
1052 TT CC CC AA GG GG TC AA GG CC AC 
1053 CT CC CA AA GA GC TC AG GG CC AC 
1054 CT CA CC CC GG GC TT AA GG CT AC 
1056 TT CC CC AC GG GG CC AA GG CC AA 
1057 TT CC CC AA GG GC TC AA GG CC AA 
1058 CC CA CA CC GG GC TC AA GG CC AC 
1061 CT CC CA CC GG GG TC AA GC CC CC 
1062 CT CA CC CC GG GC TC AG GG CC AC 
1063 CC CA CA AC GG GG CC AG GG CC CC 
1064 CT CC CA CC GA GC TT AG GC CC CC 
1065 CC AA CC CC GG GC TT AA GG CT AC 
1066 CT CA CC CC GA GG TC AG GG CC AA 
1071 TT CC CC AA GG GG TC AG GG TT AA 
1072 TT CC CC AC GA GG CC AG GG CT AA 
1073 CT CC CA CC GA GC TC AG GG CC AA 
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8. 2. Traditional Chinese medicine compounds 
Table.8.2. TCM drugs and their solvents. 
No. code 
Name/code from 
another project 
CAS-no. 
mole mass 
(g/mol) 
Chemical 
formula 
Molecular structure Stock solution / solubility 
1 TCM-1-RAB Artesunate 83507-69-1 384 C19H28O8 
 2 mg in 500 µl DMSO, then add 500 µl 
water 
2 TCM-2-RAB Puerarin 3681-99-0 416 C21H20O9 
 
2 mg in 1 ml water under heating 
3 TCM-4-RAB Baicalein 491-67-8 270 C15H10O5 
 
2 mg in 1ml EtOH under heating, then 
add 1 ml water 
4 TCM-5-RAB Baicalin 21967-41-9 446 C21H18O11 
 2 mg in 1ml EtOH under heating, then 
add 1 ml water 
5 TCM-6-RAB Nardosinon 23720-80-1 250 C15H22O3 
 
2 mg in 100 µl EtOH under heating, 
then add 900 µl water 
6 TCM-7-RAB Isonardosinon 27062-01-7 250 C15H22O3 
 2 mg in 100 µl EtOH under heating, 
then add 900 µl water 
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No. code 
Name/code from 
another project 
CAS-no. 
mole mass 
(g/mol) 
Chemical 
formula 
Molecular structure Stock solution / solubility 
7 TCM-8-RAB 
Tetrahydronardosin
on 
- 252 C15H24O3 
 2 mg in 100 µl EtOH under heating, 
then add 900 µl water 
8 TCM-9-RAB Nardofuran 42438-76-6 250 
C15H22O3 
  
2 mg in 500 µl DMSO, then add 500 µl 
water 
9 TCM-11-RAB Cantharidin 56-25-7 196 C10H12O4 
 2 mg in 500 µl DMSO, then add 500 µl 
water 
10 TCM-12-RAB Arsenic trioxide 1327-53-3 198 As2O3  1 mg / ml PBS 
11 TCM-13-RAB Quercetin 117-39-5 338 C15H10O7 
 2 mg in 100 µl NaOH under heating, 
then add 900 µl water 
12 TCM-15-RAB Ascaridol 512-85-6 168 C10H16O2 
 
1 mg / ml DMSO 
13 TCM-16-RAB Scopoletin                 92-61-5 193 C10H8O4 
 2 mg / ml DMSO 
14 TCM-17-RAB Isoscopoletin             776-86-3 193 C10H8O4 
 
2 mg / ml DMSO 
15 TCM-19-RAB Sophoraflavon G - 424 C25H28O6 
 
2 mg / ml DMSO 
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No. code 
Name/code from 
another project 
CAS-no. 
mole mass 
(g/mol) 
Chemical 
formula 
Molecular structure Stock solution / solubility 
16 TCM-20-RAB Kushenol I 99119-69-4 438 C25H26O7 
 
2 mg / ml DMSO 
17 TCM-21-RAB Kurarinon 34981-26-5 438 C26H30O6 
 
2 mg / ml DMSO 
18 TCM-22-RAB Norkurarinol - 424 C25H28O7 
 
2 mg / ml DMSO 
19 TCM-23-RAB 
2'-Methoxy-
kurarinone 
- 452 C27H32O6 
 
2 mg / ml DMSO 
20 TCM-24-RAB TCM-221B - - - Under investigation 1 mg / ml DMSO 
21 TCM-25-RAB TCM-222B - - - Under investigation 1 mg / ml DMSO 
22 TCM-26-RAB TCM-224B - - - Under investigation 1 mg / ml DMSO 
23 TCM-27-RAB TCM-225B - - - Under investigation 1 mg / ml DMSO 
24 TCM-29-RAB TCM-227B - - - Under investigation 1 mg / ml DMSO 
25 TCM-30-RAB TCM-228B - - - Under investigation 1 mg / ml DMSO 
26 TCM-31-RAB TCM-229B - - - Under investigation 1 mg / ml DMSO 
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No. code 
Name/code from 
another project 
CAS-no. 
mole mass 
(g/mol) 
Chemical 
formula 
Molecular structure Stock solution / solubility 
27 TCM-32-RAB TCM-230B - - - Under investigation 1 mg / ml DMSO 
28 TCM-33-RAB TCM-231B - - - Under investigation 1 mg / ml DMSO 
29 TCM-34-RAB KIB-LIU-001 - 334 C20H30O4 
 
12 mg / ml DMSO 
30 TCM-35-RAB KIB-LIU-002 - 334 C20H30O4  12 mg / ml DMSO 
31 TCM-38-RAB KIB-LIU-005 - 318 C20H30O3 
 12 mg / ml DMSO 
32 TCM-41-RAB KIB-LIU-008 - 316 C21H32O2  4 mg / ml DMSO 
33 TCM-42-RAB HGM1 - 426 C30H50O 
 
1 mg / ml DMSO 
34 TCM-44-RAB HGM3 - 227 C14H13NO2  0.5 mg / ml DMSO 
35 TCM-47-RAB HGM4 - 227 C14H13NO2  12 mg / ml DMSO 
36 TCM-48-RAB HGM5 - 279 C18H17NO2  12 mg / ml DMSO 
37 TCM-49-RAB HGM7 - 295 C19H21NO2 
 
12 mg / ml DMSO 
38 TCM-50-RAB HGM8 - 269 C18H23NO 
 
12 mg / ml DMSO 
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No. code 
Name/code from 
another project 
CAS-no. 
mole mass 
(g/mol) 
Chemical 
formula 
Molecular structure Stock solution / solubility 
39 TCM-51-RAB 
25-O-Acetyl-23,24-
dihydrocucurbitacin F 
- 560 C32H47O8 
 
2 mg / ml DMSO 
40 TCM-52-RAB 
23,24-
Dihydrocucurbitacin F 
- 521 C30H48O7 
 
2 mg / ml DMSO 
41 TCM-53-RAB Arjunolic acid 465-00-9 489 C30H48O5 
 
2 mg / ml DMSO 
42 TCM-54-RAB KIB-LIU9 - 335 C22H29NO3 
 
4 mg / ml DMSO 
43 TCM-55-RAB KIB-LIU10 - 403 C23H33NO3S 
 
4 mg / ml DMSO 
44 TCM-56-RAB KIB-LIU11 - 425 C23H39NO4S 
 
4 mg / ml DMSO 
45 TCM-57-RAB KIB-LIU12 - 409 C23H39NO3S 
 
2 mg / ml DMSO 
46 TCM-58-RAB KIB-LIU13 - 602 C32H42O11 
 
2 mg / ml DMSO 
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No. code 
Name/code from 
another project 
CAS-no. 
mole mass 
(g/mol) 
Chemical 
formula 
Molecular structure Stock solution / solubility 
47 TCM-59-RAB KIB-LIU14 - 1030 C51H82O21 
 
2 mg / ml DMSO 
48 TCM-60-RAB KIB-LIU15 - 1030 C51H82O21 
 
2 mg / ml DMSO 
49 TCM-61-RAB KIB-LIU16 - 1192 C57H92O26 
 
2 mg / ml DMSO 
50 TCM-62-RAB KIB-LIU17 - 1210 C57H94O27 
 
4 mg / ml DMSO 
51 TCM-71-RAB WYF-1 - - - 
 
2 mg / ml DMSO 
52 TCM-72-RAB WYF-3 - - -  2 mg / ml DMSO 
53 TCM-73-RAB WYF-5 - - -  2 mg / ml DMSO 
54 TCM-74-RAB WYF-6 - - - 
 
2 mg / ml DMSO 
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No. code 
Name/code from 
another project 
CAS-no. 
mole mass 
(g/mol) 
Chemical 
formula 
Molecular structure Stock solution / solubility 
55 TCM-75-RAB WYF-7 - - - 
 
2 mg / ml DMSO 
56 TCM-77-RAB WYF-9 - - - 
 
2 mg / ml DMSO 
57 TCM-78-RAB WYF-10 - - - 
 
2 mg / ml DMSO 
58 TCM-79-RAB WYF-11 - - - 
 
2 mg / ml DMSO 
59 TCM-81-RAB WYF-13 The n-BuOH fraction of EtOH extract from Ardisia Solanacea 2.5 mg / 1.25 ml DMSO 
60 TCM-83-RAB LGF-1 - - - Under investigation 2 mg / ml DMSO 
61 TCM-84-RAB LGF-2 - - - Under investigation 2 mg / ml DMSO 
62 TCM-85-RAB LGF-3 - - - Under investigation 2 mg / ml DMSO 
63 TCM-86-RAB LGF-4 - - - 
 
2 mg / ml DMSO 
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No. code 
Name/code from 
another project 
CAS-no. 
mole mass 
(g/mol) 
Chemical 
formula 
Molecular structure Stock solution / solubility 
64 TCM-87-RAB LGF-5 - - - 
 
2 mg / ml DMSO 
65 TCM-88-RAB LGF-6 - - - Under investigation 2 mg / ml DMSO 
66 TCM-89-RAB LGF-7 - - - 
 
2 mg / ml DMSO 
67 TCM-90-RAB LGF-9 - - - 
 
2 mg / ml DMSO 
68 TCM-91-RAB LGF-10 - - - Under investigation 2 mg / ml DMSO 
69 TCM-92-RAB LGF-11 - - - Under investigation 2 mg / ml DMSO 
70 TCM-93-RAB LGF-12 - - - Under investigation 2 mg / ml DMSO 
71 TCM-94-RAB LGF-13 - - - 
 
2 mg / ml DMSO 
72 TCM-95-RAB LGF-14 The n-BuOH fraction of EtOH extract from Homalomena occulta 1.3 mg / 650 µl DMSO 
73 TCM-S1-RAB water 
74 TCM-S2-RAB PBS 
75 TCM-S3-RAB DMSO 
76 TCM-S4-RAB 10% NaOH 
77 TCM-S5-RAB 50% DMSO 
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No. code 
Name/code from 
another project 
CAS-no. 
mole mass 
(g/mol) 
Chemical 
formula 
Molecular structure Stock solution / solubility 
78 TCM-S6-RAB 50% EtOH 
79 TCM-S7-RAB 10% EtOH 
80 TCM-S8-RAB 30% EtOH 
 
 
 208 
 
  
Acknowledgement 
209 
 
Acknowledgements 
I’m grateful to Almighty ALLAH for helping and enabling me to complete the thesis. 
I would like to appreciate and thank PD Dr. Odilia Popanda and Dr. Peter Schmezer 
for their guidance throughout my PhD. Without their help and support I would not 
have been able to organize and complete this thesis. I am also thankful to Prof. 
Thomas Efferth for giving me the opportunity to work on this interesting project as 
well as for his guidance and help. 
I also thank Dr. Christoph Plass for providing me with the opportunity to work on 
my PhD thesis in the Division of Epigenomics and Cancer Risk Factors at Deutsches 
Krebsforschungszentrum (DKFZ) in Heidelberg. 
I am also thankful to PD Dr. Rajiv Kumar (Division of Molecular Genetic 
Epidemiology, DKFZ) and Prof. Dr. Michael Wink (Institut für Pharmazie und 
Molekulare Biotechnologie, Abteilung Biologie, University of Heidelberg) for their 
keen interest and valuable comments. 
Special thanks to Maria Timofeeva, Julia Strathmann, Karin Klimo and Sabine 
Behrens (Division of Cancer Epidemiology, DKFZ) for their help in experimental and 
statistical analysis. 
I am also grateful to all the participants of larynx cancer case control study. I am 
grateful to Prof. H. Becher and Dr. H. Ramroth (Department of Tropical Hygiene and 
Public Health, University of Heidelberg) for their help with the larynx cancer study 
and the statistical analysis. I would also like to mention Prof. A. Dietz, Prof. Dr. H. 
Weidauer, Prof. Dr. P. Plinkert, Prof. Dr. K. Hörrmann, Prof. Dr. K. Reck, Prof. Dr. K.-
W. Delank, Prof. Dr. C. Naumann and Prof. Dr. B. Lippert for their participation in 
larynx cancer study.  Our collaborator for TCM project was Prof. X. Hao (Kunming 
Institute of Botany, the Chinese Academy of Sciences, Kunming, China). 
I acknowledge support by the Higher Education Commission (HEC), Pakistan and 
DAAD. 
I also wish to thank my lab fellows, Jitti, Sebastian, Lea, Céline, Peter, Otto, Reini, 
Claudia, Katrin and Andreas (DNA Repair and Epigenomics, DKFZ) for their excellent 
Acknowledgement 
210 
moral and technical support. Special thanks to Christine for the help with 
Zusammenfassung. 
I would like to express gratitude to my family. Special thanks to my parents from 
the depth of my heart for all their love and prayers, my brothers Mann, Mohib and 
Navid for the support, my sweet nieces Guria, Marium and Muniba for filling my life 
with color and hubby dear Nafees for all the understanding and care. I want to 
thank my Grandma, my in-laws, my aunts, uncles, all my cousins and Sobia for their 
wishes. Thanks to all my friends Nusrat, Azima, Behjat, Uzma, Saba, Kiran, to name 
some of them. 
At the end, I would also like to remember my old friends who are long gone, for 
they helped me to become what I am today.   
 
 
‘May Allah grant you goodness’ 
 
Curriculum Vitae 
211 
 
Curriculum Vitae 
Personal Information 
Name    Rashda Abbasi 
Father’s name   Ejaz Ahmad Abbasi 
Date of birth   2nd July 1976 
Marital status   Married 
NIC #    37405-3586115-0 
Nationality   Pakistani 
Honors and Awards: 
 2nd Best poster prize, PhD retreat 2008, Weil der Stadt, Germany. 
 Overseas Scholarships Scheme for PhD in Selected Fields in Germany by 
DAAD-HEC. 
 First position in faculty of sciences in M.Sc. (1997 - 1999) Silver Medal. 
 First position in department of Zoology (M. Sc.) in University of Arid 
Agriculture. 
 Won the Fauji Foundation academic distinction award, 2000. 
Education and Research Experience 
 2006 - 2009, Division of Epigenomics and Cancer Risk Factors, Deutsches 
Krebsforschungszentrum (DKFZ) in the Helmholtz Association. PhD 
candidate, Thesis title ‘Nucleotide excision repair pathway modulating both 
cancer risk and therapy’. First supervisor: Prof. Dr. T. Efferth. Worked under 
the supervision of Prof. Dr. O. Popanda, Dr. P. Schmezer and Prof. Dr. 
Christoph Plass. 
 2002 - 2005, As Scientific Officer in Biomedical and Genetic Engineering 
Division, KRL, Islamabad, Pakistan. 
Curriculum Vitae 
212 
 2001 - 2002, worked as senior section teacher in Bismah Army Public 
School, Hamza Camp, Rawalpindi, Pakistan. 
 1999 - 2001, Quaid-i-Azam Uni. Islamabad, Pakistan. M. Phil scholar, 
Dissertation title ‘Study of Genetic Disorders in Pakistani Families 
(Deafness)’. Supervisor: Dr. SA. Shami, external supervisor: Dr. R. Qamar, 
BnGE Div. KRL Islamabad, Pakistan. ‘CGPA 4.1/5.00’. 
 1997 - 1999, University of Arid Agriculture, Rawalpindi, Pakistan. MSc 
student, Report title ‘Effect of Genotype on quality of Bovine Semen’. 
Supervisor: Dr. Z. Hussain, external supervisor: Dr. N. Ahmad, NARC, 
Islamabad, Pakistan ‘CGPA 3.94/4.00’. 
 1995 - 1997, Govt. College for Women, 6th road, Rawalpindi. BSc student. 
Subjects: Zoology, Botany, Chemistry. 
 1992 - 1995, Govt. College for Women, 6th road, Rawalpindi. Higher 
Secondary School (HSSC). Subjects: Pre-Medical. 
 Before 1992, Rawalpindi Grammar School, Rawalpindi. Secondary School 
(SSC). Subjects: Science. 
Previous publications 
 Forshew T, Johnson CA, Khaliq S, Pasha S, Willis C, Abbasi R, Tee L, Smith U, 
Trembath RC, Mehdi SQ, Moore AT, Maher ER. Locus heterogeneity in 
autosomal recessive congenital cataracts: linkage to 9q and germline HSF4 
mutations. Hum Genet. 2005 Sep;117(5):452-9. Epub 2005 Jun 16. 
 Abbasi R, Shami SA, Qamar R, Ayub Q, Khaliq S. A Pakistani family with 
Autosomal recessive sensorineural hearing loss linked to DFNB7/11. (2001). 
American Journal of Medical Genetics (Abstract). 
Conferences / retreats attended. 
 10th Biennial Meeting of the Deutsche Gesellschaft für DNA-
Reparaturforschung (2nd to 5th September 2008), Berlin. 
 Heidelberg Forum for young life scientists (10th to 11th September 2009), 
Heidelberg, Germany. 
Curriculum Vitae 
213 
 
 PhD retreat 2007, Weil der Stadt, Germany. 
 PhD retreat 2008, Weil der Stadt, Germany. 
Social activities 
 Member of the PhD retreat committee 2008 held in Weil der stadt, 
Germany 
 Member of German DNA repair society ’Deutsche Gesellschaft für DNA-
Reparaturforschung (DGDR)’. 
 
 
 214 
Publications from the thesis 
215 
 
Publications from thesis 
 Abbasi R, Ramroth H, Becher H, Dietz A, Schmezer P, & Popanda O (2009). 
Laryngeal cancer risk associated with smoking and alcohol consumption is 
modified by genetic polymorphisms in ERCC5, ERCC6, and RAD23B but not 
by polymorphisms in five other nucleotide excision repair genes. Int J 
Cancer 125, 1431-1439. 
 Abbasi R, Ramroth H, Becher H, Dietz A, Schmezer P, & Popanda O (Poster). 
Laryngeal cancer risk associated with smoking and alcohol consumption is 
modified by genetic polymorphisms in the nucleotide excision repair genes 
ERCC6 and RAD23B. 10th Biennial Meeting of the Deutsche Gesellschaft für 
DNA-Reparaturforschung, 2nd to 5th September 2008, Berlin, Germany. 
 Abbasi R, Ramroth H, Becher H, Dietz A, Schmezer P, & Popanda O (Poster). 
Laryngeal cancer risk associated with smoking and alcohol consumption is 
modified by genetic polymorphisms in the nucleotide excision repair genes 
ERCC6 and RAD23B. Heidelberg Forum for young life scientists, 10th to 11th 
September 2009, Heidelberg, Germany.  
 R. Abbasi, H. Ramroth, H. Becher, A. Dietz, P. Schmezer and O. Popanda, 
(Poster). Laryngeal cancer risk associated with smoking and alcohol 
consumption is modified by genetic polymorphisms in the nucleotide 
excision repair genes ERCC6 and RAD23B. PhD Retreat, 24th to 27th July 
2008, Weil der Stadt, Germany. 
 Abbasi R, Becher H, Ramroth H, Dietz A, Popanda O, & Schmezer P (Talk). 
Nucleotide excision repair as an important pathway influencing laryngeal 
cancer risk. PhD Retreat, 22nd to 24th July 2007, Weil der Stadt, Germany. 
 
 
  
  
  
 
  
  
 
